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Zusammenfassung 
I 
Zusammenfassung 
Die vorliegende Arbeit beschreibt mittels Protein-Überexpression und -Knockdown Analysen eine 
essentielle Rolle für den Chromatin remodelierenden Faktor Brg1 in der embryonalen Musterbildung 
von Xenopus. Während eine ubiquitäre Depletion von Brg1 Protein zu einem Absterben der 
Embryonen führt, überleben dorsal bzw. ventral Brg1 depletierte Embryonen bis zum 
Kaulquappenstadium und erlauben damit eine phänotypische Analyse. Bereits ab der späten Blastula 
sind die Folgen einer lokalen Verminderung des Brg1 Proteinspiegels zu erkennen. Insbesondere zwei 
dorsal liegende Signalzentren - die BCNE und das Nieuwkoop Center - sind in ihrer transkriptionellen 
Signatur stark beeinträchtigt. Diese Defekte setzen sich in der Gastrulation weiter fort und führen zu 
einem funktionell abgeschwächten Organizer. Homotope Transplantationen von Brg1-depletiertem 
Gewebe in Wildtyp Embryonen belegen, dass das Brg1 Protein in der BCNE Region benötigt wird, um 
eine normale Kopfentwicklung zu ermöglichen. Jedoch zeigt die zielgerichtete Depletion von Brg1 in 
der vegetalen Hemisphäre auch, dass Brg1 eine über die BCNE hinausgehende Funktion besitzt. 
Insgesamt belegen die embryologischen Analysen von Brg1-defizienter Embryonen ein gestörtes 
Gleichgewicht zwischen dorsalisierenden und ventralisierenden Faktoren, welches zu erheblichen 
Entwicklungsschäden innerhalb des Körperbauplans führt.  
Um mehr Informationen über die Zielgene von Brg1 zu erfahren, wurde eine genomweite 
Transktiptomanalyse von Brg1-depletierten Embryonen im späten Blastulastadium durchgeführt. 
Hier zeigte sich, dass hauptsächlich Gene, die mit Embryonalentwicklung und Musterbildung 
assoziiert sind, in ihrer Transktiption beeinträchtigt sind. Zu den Brg1-benötigenden Genen zählen 
sowohl dosalisierende als auch ventralisierende Loci. Dies widerspricht der Zuordnung von Brg1 zu 
einem bestimmten Differenzierungsprogramm und deutet auf eine generelle Funktion hin. Da die 
transktiptionelle Veränderungen im Blastulastadium einen Zusammenhang mit der zygotischen 
Genomaktivierung vermuten ließen, wurde eine weitere Transkriptomanalyse durchgeführt, in 
welcher das Expressionslevel von Embryonen unmittelbar vor und nach der MBT verglichen wurde. 
Dabei zeigte sich, dass insbesonders Gene, die eine massive Transktriptionsteigerung erfahren, von 
Brg1 abhängig sind. Brg1 ist also ein essentieller Amplifikator der transkriptionellen 
Genomaktivierung. Die von ihm ausgelöste Aktivierungswelle wird benötigt um eine embryonale 
Induktion der frühen Signalzentren auszubalancieren, so dass eine intakte Musterbildung und 
Embryonalentwicklung gewährleistet werden kann. Damit ist Brg1 ein essentieller Bestandteil der 
embryonalen Musterbildung im Wirbeltier.  
 
 

Summary 
III 
Summary 
This study establishes by gain- and loss-of function analysis an essential role for the chromatin 
remodeling factor Brg1 during embryonic patterning in Xenopus. While embryos depleted 
ubiquitously for Brg1 protein die from gastrulation onwards, embryos locally depleted on either 
dorsal or ventral sides survive until tadpole stage and display specific phenotypes. Already at late 
blastula, antisense knockdown of Brg1 protein levels reduced critical gene expression in two dorsal 
signaling centers, i.e. the BCNE and the Nieuwkoop center. This impairment is sustained during 
gastrulation and results in a functionally impaired Spemann organizer. Homotopic transplantations of 
Brg1-depleted tissue into wild typ embryos indicate a requirement for Brg1 in the BCNE for the 
differentiation of normal eye and brain structures. The local knockdown of Brg1 protein in the 
vegetal hemisphere, however, reveals the existence of additional functions for Brg1 outside the 
BCNE. Taken together, the embryological results indicate a disequilibrium between dorsalizing and 
ventralizing pathways in Brg1-depleted embryos, which leads to detrimental malformations of the 
embryonic body plan, in particular in dorso-anterior structures.  
To obtain more information about Brg1 target genes a genome-wide transcriptome analysis at the 
late blastula stage was performed. Strikingly, developmental and pattern specific genes were 
preferentially altered in their transcription. The Brg1-dependent genes include both dorsalizing and 
ventralizing factors, consistent with my embryological results. This result denies a link between Brg1 
and a single developmental program, but suggests more general functions. Since the earliest 
transcriptional changes observed in Brg1 morphant embryos occur at late blastula stage, a 
connection between Brg1 and global zygotic genome activation was suspected. This hypothesis was 
investigated with a second microarray experiment, in which the transcriptomes of wild type Xenopus 
embryos were compared immediately before and after the onset of zygotic transcription. This data 
set revealed that preferentially those genes depend on Brg1, which become strongly activated at the 
MBT. Therefore, Brg1 serves an essential function as a dose-dependent transcriptional amplifier of 
the zygotic genome activation. The full amplitude of transcriptional response, which Brg1 generates, 
is needed to counterbalance the activities of the early signaling centers to achieve a proper 
embryonic patterning and development. This identifies Brg1 as an essential component of embryonic 
patterning in vertebrates.  
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1 Introduction 
1.1 Xenopus as a model organism 
The African claw frog is a long standing model organism in developmental research. Due to its 
extrauterine development, easy handling and its big egg size, researchers studied and characterized 
the development of Xenopus already beginning of last century. The detailed experiments that were 
performed reached from labeled cell tracking within the developing embryo up to cell or tissue 
transplantation. This opened up fundamental knowledge about e.g. the gastrulation processes and 
cell specification and commitment. Given that Xenopus and human evolutionary are only 344 million 
years apart, segregates Xenopus among other model organisms like worm, fly and fish as the closest 
relative to humans (Schmitt et al, 2014). This indicates high homolog rates in humans, chromosomal 
symmetry, a similar organ blueprint and makes biochemical analyses between Xenopus and humans 
valid. The just mentioned similarities paired with the diploid genome of Xenopus tropicalis and the 
big knowledge about cell biology highlights Xenopus in a leading position for biomedical research in 
the post-genomic era.  
 
1.1.1 Life cycle of Xenopus 
The Xenopus egg can be distinguished into two entities. The upper pigmented animal pole and the 
lower non-pigmented vegetal pole. After fertilization, the embryo undergoes 13 holoblastic cell 
divisions that consist of alternating S and M phases only. G-phases are excluded from the cell cycle in 
order to rapidly increase embryonic cell numbers. At the end of this period of cleavage divisions, the 
embryo reaches the blastula stage. Its spherical shape is not changed, but inside the embryo a 
fluid-filled cavity, called blastocoel, has formed underneath the animal pole. If animal pole cells are 
cultured individually they form epidermal tissue. The floor is lined with bigger yolk-rich cells that later 
will form mesendodermal cells. At this particular developmental stage, approximately 6 hours after 
fertilization the “midblastula-transition” (MBT) takes place. The embryo undergoes major 
rearrangements on both cellular and genomic level. The gap-phases are included into the cell cycle, 
tissues show asynchronous cell division and cells become motile (Newport & Kirschner, 1982a). Also 
on genomic level major changes are happening. The zygotic genome is activated and maternal 
protein is successively degraded. With this burst of transcription also pluripotency is established, 
which is needed for the specification process during development. In summary, major 
rearrangements happen to prepare the embryo for the upcoming gastrulation, in which cells start to 
migrate and the three germ layers and body axes are specified. The first visible morphological feature 
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of gastrulation is the appearance of the dorsal lip. Cells in the dorsal marginal zone, called “bottle 
cells”, undergo apical constriction, start to elongate and initiate the involution process, which defines 
gastrulation (Hardin & Keller, 1988). The leading cells actively migrate into the embryo, while the 
cell-cell contacts results in an involution process which spreads from dorsal to ventral. During 
gastrulation the three germ layers and the body axes are specified. Furthermore, convergent 
extension movements lead to an elongation of the embryo along the antero-posterior axis. Within 12 
hours post fertilization this crucial developmental period is accomplished. After gastrulation, the 
neural plate forms and at the boarders the neural folds rise and fuse from posterior to anterior. The 
underlying mesoderm thereby forms the notochord which then secretes factors that specify somites 
and the neural crest cells. Meanwhile, the neural plate forms the CNS and brain structures. After 
neurulation the main body axes are established and brain structures are specified. Following the 
neurulation, the organogenesis takes place. At the same time the embryo has elongated much 
further and the tail is formed. After approximately three days the embryo hatches and 
embryogenesis is completed. Now the tadpole has to be fed in order to grow and go through 
metamorphosis in which the limbs are formed and the tail again gets reduced. After additional 12 
month the frogs are sexually mature (after (Nieuwkoop & Faber, 1994)).  
 
1.1.2 The zygotic genome activation 
In higher eukaryotes the first developmental processes are dependent solely on maternal 
information, whereas the zygotic genome has to be activated. In mice and humans the zygotic 
activation is one of the earliest steps after fertilization, namely at the 2 or 4 cell stage, respectively 
(Baroux et al, 2008). However in other species like Drosophila, zebrafish and Xenopus this event 
happens much later after the 10th or 13th cell division and is one feature of the midblastula transition 
(Kane & Kimmel, 1993; Newport & Kirschner, 1982b). This process can be subdivided in two major 
steps. First the maternal transcript destabilization and second the transcriptional activation of the 
zygotic genome. In Drosophila, it has been shown that 35% of the maternal transcripts are 
destabilized and successively degraded over the time of the “zygotic genome activation” (ZGA) (De 
Renzis et al, 2007). There are several mechanisms how the destabilization is achieved in Drosophila. 
Already with egg activation a major cascade is started, in which the transcription of Smaug, an 
RNA-binding protein which recognizes cis-regulatory elements in maternal transcripts, is induced. 
Smaug-binding recruits a deadenylase complex which removes the poly-A tail and thereby 
destabilizes the maternal transcripts (Semotok et al, 2005; Smibert et al, 1996; Tadros & Lipshitz, 
2009). In Xenopus it was shown that maternal transcripts are destabilized via an AU-rich cis element 
(ARE)-mediated pathway. Maternal transcripts with such a cis-element are recognized and bound by 
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the Embryo Deadenylation Element Binding Protein (EDEN-BP). Upon fertilization a phosphatase is 
activated, which dephosporylates EDEN-BP and thereby promotes deadenylation, which leads 
successively to destabilizing of the maternal transcripts. However, no deadenylation is observed until 
the onset of the zygotic transcription, which indicates that an additional zygotic factor is required to 
initiate the destabilization process (Detivaud et al, 2003; Tadros & Lipshitz, 2009). In both, Drosophila 
and in zebrafish, it was shown that microRNAs are also involved in the destabilization process. This 
suggests a de novo synthesized transcript at MBT as a possible candidate also for Xenopus to initiate 
the degradation of maternal protein.  
 
 
Figure 1.1: Overview of zygotic genome activation in Drosophila and Xenopus. Depicted are early 
developmental stages of Drosophila and Xenopus embryos. In the background the changes in gene expression 
is displayed schematically. The red curve represents the maternal RNA and its successive degradation with 
onset of ZGA. The two blue curves indicate minor (light blue) or major (dark blue) waves of zygotic genome 
activation (modified from (Tadros & Lipshitz, 2009)). 
 
The second step is the transcriptional activation of the zygotic genome. The timing of the activation 
was long time under debate. Besides the hypothesis of an intrinsic maternal clock, which gets 
activated by the time of fertilization and “counts” the numbers of cell divisions, there are strong 
evidences that argue for the model of a critical “nucleocytoplasmic ratio” (Howe & Newport, 1996; 
Newport & Kirschner, 1982b; Tadros & Lipshitz, 2009). This model hypothesizes that distinct 
maternal repressive factors are diluted out through the earliest cell division. Over 30 years later four 
factors were characterized in Xenopus, which support this hypothesis (Collart et al, 2013). It was 
shown that overexpression of maternal DNA replication factors Cut5, RecQ4, Treslin and Drf1 lead to 
a prolonged synchronous cell cycle, beyond the 13th cell division, which results in vivo in a delay of 
transcriptional activation of several genes at the MBT. With the activation of the zygotic genome, 
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hundreds of genes are either de novo synthesized or undergo a rapid transcriptional upregulation. 
This phase of extensive changes in the transcriptome needs a very tight and efficient regulation. 
Unfortunately in Xenopus, very little is known about the mechanism and the regulation behind this 
burst of transcription. In Drosophila, in contrast, over the last years the research and knowledge 
about this critical phase of early development has grown. It was shown that a majority of early 
transcribed genes in the Drosophila embryo share a cis-regulatory hepta repeat. Shortly after finding 
this common motif, the transcription factor Zelda was characterized, which binds to this element and 
initiates the transcription of early zygotic genes (Harrison et al, 2011; Liang et al, 2008). Regarding 
the synchrony of transcription, a mechanism through paused RNA polymerase II is suggested (Lagha 
et al, 2013). This is very likely as promoter regions are preinitiated and only need a start signal which 
could be either another protein or microRNA. 
 
1.1.3 Axial patterning during Xenopus development 
1.1.3.1 Phase I: Fertilization to MBT 
The body of Bilateria contains three body axes. The dorso-ventral, the antero-posterior and the 
left-right body axes. This body plan is determined very early during embryogenesis. In the amphibian 
embryo already the fertilization determines the dorso-ventral body plan. In the oocyte ventral Bmp2 
is distributed ubiquitously and during oocyte maturation specific mesendodermal-fate promoting 
factors, like VegT, and a dorsalizing activity are transported to the vegetal pole (Houston, 2012; King 
et al, 2005). After sperm entry, the egg undergoes the cortical rotation and the dorsalizing activity is 
shifted and thereby activated (Gerhart et al, 1989; Houston, 2012; Larabell et al, 1997). A schematic 
overview of this period is depicted in Figure 1.2. Although well studied, the process of the cortical 
rotation is still not completely resolved. Approximately 45 min after fertilization, vegetal 
microtubules polymerize thereby causing a 30° rotation of the cortex, usually in the opposite 
direction to the sperm entry point. The rotation of the cortex accordingly induces also a translocation 
of the underlying subcortical cytoplasm (Houston, 2012). With this cytoplasmic translocation the 
dorsalizing activity is activated and accumulates on the prospective dorsal side that later on 
establishes the first patterning centers in blastula embryos. So far, it is known that the dorsalization 
is mediated by nuclear ß-catenin, but whether ß-catenin is activated by cytoplasmic factors or via an 
extracellular wnt-signal, is not solved yet. Since Wnt11 mRNA is maternally expressed, accumulates 
in the vegetal cortical cytoplasm during oogenesis and is translocated with cortical rotation, it is very 
likely that the dorsalizing activity is induced by maternal Wnt11 and mediated by maternal ß-catenin 
(Houston, 2012).  
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Figure 1.2: Schematic events of cortical rotation and its consequences. (a) During oogenesis VegT and 
dorsalizing factors are translocated to the vegetal pole. (b) Sperm entry triggers polymerization of microtubules 
in the egg and lead to a ~30° shift of the egg cortex relative to the inner cytoplasm. Cortical and subcortical 
cytoplasmic factors are thereby translocated, amongst them the dorsalizing activity. (c) ß-catenin is stabilized in 
the nuclei of prospective dorsal cells and induces a specific gene regulatory network. GV, germ vesicle; SEP, 
sperm entry point; V, ventral; D, dorsal (adapted from (Houston, 2012). 
 
1.1.3.2 Phase II: MBT to gastrulation 
Given that preMBT cells are immobile, the expression pattern of maternal mRNAs and proteins are 
similar at the time of fertilization and at blastula stage. The vegetally located maternal T-Box 
transcription factor VegT and dorsally localized ß-catenin in combination with the burst of 
transcription lead to distinct protein gradients and signaling centers, which pattern the embryo. At 
blastula stage two signaling center arise, the “blastula Chordin- and Noggin-expression center” 
(BCNE) and the “Nieuwkoop center”. In the dorsal-vegetal quadrant of a blastula embryo, vegT and 
ß-catenin are coexpressed. The cooperation of the two transcription factors first induces a high 
expression of nodal-like signaling (Agius et al, 2000). The combination of VegT, ß-catenin and high 
nodal-like signaling successively leads to the expressions of genes which are associated with the 
“Nieuwkoop center” and have important roles during axial patterning (Agius et al, 2000; Robertis & 
Kuroda, 2004). One of these genes is cerberus, which is required for head formation in later stages 
(Kuroda et al, 2004). For cerberus, at least four inductive transcriptions factors are known which 
underlines the needed interplay of various signaling pathways (Heasman, 2006; Yamamoto et al, 
2003). One is Xlim1, which is a target gene of maternal VegT and another is Siamois, which is a target 
of the ß-catenin signaling. Cerberus is expressed in involuting mesendodermal cells and acts as an 
inhibitor for BMP-, wnt- and nodal signaling (Bouwmeester et al, 1996; Piccolo et al, 1999a).  
The second signaling center is located in the dorso-animal quadrant and is characterized by 
an excess of maternal nuclear ß-catenin protein. As the name already implies, the BCNE is defined by 
expression of BMP-inhibitors Chordin and Noggin (Kuroda et al, 2004). Recently it was discovered 
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that Noggin proteins under physiological conditions, besides BMP, also inhibit Nodal and Wnt factors, 
albeit to less extent, and thereby help to develop forebrain structures (Bayramov et al, 2011). BCNE 
cells later on give rise to the central nervous system and notochord cells and are essential for proper 
dorso-anterior development (Robertis & Kuroda, 2004). Although both genes are coexpressed and 
have similar functions, a hierarchy of the two factors was observed. Whereas Chordin is required and 
sufficient for dorso-anterior development, Noggin is dispensable and a loss can be compensated 
(Kuroda et al, 2004).  
In the ventro-vegetal quadrant of blastula embryos solely maternal VegT and TGF-ß factor 
Vg1 inductive signals are present. Since ß-catenin is not nuclear, the nodal concentration is low and 
endodermal signals are induced. One of the first targets of VegT and Xnr proteins is the gene mixer, 
which then induces endodermal genes like the gata factors and sox17α (Heasman, 2006; Xanthos et 
al, 2001) .  
 
 
 
 
 
 
 
 
1.1.3.3 Phase III: Gastrulation 
At the MBT, cells start to divide asynchronously and some cells become mobile, which is an essential 
feature for the upcoming gastrulation. Cells in the dorsal marginal zone (DMZ) involute into the 
embryo and by this process inductive signals specify the three germ layers. Furthermore, the 
dorso-ventral and antero-posterior body axes are determined (Newport & Kirschner, 1982a). With 
the beginning of gastrulation, bmp4 is ventrally expressed and induces genes like vent1 and vent2 
(Heasman, 2006; Onichtchouk et al, 1998). The vent genes are important for keeping the identity of 
ventral mesoderm. In ventral marginal zone (VMZ) antisense knockdown studies it was shown that a 
loss of Vent function induces muscle containing secondary body axes, indicating dorsalization of 
ventral mesoderm. (Onichtchouk et al, 1998). Simultaneously on the dorsal side, cells that belong to 
Figure 1.3: Scheme of inductive signals in 
the blastula. At Mid-blastula the 
Nieuwkoop center forms in dorso-vegetal 
compartments, when vegetal VegT 
expression overlaps with dorsalizing nuclear 
ß-catenin stabilization. The BCNE forms in 
the dorso-animal part in which mainly 
maternal ß-catenin is active. In late-blastula 
embryos the nodal factors specify the 
overlying cells as mesoderm (adapted from 
(Robertis & Kuroda, 2004). 
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the Nieuwkoop center initiate the involution process and form the Spemann organizer. These 
organizer cells secrete BMP, Nodal-like and Wnt inhibitors in order to counteract ventralizing 
signaling. Noteworthy, many of the secreted proteins are already present at blastula stage, like 
Chordin, Noggin (De Robertis et al, 2000). Both, dorsal and ventral factors, spread into the equatorial 
zones and thereby refine the gradients to balance fate determination in the embryo (De Robertis et 
al, 2000; Lee et al, 2006). This basal principal of antagonistic signals is further refined by feedback 
mechanisms. For example Sizzled has an important function in DV-patterning. It is under 
transcriptional control of BMP-signaling and is expressed on the ventral side. It was shown that 
Sizzled protein acts as a proteolytic inhibitor of Xolloid-related, a metalloproteinase, which is 
expressed ventrally and clips Chordin protein, resulting in a release of the bound BMP protein. The 
inhibitory effect of Sizzled against Xolloid-related then leads to stabilization of Chordin protein on the 
ventral side and therefore to a negative feedback loop of BMP-signaling (Lee et al, 2006). Such a 
mechanism indicates that DV-tissue can only form if both counteracting signals are present and 
interact with each other. 
 
 
Figure 1.4: Schematic illustration of all movements and signaling centers during gastrulation. A shows a 
scheme of an early gastrula embryo with the organizer territory and specified germ layers. B shows an 
overview of cellular movement during gastrulation and neurulation. The Organizer involutes into the embryo 
and specifies head and CNS structures into the overlying ectoderm. Cells arising from the BCNE do not involute 
and form the neural plate and CNS during neurulation. In the tailbud scheme the final body plan is set and 
organogenesis starts. CNS, central nervous system (Modified from (De Robertis et al, 2000).  
 
During gastrulation, the antero-posterior axis (AP-axis) is established. As mentioned above, cells of 
the Nieuwkoop center are the first ones that involute. This migration is guided by proteins such as 
Fibronectin (Rozario et al, 2009). The first involuting cells, defined as prechordal mesoderm, will 
become the most anterior part of the embryo while still secreting BMP-, Wnt- and Nodal- inhibitors. 
The secreted proteins spread into the overlying ectoderm and induce head structures (Durston et al, 
2010). They are followed by the prospective chordamesoderm, which undergoes convergent 
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extension movements while migrating (Heasman, 2006; Ninomiya et al, 2004). This leads to an 
elongation of the embryo along the antero-posterior axis. Furthermore, the lateral non-organizer 
mesoderm establishes the transient expression of the Hox cluster genes, which then become 
stabilized by the organizer mesoderm cells. The refinement of the Hox gene expression continues 
through the neurulation process until the AP-axis is set (Durston et al, 2010).  
 
1.2 Chromatin dynamics 
Chromatin is defined as the association between DNA and its binding proteins. It has the ability of 
constantly rearranging, which is the key feature for cell survival and differentiation. Every cell 
contains the same DNA amount, the same genomic sequence. However during DNA-replication, 
mitosis and differentiation, specific genomic loci have to be opened, silenced, enhanced or 
repressed. These different needs results in unique chromatin states for each cell subtype. The 
regulation above the genetic level is named “Epigenetics”. One definition of Epigenetics was 
formulated in 1994: ”Nuclear inheritance which is not based on differences in DNA sequence” 
(Holliday, 1994).  
 
1.2.1 Chromatin structure 
Nucleosomes are the repeating unit of chromatin and consist of an histone octamer with ~ 147 bp of 
DNA wrapped around it (Luger et al, 1997). The histone octamer consists of four dimers of H2A, H2B, 
H3 and H4. Nucleosome assembly starts with the deposition of an H3-H4 tetramer onto the DNA 
followed by the H2A-H2B tetramer. Histones are composed of a globular domain, which lies in the 
core of the nucleosome. Besides the globular domain, histones also carry flexible N-terminal histone 
tails, which protrude from the nucleosome and are favorable targets of post-translational 
modifications (PTM) (Allis et al, 2007). This highly organized composition ensures a multitude of 
protein-protein interactions, which regulate the octamer stability. Several electrostatic and hydrogen 
bonds additionally strengthen the connections within the octamer but also the connection to the 
DNA. (Luger et al, 2012). The DNA between adjacent nucleosomes is called “linker DNA”, and makes 
chromatin more flexible. Accordingly, chromatin forms nucleosomal arrays and short-range 
interconnection between the nucleosomes, which results in so called “fibers” (see Figure 1.5). It is 
thought that the chromatin fibers are organized in further “secondary” structures. One example is 
the 30 nm fiber, which was postulated as the chromatin structure, in which chromosomes are 
compacted in mitotic cells. However, some studies could not support this hypothesis in vivo (Nishino 
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et al, 2012; Robinson et al, 2006). Besides the highly controversial predictions of the chromatin 
organization there are aspects of common agreement. Firstly, the composition of the histone 
octamer affects the overall stability of the nucleosome and thereby also the overlying chromatin 
organization. For all histones, isoforms are known which contribute to the nucleosomal composition 
and change the nucleosomal stability. Secondly, the modified N-terminal tails of histones play a 
crucial role in chromatin organization. Thirdly, incorporation of linker histone H1 leads to a higher 
compacted and dense chromatin fiber. Fourthly, higher ordered chromatin is dynamic and 
interconnected with its environment, e.g. the nuclear envelope and lamina (Allis et al, 2007; 
Dambacher et al, 2013).  
 
Figure 1.5: Chromatin dynamics and higher order structure. DNA is wrapped around nucleosomes and the 
linker DNA connects the nuclesomal subunits. This evenly spaced nucleosomal array displays a 10 nm fiber, like 
beads on a string. The fibers can interconnect and thereby create a more compacted chromatin structure, 
often referred to 30 nm fiber. To keep the architectural integrity chromatin structural proteins like Histone H1 
(here: architectural proteins) have to be incorporated. A higher order structure of chromatin is necessary in 
order to organize and compact the DNA. Histone variants and histone modifications help to form, organize and 
change chromatin structure (modified after (Luger et al, 2012)). 
 
A long-standing agreement was the division of chromatin in euchromatin and heterochromatin. 
Euchromatin is characterized by permissive, open, decondensed chromatin, which is highly accessible 
for transcription factors and RNA polymerases. Heterochromatin, in contrast, is defined as a highly 
condensed, repressive, closed chromatin structure, which is associated with repressed genes and 
pericentric or telomeric chromosomal regions. Interestingly, several recent studies have suggested 
that the accessibility of heterochromatin for DNA-binding-proteins, like transcription factors, does 
not differ significantly (Chen & Widom, 2005; Filion et al, 2010). However, some chromatin 
conformation and post-translational modification are clearly associated with either permissive, open 
chromatin or condensed, repressive chromatin.  
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As embryogenesis proceeds, it is obvious that chromatin rearranges throughout the 
development. Pluripotent genes get restricted and tissue specific gene expression is stabilized. A 
study performed in Xenopus showed, that repressive histone marks increase during development in 
contrast to active histone modification which show a peak of enrichment before the onset of 
gastrulation (Schneider et al, 2011). In accordance to this, Heterochromatin Protein 1 stabilization on 
DNA is strengthened over differentiation (Meshorer et al, 2006). Additionally, DNA-dense regions, 
indicating a condensed state of chromatin, accumulate in differentiating cells (Xie et al, 2013; Zhu et 
al, 2013). Thus, the overall agreement is that ES cells are very permissive and display hyperdynamic 
plasticity. But during differentiation this plasticity is restricted, resulting in distinct cell type with a 
distinct gene expression profile. In 2011, the group around Bas van Steensel used genome-wide 
DamID mapping in Drosophila Kc167 cells and classified five different chromatin types, defined by the 
presence of distinct proteins and/ or histone modifications (Filion et al, 2010; van Steensel, 2011).  
 
1.2.2 Posttranslational modifications 
The flexible histone tails that protrude from nucleosomes are, as mentioned above, a favored target 
for posttranslational modifications, which affect chromatin dynamics, structure and gene expression. 
A large set of chromatin-modifying enzymes were discovered over the last decade. The combinatorial 
possibilities of various histone modification paired with enrichments of distinct modifications at 
particular loci have led to the proposition of the “histone code” (Jenuwein & Allis, 2001). This code 
should give information about chromatin features depending on their marks and the binding of 
chromatin-modifying enzymes.  
One of the best studied histone modification is methylation. Two amino acids can be 
methylated: arginine and lysine. Protein arginine methltransferases (PRMTs) methylate the two 
amino groups in the side chain of an arginin. This is possible either in a symmetric way: one CH3 on 
each nitrogen atom, or in an asymmetrical way: two CH3 on one nitrogen (Bedford & Clarke, 2009). In 
2010, a distinct function for Prmt2 during Xenopus development was revealed. In preMBT embryos, 
maternal ß-catenin recruits Prmt2 to specific loci of dorsalizing genes and marks the promoter region 
with asymmetrical H3R8me2. This mark was sufficient to establish the dorsalizing program in vivo 
(Blythe et al, 2010). 
Besides arginine, also lysine residues can be methylated. Up to three methyl groups can be 
attached to the lysine side chain amino group. Some methyltransferases are very specific for one 
particular reaction. One example is PrSet7, which sets the monomethylation on H4K20, whereas the 
Suv4-20 proteins catalyze the conversion of monomethyl to the di- or tri methylated state (Pannetier 
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et al, 2008; Schotta et al, 2004). Presumably, the best studied methylation marks are on lysine 4 and 
27 of histone H3. The marks are thought to be mostly counteracting, as promoters of actively 
transcribed genes are decorated with H3K4me3 and silenced genes are marked with H3K27me3 (Cao 
& Zhang, 2004; Guenther et al, 2007; Schuettengruber et al, 2009). Notably, one exception to this 
rule can be found in ES cells. In this special cell state particular genes are decorated with both marks, 
referred to as bivalent state (Azuara et al, 2006). 
 
 
Figure 1.6: Posttranslational modifications on histone N-tails. Shown are the N-terminal histone tails of the 
four core histones, H2A, H2B, H3 and H4 and the various modifications, which can be found on specific 
positions. A histone tail can be decorated with several modifications simultaneously. ph, phosphorylation; ac, 
acetlyation; ub1, ubiquitinilaytion; me, methylation (Bhaumik et al, 2007). 
Another important histone modification is the acetlyation of lysine residues. Specific histone 
acetylases catalyze the transfer of an acetyl group on to the amine group in the lysine side chain. A 
hallmark for open chromatin and active transcription is the acetlyation of H4K16. Also, this 
modification is reversible and histone deacetlyases (HDAC) specifically remove the acetyl group. 
Other histone modification, which were shown to contribute to the network of the “histone 
code” are phosphorylation, ubiquitination, sumoylation, adenylation and biotinylation. 
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1.2.3 Chromatin remodeling complexes 
Besides the chromatin modifying enzymes that write, read or erase histone modifications, chromatin 
remodeling complexes display another class of chromatin modifying enzymes. These multi-protein 
complexes rearrange nucleosomes by using the energy of ATP-hydrolysis. In doing so, they alter 
histone-DNA contacts and move nucleosomes along the DNA, evict or exchange nucleosomes or 
histones (Becker & Horz, 2002; de la Serna et al, 2006; Hargreaves & Crabtree, 2011). Three different 
subclasses of chromatin remodeling complexes are described, depending on their ATPase subunit: 
SWI/SNF, ISWI and CHD. Common to all ATPase subunits is the origin of superfamily 2 (SF2) DNA 
helicases (Mueller-Planitz et al, 2013a). 
The remodeling SWI/SNF family is characterized by the presence of a bromodomain 
containing ATPase subunit. The bromodomain mediates binding to acetylated histones (Hassan et al, 
2002). The ATPase subunits are highly conserved through evolution and can be found from yeast 
(Swi2/Snf2), over Drosophila (Brahma) to man (Brahma/SMARCA2 and Brg1/SMARCA4) (Hargreaves 
& Crabtree, 2011). Besides the catalytic subunit, the mammalian SWI/SNF complex consists of 
several “Brahma-associated factors”, the BAF proteins. Some of the BAF proteins, like 
Baf250/ARID1A and BAF155/SMACD1, are always present in the complex. Other BAF proteins, like 
BAF60/SMARCD or BAF53, contribute to complex formation in a tissue or cell signal specific fashion 
(Lessard & Crabtree, 2010; Simone, 2006; Yoo & Crabtree, 2009). Additionally, tissue- or 
signal-specific binding partners are known which also contribute to complex composition. Initially, 
Brahma was identified and isolated in a screen for dominant suppressors of Polycomb mutations 
(Tamkun et al, 1992). Similar to the findings in yeast, this suggests a role as transcriptional activator 
(Laurent et al, 1991). Meanwhile several studies have shown that the mammalian SWI/SNF complex 
is present in both, gene activation and repression, depending on the tissue and gene (Murphy et al, 
1999; Wang et al, 2010). Besides a crucial function in development, which is described in detail in 
chapter 1.3 below, the SWI/SNF complex is also required for cell cycle progression. Mutations in Brg1 
alleles were broadly characterized in malignant tumor tissue, indicating a role for SWI/SNF complex 
in cell cycle check points (Wong et al, 2000).  
 The second big chromatin remodeling family is characterized by the ATPase “Imitation SWI”, 
ISWI. ISWI is defined by a C-terminal HAND-SANT-SLIDE (HSS) domain. However, recently it has been 
shown that the ATPase domain of ISWI exclusively is involved in its chromatin remodeling activity 
(Mueller-Planitz et al, 2013b). As for Brahma and Brg1, various complexes are described in which 
only ISWI is incorporated. For example in Drosophila, three different complexes are described. The 
ACF and CHRAC complexes contain, aside from ISWI, the bromodomain containing protein Acf1. The 
NuRF complex is characterized by the NURF31 subunit, which mediates interaction with nuclear 
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hormone receptors and increases nuclesomal sliding activity of the complex. Also for ISWI containing 
complexes, numerous functions within the cell or during differentiation were described (Becker & 
Horz, 2002; Hargreaves & Crabtree, 2011).  
 The third class of ATPase remodelers is the CHD family. These ATPase enzymes are 
characterized by two N-terminal chromodomains. Several CHD ATPase enzymes were classified and 
depending on functionality further subdivided. The NuRD complex, a well studied complex containing 
CHD3/Mi-2α or CHD4/Mi-2β, was shown to bind histone deactelyases HDAC1/2, suggesting that 
NuRD represses transcription by removing acetlyation marks from histones (Hargreaves & Crabtree, 
2011). For Chd7, a direct interconnection with Brg1 in neural crest formation was described in 
Xenopus and humans (Bajpai et al, 2010).  
 
1.3 The SWI/SNF complex in development 
In Drosophila, the SWI/SNF ATPase Brahma was described as a positive regulator of homeotic genes, 
which counteracts their repression by Polycomb group genes (Tamkun et al, 1992). Flies deficient for 
Brahma function, die as unhatched larvae and both maternal as well as zygotic Brahma is required 
for Drosophila embryogenesis (Brizuela et al, 1994; Tamkun et al, 1992). In mammals, a second 
ATPase subunit of the SWI/SNF complex evolved, namely Brahma related gene 1 (Brg1). Notably, the 
two ATPase subunits are mutually exclusive and display different functions during development. 
Mice deficient for Brahma, develop normal but adult mice were 15% heavier than control siblings, 
which is explained with an increase of cell proliferation (Reyes et al, 1998). In contrast to the mild 
phenotype of Brm-/-, a loss of Brg1 causes early embryonic lethality during implantation. Noteworthy, 
Brg1 heterozygotes survive but are predisposed to exencephaly and tumors (Bultman et al, 2000). 
This striking difference between Brahma and Brg1 is also displayed on the transciptional level. The 
gene expression of both ATPase subunits were monitored during mouse development and brg1 
expression is clearly more abundant than brahma gene expression (Bultman et al, 2000). Oocytes 
depleted for Brg1 complete meiosis, but exhibit a developmental arrest at the 2 cell stage. At this 
stage of mouse development the zygotic genome activation takes place. One third of α-amanitin 
sensitive genes showed a reduction in gene expression, which indicates a requirement of Brg1 during 
the onset of zygotic transcripts (Bultman et al, 2006). Since Brg1-deficient primary mouse embryonic 
fibroblasts (PMEFs) proliferate normally, Brg1 containing SWI/SNF chromatin remodeling complexes 
are essential for embryogenesis, but not for cell vitality (Bultman et al, 2000). Further proof for the 
requirement of Brg1 in ZGA comes from the fact that mouse wild type zygotes depleted for brg1 by 
RNAi, also arrest at the 2 or 4 cell stage (Bultman et al, 2006).  
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 Little is known whether Brg1 is required during Xenopus development. One study suggested 
that it is necessary during neurogenesis. Kirsten Kroll’s laboratory investigated the expression pattern 
of Brg1 and stated an excess of brg1 transcripts in neural tissue. By knocking down Brg1 protein level 
with a translation-blocking antisense morpholino oligonucleotide, they showed that Brg1 is crucial 
for progression of neuronal cell differentiation. Neural tissue, positive for neural progenitor sox2, 
was expanded from midneurula stage 15 on, whereas terminally differentiated neural marker 
n-tubulin was diminished. Furthermore, Brg1 morphant embryos display truncated anterior 
structures and reduced eye size (Seo et al, 2005). These defects correlate well with the apparent 
exencephalic phenotype seen in heterozygote mice. Another study dealing with Brg1 function during 
Xenopus development was performed by a former PhD student in our lab, Nishant Singhal. The 
morphological phenotype he generated with a different morpholino oligonucleotide also displayed 
dorso-anterior defects. In addition, he could observe an earlier requirement for Brg1 than 
neurogenesis. The discrepancy between the two studies in Xenopus and the differences of Brg1 
function between the species is still unraveled and needs further detailed investigation. 
 Primarily, the research of SWI/SNF during development focused on Brg1. However, over the 
recent years the interest in the associated BAF increased. The protein Baf60 is a very good example. 
Three isoforms are characterized, named Baf60 a-c. Baf60a was shown to be part of various SWI/SNF 
complexes. In mouse ES cells Baf60a is incorporated in the so called esBAF complex. This complex 
was shown to be important for ES-cell renewal and pluripotency (Ho et al, 2009). Furthermore, 
Baf60a was described in the nBAF complex, which is present in postmitotic neurons (Yoo & Crabtree, 
2009). The Baf60c isoform in contrast contributes to the SWI/SNF complex present in heart and 
skeletal muscle differentiation. Mice deficient for Baf60c show malformations in both muscle tissues 
and insufficient expansion of the anterior, secondary heart field. This study revealed that Baf60c 
mediates the physical interconnection between cardiac transcription factors and SWI/SNF chromatin 
remodeling ATPase Brg1 (Lickert et al, 2004). Recently, a detailed study about the mechanism of this 
interconnection was published. In proliferating mouse myoblasts, direct binding of Baf60c to MyoD 
on myogenic gene loci was observed. During differentiation a kinase is activated, which 
phosphorylates Baf60c and thereby induces the recruitment of Brg1-containing SWI/SNF remodeling 
complex supporting the activation of the myogenic loci (Forcales et al, 2012). 
 These examples define Brg1 as a transcriptional coregulator. The interplay with ß-catenin is 
probably one of the most interesting ones, as there are various roles and requirement for ß-catenin 
signaling during embryogenesis. A physical and genetic interaction of ß-catenin and Brg1 was firstly 
described in HEK293T cells and within this study it was suggested that Brg1 and ß-catenin interact in 
order to positively regulate Tcf-responsive reporter genes (Barker et al, 2001). Besides this, a role for 
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Brg1 was also suggested in TGF-ß signaling, as Brg1 interacts with Smad2 and Smad3 (Xi et al, 2008). 
Furthermore, a dual role of Brg1 in Sonic hedgehog signaling was shown (Zhan et al, 2011). With an 
involvement in such various cell signaling pathways, it is not surprising that Brg1 plays multiple roles 
in differentiation. Additional functions of Brg1 were described during ES-cell renewal, 
reprogramming and cancerogenesis (Bultman et al, 2000; Ho et al, 2009; Singhal et al, 2014; Singhal 
et al, 2010). Together, this data underlines Brg1 as a multifaceted regulator within development, 
differentiation and chromatin dynamics.  
 
1.4 Objectives 
The focus of this thesis is to clarify the functional role of Brg1 during early development in Xenopus. 
Unpublished data from Nishant Singhal, a former lab member, had suggested a functional link 
between Brg1 and canonical Wnt signaling, but had not provided conclusive evidence for this 
hypothesis. Therefore, the following goals were set in order to approach detailed informations:  
• Characterize the morphological and molecular consequences of ubiquitous and region-specific 
perturbation of Brg1 activity by gain- and loss-of-function approaches in vivo 
• Distinguish autonomous functions from paracrine functions of Brg1 
• Determine the Brg1-dependent transcriptome 
Ideally, the results from these approaches should allow to formulate a unifying hypothesis, which 
describes accurately the developmental regulatory impact of Brg1 in a vertebrate model organism. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Animals 
In this work pigmented African claw frog Xenopus laevis and Xenopus tropicalis were used. Frogs 
were purchased from Nasco (Ft, Atkinson, USA). Frog husbandry was performed after the guidelines 
of the Deutsches Tierschutzgesetzt. The developmental stages were defined after P.D. Nieuwkoop 
and J. Faber (Nieuwkoop & Faber, 1994) 
 
2.1.2 Bacteria 
For DNA cloning and plasmid preparation DH5α E.coli from NEB were used. 
DH5α 
F´proA+B+ lacIqΔ(lacZ)M15 zzf::Tn10 (TetR) / fhuA2Δ (argF-lacZ)U169 phoA 
glnV44 f80 D(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17 
NEB 
 
2.1.3 Enzymes 
The following enzymes were used: 
enzyme company 
Advantage®2 Polymerase Mix BD Biosciences 
Alexa Fluor® 488, 594 Invitrogen 
Alkaline phosphatase Roche 
BSA fraction V Roth 
Dig-NTPs Roche 
DTT Promega 
G (5’)pppGcap analog NEB 
NTP-mix Roche 
Restriction endonucleases NEB 
RNase A Sigma-Aldrich 
RNAsin Promega 
Transcription buffer 5x Promega 
T3, T7, Sp6 RNA polymerase Promega 
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enzyme company 
Proteinase K Sigma-Aldrich 
RNAse-free DNAse I Promega 
PeqGOLD protein marker V Peqlab 
Taq DNA polymerase NEB 
  
2.1.4 Chemicals 
The chemicals used on a regular basis for solutions and buffers are ordered from Fluka, Merck, Sigma 
or USB.  
Special chemicals are listed in the following table. 
chemical company 
Agarose Gibco/BRL 
Ampicillin Difco 
ß-glycerol phosphate 
Sigma-
Aldrich 
5-Bromo-4-Chloro-3-indoyl-
phosphate, BCIP 
Biomol 
Calf serum Gibco/BRL 
Gentamycin 
PAA labor. 
GmbH 
Glycogen Fermentas 
Human choriongonadotropin, 
Gonasi 500 
ISBA, 
Farmac. 
 
chemical company 
Lamb Serum Gibco/BRL 
Levamisol Vectro Lab 
Nitro blue tetrazolium, NBT Biomol 
Phenylmethanesulfonylfluoride, 
PMSF 
Sigma-
Aldrich 
Sodium orthovanadate 
Sigma-
Aldrich 
Sodiumfluorid 
Sigma-
Aldrich 
TRIzol® Reagent Ambion 
Xgal Roth 
2.1.5 Antibodies 
The following antibodies were used in this thesis for the respective methods: 
 dilution method company 
primary antibodies    
rat α-Brg1, monoclonal 1:3 Western Blot Dr. Elisabeth Kremmer 
mouse α-alpha tubulin, monoclonal 1:8000 Western Blot Sigma 
rabbit α-ACTIVE®Caspase3 pAB, polyclonal 1:20000 ICC Promega 
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 dilution method company 
secondary antibodies    
goat α-mouse 700 1:10000 Western Blot Biomol 
donky α-rat IR800CW 1:10000 Western Blot Biomol 
α-rabbit IgG AP-Conjugate 1:1000 ICC Promega 
sheep α-Digoxigenin-AP  Fab fragment 1:2000 WMISH Roche 
 
2.1.6 Oligonucleotides 
2.1.6.1 Oligonucleotides for cloning 
Oligonucleotides (primers) for cloning were designed and purchased from Sigma-Aldrich: 
plasmid  vector 5’-sequence-3’ 
XhoI_Luciferase for 
pCS2+
GW 
-CA CTCGAG_GAAGACGCCAAAAACATAAA- 
Luciferase_XbaI rev 
pCS2+
GW 
-CG TCTAGA_CACGGCGATCTTTCC- 
attB1_BISH for 
pCS2+
GW 
-GGGACAAGTTTGTACAAAAAAGCAGGCTTAACT_ 
GATAGTTGGTGGAAAACGTCAGAAGGA- 
BISH_attB2 rev 
pCS2+
GW 
-GGGGACCACTTTGTACAAGAAAGCTGGGTC_ 
TCCCATCATGCTATGTGCGG- 
ClaI-Siamois for pCS2+ -CAG ATCGAT_ATGACCTATGAGGCTGAAATGG- 
Siamois_XhoI rev pCS2+ -CAG CTCGAG_TCAGTTTGGGTAGGGC- 
ClaI_chordin for pCS2+ -CA ATCGAT_ATGCAGTGTCCCC- 
Chordin_XhoI rev pCS2+ -CA CTCGAG_CTAAAAACTCCATGGA- 
 
2.1.6.2 Oligonucleotides for quantitative RT-PCR 
The following primers were designed using the online software Primer3 
(http://biotools.umassmed.edu/bioapps/primer3_www.cgi), purchased from Sigma-Aldrich and 
quantitative RT-PCR was performed with the Roche Light Cycler 480 System. The following primer 
sequences target X. laevis gene sequences: 
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gene  5’-sequence-3’ 
foxa4 for -GGAAACAAGCCAGGAGATGA- 
foxa4 rev -GAGTCCCTACCCCCATCATT- 
gs17 for -CTGGGGCTTGAGTCCTACAG- 
gs17 rev -AGCTTCCTGGCTGGTGATTA- 
gsc for -GCTGGCAAGGAGAGTTCATC- 
gsc rev -TTCCACTTTTGGGCATTTTC- 
h4 for -GACCGCGGTCACCTACACC- 
h4 rev -CTGGCGCTTCAGAACATACA- 
siamois for -GAGCCTCAGGTCAGCAAAAC- 
siamois rev -GGTACTGGTGGCTGGAGAAA- 
xnr3 for -AAGGTGAATGGATTTCGGAGACT- 
xnr3 rev -GCTGCCCCATCCGATCT- 
xnr5 for -GCTGCACCGCTACCTCTATC- 
xnr5 rev -TCAGCTAGGAGACCATTGCAT- 
xnr6 for -GGGAATGCTACAGACCTTTCAGT- 
xnr6 rev -ACATGTCAAAAGATAATGCCCAG- 
 
Quantitative RT-PCR primers targeting X. tropicalis gene sequences: 
gene  5’-sequence-3’ 
bmp4 for -AGCCCAGTAAGGATGTGGTG- 
bmp4 rev -GGTCTCTCCGGGTACTCCAT- 
cerberus for -TCCATGTTCCAAATCAGCAA- 
cerberus rev -AATTCAGTGCCAGGTGGTTC- 
chordin for -TCTGCTATACAGCGGCCTTT- 
chordin rev -TACCCAGACCAGTCACCACA- 
crbp for -CTGGCAAGTCCTCCAATGATA- 
crbp rev -CTCTGTCTCCACCACCACCT- 
crx for -CCCACGGAAACAAAGAAGAG- 
crx rev -TTTAGCAAAGAGGGCTTCCA- 
egr1 for -CTCTCACACCCCTGTCTACCA- 
egr1 rev -CATTCTGCTTGGCTTGATGA- 
follistatin for -TACCCAACAGCACCCTCTTC- 
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follistatin rev -GGGCCACAGTCTACGTTCTC- 
foxc1 for -GACCCGGACTCGTACAACAT- 
foxc1 rev -CTTTCAGGAGCCGATCTTTG- 
foxd3 for -CCCAGGCAAGGGAAACTACT- 
foxd3 rev -AATGAGTCCGGCTGTTGTCT- 
foxd4l1 for -ACCATGCCAACTCACCTTTC- 
foxd4l1 rev -TTATCAGCATCCAGGGCTTC- 
foxi1 for -TCCTCAGCGACCTTCAAACT- 
foxi1 rev -CATGAAATGGCTTGTGTTGG- 
foxi4.2 for -CTCCTACTCTGCCCTCATCG- 
foxi4.2 rev -AGCCTGCTTTGCTCTTTTTG- 
gapdh for -ACCCAGAAGACTGTGGATGG- 
gapdh rev -GTTGAGGCAGGGATGATGTT- 
gata4 for -ACGAAAGCGCAAACCTAAGA- 
gata4 rev -GAGCTGGTGGAAGGAGTGAG- 
gata6 for -GCTCGGCTACGATCACTCTC- 
gata6 rev -GGAGCCAACTCTGCTAGTGG- 
gs17 for -AGGGGGCATAAAGAGTGGTC- 
gs17 rev -CGAGGAGCAAACTGTGGAGT- 
hes4 for -AAGTCACCCGATTCCTCTCC- 
hes4 rev -GGGTTGCTGGTAATTCATGG- 
jhdm1 for -TTAAAGCATGGGGTGAAAGC- 
jhdm1 rev -GAGATGCCCAGGTCTGATGT- 
kiaa1279 for -GGCTGCAAAAGAGAATGAGG- 
kiaa1279 rev -TTTTACCCAACATCGTGCAA- 
Irx2 for -AATCACCAACAGGACGGAAG- 
Irx2 rev -GATCCGAGGTGGCTATTTCA- 
meis3 for -TTATGGGCACCCTCTGTTTC- 
meis3 rev -TGGGAATGACCCTGAATTGT- 
noggin for -CGGAGGAGAGACTTGGAGTG- 
noggin rev -CTGTGCTTTTTGCCCTGAA- 
nr6a1 for -CAGAAAGCAATCAGCCTTCC- 
nr6a1 rev -AGTGAGCCGAATCCATTGAG- 
odc for -CCCTGGTTCAGAGGACGTTA- 
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odc rev -AGTATCTCCCAGGCTCAGCA- 
otx2 for -CAGCACCTCAGTTCCAGTCA- 
otx2 rev -TCATGGGGTAAGACCTCTGC- 
prdm1 for -TGTCATAAGCGGTTCAGCAG- 
prdm1 rev -TGCACTGGTAGGGCTTCTCT- 
siamois for -GAACGGAGGGAATGTAAGAGG- 
siamois rev -TCTGAAGGAAGTGGGTTTGC- 
sizzled for -CCTGATGGGACACACTAGCA- 
sizzled rev -CCGGTCTGTAGGAGGTTCTG- 
sox1 for -AGAACCCCAAGATGCACAAC- 
sox1 rev -GCCTCCGACATAACTTTCCA- 
sox2 for -AGATGGCTCAGGAGAACCC- 
sox2 rev -TCGTCGATGAATGGTCTTTTC- 
sox11 for -CAAGAAATGCCCCAAGCTAA- 
sox11 rev -GGACTTGATGGTGAGCGACT- 
sox21 for -GAGGAAGCCCAAGACCCTAC- 
sox21 rev -CCATGTAACCCAGCAACCTT- 
tgif for -CTCGCCCTTCTGTGATCTGT- 
tgif rev -TAAGTTGCTCGCTTCGGTCT- 
twin for -ACACAGCACTGACCCTACAAGA- 
twin rev -GATCAGGAATCAGGCCAAAA- 
xnr3 for -ACGTATTTGCCTCCCTTCCT- 
xnr3 rev -TCCTTTGTGTCCTTGGTATGG- 
xnr5 for -TCAGGCTCCTCATGGAAAGT- 
xnr5 rev -TGCTTGTGAAGTTGCCTTTG- 
xnr6 for -AAACCGTCTGCCAATCTGAC- 
xnr6 rev -TGGTTCCTTCCTCGATCTTG- 
zic1 for -GACACTACGGGCCACTTGAT- 
zic1 rev -AGCCTCATCTGTCCGTTCAC- 
zic2 for -TACTTTTCCCCGGCATACAC- 
zic2 rev -TCCGTCCTACCGAACATCTC- 
zic3 for -TGAACCGTCCTCAGAAAACC- 
zic3 rev -GGACATTCCTCCCAGTAGCA- 
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2.1.6.3 Morpholino oligonucleotide 
Three different morpholino oliogonucleotides were tested for inhibiting Xenopus Brg1 mRNA 
translation. BMO1 and BMO2 target both Xenopus laevis and Xenopus tropicalis Brg1 gene 
sequences. BMO3 binds only the Xenopus laevis Brg1 gene sequence. The Control morpholino is 
directed against the human ß-globin mRNA. All morpholinos were purchased via GeneTools, LLC, 
USA. 
morpholino 5’-sequence-3’ 
BMO1 -CCATTGGAGGGTCTGGGGTGGACAT- 
BMO2   -GACATCACTGCAGGGAGAAGATCCA- 
BMO3 -CAGGGAGAAGATCCAGTCACTGCTA- 
CoMO -CCTCTTACCTCAGTTACAATTTATA- 
 
2.1.7 Plasmids 
2.1.7.1 Synthetic mRNA templates 
For microinjections, in vitro transcription of the following plasmids was performed: 
plasmid linearization polymerase 
xBrg1 WT NotI SP6 
hBrg1 WT HpaI SP6 
Chordin XbaI SP6 
Siamois NotI SP6 
Wnt8 NotI SP6 
Xnr5 XbaI T7 
Activin SmaI SP6 
Nuclear lacZ NotI SP6 
BISH_luciferase NotI SP6 
 
2.1.7.2 Synthetic RNA in situ probes 
The following plasmids were used for in vitro transcription to generate dig-labeled antisense RNA for 
in situ RNA hybridization: 
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plasmid linearization polymerase 
Cerberus BamHI T7 
Chordin EcoRI T7 
Foxa4 EcoRI T7 
foxD5 XbaI T7 
Goosecoid EcoRI T7 
Hhex NotI T7 
Hoxb9 BamHI T7 
Krox20 EcoRI T7 
Myf5 BamHI T7 
MyoD EcoRI T7 
Noggin EcoRI T7 
Otx2 EcoRI T3 
Siamois HindIII T7 
Vent1 SalI T7 
Vent2 BamHI T7 
Xbra HindIII T7 
Xnr3 EcoRI T7 
Xnr5 NotI T7 
 
2.1.8 Equipment 
 
product company 
Centrifuge 5417C Eppendorf 
G:BOX Syngene 
Glass 1BBL W/FIL 1.0 mm WPI 
Leica DFC 310FX Leica 
Li-Cor Odyseey 
Light Cycler 480 System Roche 
Microneedle puller P-87 
Sutter 
Instrument 
Micromanipulator Mm-33 
Science 
Products 
product company 
Minitherm 2  Dinkelberg 
Nanodrop ND-1000 PeqLab 
PCR Express Hybaid 
Stereomicroscope Stemi SV6 Zeiss 
Stereo-fluorescence System 
M205FA 
Leica 
Optical microscope DM Leica 
Microinjector Pli-100 
Digitimer 
Ltd. 
Lumat LB9501 Berthold 
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2.1.9 Software 
 
product company 
CLC Sequence Viewer 6 CLCbio 
Endnote X7 Thomson 
Gene Snap Image Acquisition 
Software 
Syngene 
Illustrator CS5 Adobe 
ImageJ 
Wayne 
Rasband 
product company 
Leica Application Suite V3 
3.0 
Leica 
Light Cycler 480 Software 
Release 1.5.0 SP1 
Roche 
Photoshop CS5 Adobe 
Odysee Application Software 
Version 3.0 
Odyseey 
 
 
2.2 Methods 
2.2.1 DNA standard methods 
2.2.1.1 Gel electrophoresis 
To visualize nucleic acid fragments with different sizes agarose gel electrophoresis was performed. 
Therefore 0.6 g agarose was dissolved in 60 ml 1x TBE buffer, resulting in a 1% agarose solution. To 
the DNA containing samples 6x Gel loading dye (NEB) was added and loaded onto the gel. After 
running and separating the fragments, the result was documented using the Gel documentation 
System G:BOX. 
stock solution: 
10x TBE pH 8,6 
100 mM Tris/HCL  
83mM borate 
0,1 mM EDTA 
 
2.2.1.2 Isolation of DNA fragments from agarose gel 
In order to isolate and extract a particular DNA fragment, a 1% TAE agarose gel was prepared. After 
running the gel, the appropriate DNA fragment was cut out under UV light and DNA was extracted by 
using the QIAquick® Gel extraction Kit (Quiagen) after the  manufacturer’s protocol.  
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stock solution: 
20x TAE 
2 M Tris 
1 M glacial acetic acid 
0,05 M EDTA 
 
2.2.1.3 DNA digestion 
For standard cloning procedures and in vitro transcription the above mentioned plasmid templates 
had to be enzymatically digested or linearized. The following protocol was used: 
reagents volume/concentration 
template plasmid 2-10 µg 
10 x buffer 4 µl 
10 x BSA 4 µl 
Enzyme 20/U 3 µl 
H2O add 40 µl 
 
The reaction was incubated for 2 hours at 37°C followed by a clean-up step using the QIAquick® PCR 
purification Kit (Quiagen) after manufacturer’s instruction. 
 
2.2.1.4 Ligation 
For cloning DNA, fragments had to be ligated into the pCS2+ or pCS2+GW vector backbone. The DNA 
fragments and the linearized vector were incubated with 1 µl of 10x T4 Ligation buffer and 1 µl Ligase 
T4 in a total volume of 10 µl. The reaction took place over night at 16°C.  
 
2.2.1.5 Chemical transformation 
For standard cloning procedures 3-5 µl of the plasmid was incubated in 100 µl DH5α bacteria for 30 
min on ice. After a 90 sec heatshock on 42°C, 1 ml LB-Media was added and the reaction was 
incubated on 37°C for 1 hour shaking. After the incubation step the bacteria were centrifuged 2 min 
with 5000 rpm. 1 ml of the supernatant was discarded and the bacteria were resuspended in the left 
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over liquid. 100 µl of the bacteria were plated on a LB/agarose dish with the appropriate antibiotics 
for selection. The plate was incubated over night at 37°C. 
 
2.2.1.6 Plasmid preparation 
To amplify a single clone grown on the LB/agarose plate this particular clone was inoculated in 100 
ml LB-Media with the appropriate antibiotics added and incubated over night shaking at 37°C. The 
next day the plasmid was extracted using the QIAGEN® Plasmid Midi Kit after manufacturer’s 
instructions. 
 
2.2.1.7 Gateway® cloning 
The Gateway® cloning technology was established by the company “life technologies”. The 
technology is based on recombinant events that circumvent the classical cloning technique via 
enzyme digestions and ligation steps. Firstly, the desired fragment has to be amplified in a PCR with 
oligonucleotides that contain distinct recombinant sequences, the attB-sides, flanking the gene 
sequence. The fragment had to be recombined into the “donor-vector”, which contains a cassette 
that has the recombinant complementary sequence. The protocol is the following: 
BP-reaction  
attB-containing PCR fragment 30-150 ng 
donor vector 150 ng 
TE buffer add 4 µl  
BP-clonase II 1 µl 
 
The reaction was incubated 1-2 hours at 25 °C. Afterwards DH5α bacteria get transformed and plated 
onto a LB/zeocin agar plate as the donor vector contains a zeocin resistance. Clones have to be 
inoculated and the “entry clone”, donor vector backbone with desired DNA-fragment, had to be 
extracted via the QUIAGEN® Plasmid Midi Kit after manufacturer’s instruction.  
In another step the desired DNA fragment is recombined from the entry vector into the “destination 
vector”. Therefore the gateway cassette A was introduced into a variant pCS2+ expression vector, 
called pCS2+GW. The following protocol was used to recombine the DNA fragment into the 
pCS2+GW: 
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LR-reaction  
entry clon 150 ng 
destination vector 150 ng 
TE buffer Add 4 µl 
LR-clonase 1 µl 
  
The reaction was incubated 1-2 hours at 25°C, followed by transformation of DH5α cells and plating 
on to a LB/agarose plate with ampicillin. To extract the vector a clone was picked, inoculated and a 
plasmid preparation was performed with the QUIAGEN® Plasmid Midi Kit after the manufacturer’s 
instruction. 
 
2.2.1.8 Polymerase Chain Reaction, PCR 
In this thesis the BD Biosciences Clontech PCR Systems with the Advantage DNA Polymerase was 
used according to manufacturer’s protocol. A typical thermocyclin program was: 
 temperature time cycles 
Denaturation 95°C 2 min 1x 
Denaturation 95°C 45 sec  
Annealing 52-67°C 45 sec 28x 
Elongation 68°C 90 sec- 5 min  
Elongation 68°C 10 min 1x 
Cooling 4°C ∞  
 
* The annealing temperature depends on the GC content of the primers 
** Elongation time depends on the size of the amplified DNA fragment 
 
2.2.1.9 Quantitive Reverse Transcription Polymerase Chain Reaction, qRT-PCR 
A method to quantify the amount of amplified template for each single PCR cycle is the qRT-PCR. This 
method is more precise and more informative than the standard PCR. In this study, all gene 
expression analyses were done via the relative quantitative RT-PCR. As reference genes the 
housekeeping genes H4, ODC and GAPDH were used.  
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The Roche LightCycler® system with 384 well plates was used. A volume of 10 µl/well was prepared 
with the following protocol: 
reagent volume 
cDNA template 2 µl 
Fast SYBR Green Master Mix 5 µl 
For and rev primer (each 3 µM) 1 µl 
H2O 2 µl 
All used oligonucleotides were designed with a common annealing temperature between 59,7°C and 
60,3°C with the Primer3 online software. The thermocyclin program was performed as follows: 
 
 temperature time cycles 
Denaturation 95°C 5 min 1x 
Denaturation 95°C 10 sec  
Annealing 60°C 20 sec 45x 
Elongation 72°C 10 sec  
Melting 
95°C 5 sec  
65-97°C 1 min 1x 
Cooling 40°C 30 sec 1x 
For each condition and every primer pair, technical triplicates were performed and the mean of the 
triplicates was used for further data analysis.  
 
2.2.2 RNA standard methods 
2.2.2.1 In vitro transcription of sense RNA 
For embryonic microinjections, artificial mRNA has to be generated. For this purpose the linearized 
DNA plasmid of the requested construct is used as template. In order to obtain a stable and 
functional mRNA the following protocol was used: 
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reagent volume 
Linearized template 2 µg 
5x transcription buffer 10 µl 
25 mM G (5’)pppGcap analog  5 µl 
100 mM NTPs-mix 10 µl 
100 mM DTT 5 µl 
RNAsin 40U/µl 0,5 µl 
RNA polymerase 2 µl 
RNAse-free H2O Add to 50 µl 
  
The reaction was incubated 2 hours at 37°C then another 1 µl RNA polymerase was added and the 
reaction was incubated at 37°C over night. To remove the template, 2U of DNAse was added 
following another 15 min of incubation at 37°C. Afterwards the RNA was purified with the RNeasy® 
mini kit (Quiagen) after manufacturer’s instruction and stored at -80°C.  
 
2.2.2.2 In vitro transcription of antisense RNA 
For whole-mount in situ hybridization a digoxygenin-labeled complementary antisense RNA was 
generated. Again a linearized DNA plasmid of the requested gene is used as template. The reaction 
protocol is the following: 
reagent volume 
Linearized template 2 µg 
5x transcription buffer 10 µl 
10 mM DIG-NTPs-mix 5 µl 
100 mM DTT 5 µl 
RNAsin 40U/µl 0,5 µl 
RNA polymerase 2 µl 
RNAse-free H2O Add to 50 µl 
 
The reaction was incubated for 2 hours at 37°C. Afterwards another 1 µl of RNA-Polymerase was 
added and the reaction was incubated over night at 37°C. To digest the template, 1 µl of DNAse was 
added, followed by 15 min incubation at 37°C. The dig-labeled in vitro synthesized antisense RNA was 
purified with the RNeasy® mini kit (Quiagen). For stabilization formamide was added in a 1:1 ratio 
and the Dig-labeled RNA was stored at -20°C.  
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2.2.2.3 RNA isolation 
10 X. tropicalis embryos or 10 dissected X. laevis explants were collected, lysed in 300 µl TRIzol, shock 
frozen in liquid N2 and stored at -80°C. After thawing the samples for 5 min at RT, the cell debris was 
separated by a 10 min centrifugation step at 14000 rpm at 4°C. The supernatant was transferred into 
a new low-binding 1.5 ml eppendorf tube, mixed with 60 µl of Chloroform and kept for 2 min at RT. 
The solution was then centrifuged at 14000 rpm at 4°C for 15 min. The upper colourless organic 
phase was transferred to a new low-binding tube and the Chloroform extraction was repeated. After 
transferring the colourless phase to another low-binding tube, 1 µl of a 2 mg/ml Glycogen solution 
was added as a carrier for the precipitated RNA nucleotides. To precipitate the RNA, 150 µl 
Isopropanol was added, mixed for 30 sec and incubated at RT for 10 min. The solution was 
centrifuged again for 10 min at 14000 rpm at 4°C. Now the precipitated RNA accumulates as a pellet. 
The supernatant was discarded and the RNA pellet was washed with 70% Ethanol and successively 
centrifuged for 5 min with 10000 rpm at 4°C. Again the supernatant was discarded. To remove the 
remaining Ethanol the tube was put into a 50°C heating block with open lid. Afterwards the RNA 
pellet was resuspended in 30 µl of RNAse-free water and a clean-up step with the RNeasy® mini kit 
including the DNAse on-column digestion was performed. The isolated RNA was measured using the 
Nanodrop ND-1000 from PeqLab and stored at -80°C.  
 
2.2.2.4 cDNA synthesis 
To analyze distinct gene expression in whole embryos or explants tissue the isolated RNA was 
reversed to complementary DNA. The cDNA was then used as template for quantitative RT-PCR. For 
this purpose the DyNAmo cDNA Synthesis Kit was used after the manufacturer’s instructions.  
 
2.2.2.5 Whole mount RNA in situ hybridization 
To prepare embyros used for whole mount in situ hybridization, they were fixed at the desired stage 
for 2 hours at RT or over night at 4°C in MEMFA and stored at -20°C in 100% Ethanol for at least 2 
hours.  
To rehydrate, embryos were washed 1x in 75% EtOH/PBSw, 50% EtOH/PBSw, 25% EtOH/PBSw and 
3x PBSw, each step 5 min at RT. In order to permeablize the cells and increase the RNA accessibility, 
the embryos were incubated in 10 µg/ml proteinaseK/PBSw for 20 min without agitation followed by 
two washing steps with PBSw. Embryos were refixed afterwards in 4% paraformaldehyd for 20 min 
and washed again 5 times for 5 min in PBSw. For the hybridization step, embryos were equilibrated 3 
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min in 50% hybridization solution/50% PBSw, followed by a 3 min wash in 100% hybridization 
solution. The hybridization solution was refreshed and the embryos were incubated in a waterbath 
for 1 hour at 65°C. In order to prehybridize, embryos were incubated for a minimum of 4 hours in a 
waterbath at 60°C. 3-5 µl of the dig-labeled desired antisense RNA was added to 100 µl of hybridizing 
solution and heated up for 2 min to 95°C. The probe was cooled down and then added to the 
embryos and the hybridization solution. Embryos were incubated with the antisense probe over 
night at 60°C. The next day, the unhybridized antisense RNA probe was removed and stored at -20°C. 
The probes can be reused several times. To wash out the remaining antisense RNA, the embryos 
were washed again for 10 min in fresh hybridizing solution at 60°C followed by three times 2x SSC, 
each step 20 min and twice 0,2x SSC, each for 30 min at 60°C in a waterbath. Afterwards the embryos 
were washed twice in 1x MAB for 15 min at RT and then exchanged with 1x MAB containing 2% BMB 
Blocking solution for 1 hour in order to block unspecific binding sites. After this preincubation, the 
specimen were incubated for 4 hours at RT with 1x MAB/2% BMB blocking solution supplemented 
with an 1:2000 dilution of the affinity-purified α-digoxigenin antibody coupled to an alkaline 
phosphatase. After the incubation with the antibody, the embryos were washed over night in 
1x MAB. The next day, the embryos were washed again additional 4-6 times in 1x MAB 30 min per 
wash at RT. To prepare the embryos to the upcoming colour staining reaction, they were washed 
twice in AP-buffer followed by incubation in alkaline phosphatase substrates 4,5 µl/ml NBT and 3,5 
µl/ml BCIP in AP buffer. The colour reaction took place at RT in the dark. When the desired staining 
intensity was reached, the colour reaction was stopped by rinsing the embryos with PBS, followed by 
MEMFA fixation over night at 4°C.  
To improve visibility of the colour precipitate, the pigment of the embryos had to be removed by 
bleaching. Therefore, the embryos were incubated for minimum 20 min in 75%EtOH/PBS at RT and 
then incubated in bleaching solution containing formamide and H2O2 (Mayor et al, 1995). The process 
of bleaching was performed on a light box for at least 4 hours. After bleaching of the pigmented cells, 
the embryos were put in MEMFA and stored at 4°C until pictures were documented. 
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stock solutions: 
Alkaline Phosphatase (AP)  
100 mM Trichlorethane 
100 mM NaCl 
50 mM MgCl2 
0,1% Tween-20 
 
 
 
 
Bleaching solution 
1% H2O2 
5% Formamide 
0.5 x SSC 
 
 
 
 
 
Hybridization solution 
5 x SSC 
50% Formamide 
1% Boehringer blocking       
0,1 % Torula RNA 
0.01% Heparin 
0,1% Tween-20 
0,1% CHAPS 
5 mM EDTA 
 
Maleic Acid Buffer (MAB) 
100 mM maleic acid 
150 mM NaCl, pH7,5 
 
 
 
 
 
MEMFA 
0,1M 3-(N-Morpholino)- 
propanesulfonic acid  
2 mM EGTA 
1 mM MgSO4 
3,7% formaldehyde pH7,4 
 
 
 
PBS pH7,2 
137 mM NaCl 
2,7 mM KCL 
8 mM Na2HPO4 
1,7 mM KH2PO4 
PBSw 
1x PBS 
0,1% Tween-20 
20x SSC pH 7 
3 M NaCl 
0,3 M sodium citrate 
 
 
 
 
2.2.2.6 Microarray analysis  
Genome-wide transcriptome analyses were performed with the Affymetrix GeneChip®Xenopus 
Tropicalis Genome Array. These arrays carry over 58000 probe sets, representing 51000 transcripts. 
The RNA for the analysis was isolated, the quality was controlled on the Bioanalyzer and samples 
with a RIN-value ≥7 were used for genome-wide analysis. The RIN is composed of the purity of the 
RNA and the ratio between 18S and 28S RNA-the better the RNA quality, the higher the RIN-value 
(between 0-10). The “Facility for functional genomics” at the Gene Center performed the sample 
hybridization and the microarray readout. The raw data was forwarded to Dr. Tobias Straub, Head of 
the Bioinformatics Core Unit at the Adolf-Butenandt-Institut and subjected to bioinformatic analysis. 
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2.2.3 Protein analysis  
2.2.3.1 SDS- polyacrylamid gelelectrophoresis, SDS-PAGE 
15 Xenopus embryos at NF 9 were lysed in 75 µl cold lysis buffer supplemented with protease 
inhibitors and homogenized with a 45G needle. To remove the cell debris the cell lysate were 
centrifuged for 20 min at 14000 rpm at 4°C. 50 µl of the liquid supernatant was transferred into a 
new 1.5 ml eppendorf tube and 12 µl of Rotiphoresis loading dye was added. To shear the remaining 
DNA, the sample was frozen in liquid N2 and immediately thawn to 37 °C. This procedure was 
repeated 3-5 times. Before loading 2 “embyro equivalent” onto an 8% SDS gel, the samples were 
heated up for 2 min to 92°C in order to denature the proteins. 
stock solutions: 
Lysis buffer 
10 mM Tris-HCl pH 7,5 
100 mM NaCl 
0,5 % NP-40 
 
Protease inhibitors 
1 mM NaF 
20 mM beta-glycerol 
0,1 mM NaV 
1 mM PMSF 
 
10x SDS-PAGE buffer pH 8,3 
250 mM Tris 
2 M gylcerine 
35 mM SDS 
 
2.2.3.2 Western Blot analysis 
After size-separation, proteins were transferred onto a nitrocellulose membrane using the Bio-Rad 
Wet/Tank Blotting Systems. Blotting was performed with a voltage of 120 V for 2 hours at 4 °C. 
Afterwards the membrane was washed in PBSw, the 1st antibody was applied and incubated over 
night at 4°C. After removing the 1st antibody, the membrane was washed 3 times in 5% milk/PBSw 
for 15 min. The secondary antibody was diluted and the membrane was incubated for 90 min at RT in 
the dark, followed by 3 washing steps for 15 min in 5% milk in PBSw. To detect the protein signals on 
the membrane, the Odyseey LiCOR system was used. The Odysee Application Software Version 3.0, 
was used for quantification. 
stock solution: 
Blotting puffer 
25 mM Tris 
200 mM glycerine 
0,7 mM SDS 
20% Methanol 
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2.2.3.3 Immunocytochemistry 
The vitelline membrane of NF9 embryos was manually removed using two forcipes, followed by 
fixation in MEMFA over night at 4°C. After fixation, the embryos were stored in 100% Methanol 
at -20°C. To rehydrate the embryos, successive washing steps with 75% Methanol/PBSw, 50% 
Methanol/PBSw and 25% methanol/PBSw, each step for 5 min, were performed. Afterwards the 
embryos were washed in PBT for 15 min. To block protein binding sides, the embryos were incubated 
1 hour with PBT supplemented with 10% heat inactivated lamb serum. After the blocking step, the 
primary antibody specific for the protein of interest, was added and incubated over night at 4°C. The 
antibody was removed, stored at 4°C for reuse. In order to remove possible remaining primary 
antibody, the embryos were washed 6 times, each 30 min, with PBT. Afterwards the embryos were 
incubated with the AP-coupled secondary antibody over night at 4°C. To wash away the secondary 
antibody, the embryos were washed 5 times 1 hour with PBT. For the alkaline phosphatase staining 
reaction, the embryos were washed twice 15 min with AP-buffer supplemented with 2mM levimasol. 
To start the AP-reaction the substrates NBT and BCIP were added and the embryos were kept in the 
dark until the colour staining was visible. The colour reaction was stopped by rinsing the embryos in 
1x PBS. To remove the pigmentation of the whole embryos a bleaching step was added. The embryos 
were incubated for minimum 20 min in 75% EtOH with PBS followed up by incubation with bleaching 
solution, containing formamide and H2O2, on a light source. Subsequentely, the embryos were stored 
in MEMFA at 4°C until the experiment was documented. 
stock solutions: 
PBT 
1x PBS 
2 mg/ml BSA 
0,1% TritonX-100 
AP buffer 
AP-Buffer (see WMISH)  
2 mM levamisol 
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2.2.3.4 Luciferase assay 
To quantitate morpholino blocking efficiency, a luciferase assay was employed with a target-specific 
reporter plasmid. Therefore 5 times 5 embryos per condition were pooled and lysed with 
10 µl/embryo 1x PBL-lysis buffer from the Dual-Luciferase® Reporter Assay System (Promega). To 
remove the cell debris the samples were centrifuged for 10 min at 13000 rpm at 4°C. 50 µl of the 
clear supernatant was transferred into a new eppendorf-tube and followed by another centrifugation 
step for 10 min at 10000 rpm at 4°C. 20 µl of the suspension was then added to 100 µl LARII from the 
Dual-Luciferase® Reporter Assay Kit and the luciferase activity was measured with the luminometer. 
 
2.2.3.5 ß-galactosidase staining 
The injected blastomeres were lineage-traced by coinjection of nuclear ß-gal mRNA. The embryos 
were collected in the desired developmental stage, fixed with MEMFA for 30 min at RT and 
subsequently washed with PBS 3 times each for 10 min. To start the color reaction, the Xgal-solution 
was added and the embryos were incubated in the dark until the staining was visible. To stop the 
reaction the embryos were washed again 3 times, each 10 min, in PBS. The lacZ stained embryos 
were stored in 100% Ethanol at -20°C until documentary or proceeding with a WMISH. 
solutions: 
Xgal solution, freshly made 
1x PBS 
5 mM K3Fe(CN)6 
5 mM K4Fe(CN)6 
2 mM MgCl2 
1 mg/ml Xgal 
 
2.2.4 Embryological methods 
2.2.4.1 Superovultion of Xenopus females 
Xenopus laevis female were stimulated by an injection of 800 units of human Choriongonadotropin 
(hCG) into the dorsal lymph sac. Egg laying started 12-14 hours later.  
Materials and Methods 
37 
To stimulate Xenopus tropicalis females, the frogs were primed with 10U of hCG into the 
dorsal lymph sac 12-20 hours before usage is necessary. The next day 200U of hCG were injected. 4-5 
hours later the females started laying eggs. Xenopus tropicalis females were kept at 23 °C. 
2.2.4.2 Testes preparation 
Xenopus males were anaesthetized in 5 g/l 3-Aminobenzoeacid-ethyl-ester (MS222). After a 
minimum of 30 min and no further signs of consciousness, the males were killed by decaptitation. 
The testes are located in the abdominal cavity, attached to fat tissue. With two incision of the skin, 
fat tissue and the testes can be pulled out and isolated. Testes were cleaned in 1x MBS and stored at 
4°C in 1x MBS/CS. X. laevis testes can be stored up to 10 days, X. tropicalis testes only two days.  
 
2.2.4.3 In vitro fertilization and culturing 
When female Xenopus started laying eggs, they were carefully squeezed and the freshly laid eggs 
were collected in a petri dish. A slice of one testis was cut off and minced in 1x MBS and the 
suspension was applied to the eggs. Immediately 0,1x MBS was added, mixed with the eggs and 
incubated at RT for 20 min. The eggs then were covered with 0.1x MBS and cultivated at 18-23°C.  
For Xenopus tropicalis a piece of one testis was minced in 300 µl 1x Ringer solution, mixed 
with the freshly laid eggs, after 3 minutes covered with 0,1x Barth’s solution and incubated at 23°C. 
stock solutions:
5x Barth’s solution pH 7,6 
440 mM NaCl 
5 mM KCL 
12 mM NaHCO3 
4,1 mM MgSO4 
1,65 mM Ca(NO)2 
2,05 mM CaCl2 
50 mM HEPES 
10 x MBS pH 7,8 
880 mM NaCl 
10 mM KCL 
10 mM MgSO4 
50 mM HEPES 
25 mM NaHCO3 
 
 
1x Ringer solution 
116 mM NaCl 
2,9 mM KCL 
1,8 mM CaCl2 
5 mM HEPES pH 7,2 
 
2.2.4.4 Dejellying Xenopus embryos 
The spawn of water-living amphibian animals have a very robust multi-protein network, the jelly 
coat. In order to perform microinjections this coat has to be removed by a 2% Cystein solution.  
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For X. laevis embryos approximately 60 min after fertilization the embryos are transferred in 
a 2% cysteine/0.1x MBS solution. By constant mild agitation it takes 2-3 minutes to remove the jelly 
coat. The eggs have to be washed 3 times in 0.1x MBS and then are cultivated in 0,1x MBS. 
X. tropicalis eggs have to be separated from the jelly coat 25 min after fertilization by a 2% 
cysteine solution in 1/9th Modified Ringer (MR). The embryos of X. tropicalis are more sensible to 
mechanical agitation and therefore sustain only mild agitation and approximately 10 min in the 
cysteine solution to remove the jelly coat. The embryos are washed 2 times in 0,1x Barth’s solution 
and additional 3 times with 0,1x 1/9th MR. Dejellied embryos were cultivated in 1/9th MR at 23°C until 
they reached the desired developmental stage. To avoid exogastrulation embryos had to be replaced 
after several hours to 1/18th MR.  
stock solution: 
1x Modified Ringer, MR 
100 mM NaCl 
1,8 M KCL 
2 mM CaCl2 
1 mM MgCl2 
5 mM HEPES pH 7,6 
 
2.2.4.5 Microinjections 
To manipulate Xenopus embryos or single blastomeres, an injection needle from capillaries was 
made with the Microneedle Puller (Sutter instruments, settings: heat: 800; pull: 35; vel: 140; 
time:139). The microinjection needle was put into either a fixed needle holder or a free-hand needle 
holder. The needle had to be calibrated by stepwise clipping with a forceps to allow injections of a 
5 nl drop in 30 msec and with a pressure of 30 psi. The injection volume in this thesis ranged from 
1.25 nl/blastomere - 5 nl/blastomere. Embryos were injected from 2 cell stage up to the 16 cell stage. 
The total volume injected was limited to 10 nl/ embryo for X. laevis and 5 nl/ embryo for X. tropicalis. 
After injection, X. laevis embryos were cultivated in 0,1x MBS/Gentamycin and buffer was 
refreshed on a daily basis. To avoid attaching of the embryos to the petri dish surface, it was coated 
with 1% Agarose/ 0,1xMBS. 
Prior to (15 min) and after (1hour) injections, the X. tropicalis embryos were transferred to 
1/9th MR with 2% Ficoll, then transferred in 1/9th MR/Gentamycin for several hours and finally 
transferred to 1/18th MR/Gentamycin until the desired developmental stage was reached. Petri 
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dishes were covered with 1% agarose in 1/18th MR. X. tropicalis embryos were only cultivated at 20°C 
(RT) or 23°C. 
 
2.2.5 Embryological explantations 
2.2.5.1 Ectodermal explantation 
To target microinjections to the animal cap region, the mRNAs were injected radially into the animal 
pole between the 2 - 8 cell stage and cultivated in 0,1x MBS until the blastula stage. The embryos 
were then transferred into 1x Steinberg Solution and the vitelline membrane was carefully removed 
with two forcipes. Next the Blastocoel roof was cut out with two forcipes and the ectodermal 
explants were transferred separately into one well of a 96 well plate. The wells were covered with 
1% agarose in 1x Steinberg solution and filled with 1x Steinberg solution. The animal caps were 
cultivated until uninjected control embryos reached the midgastrula stage. 
stock solution: 
10 x Steinberg Solution 
580 mM NaCl 
6,7 mM KCL 
3,4 mM CaNO3 
8,3 mM MgSO4 
50 mM Tris 
0,1 g Kanamycin 
 
2.2.5.2 Transplantation 
In this thesis homotopic BCNE transplants were examined. A morphant BCNE was transplanted into a 
wild type host embryo. At the 2 cell stage embryos were injected in both blastomeres with BMO1. At 
the 16 cell stage the two dorso-animally located blastomeres were injected with Alexa 488 or Alexa 
594 in morphant or wild type embryos, respectively. At blastula stage the embryos were transferred 
into 0.8x MBS/gentamycin and the vitelline membrane was removed. The area of the BCNE was 
identified by fluorescence of the lineage tracer. The red BCNE in the host embryo was removed and 
exchanged with the green morphant or WT BCNE. To stabilize the transplant, it was covered with a 
cover slip. After 1 hour the cover slip was removed and the transplanted embryo was transferred 
into 0,1x MBS/gentamycin and cultivated at RT in a 1% agarose-coated petri dish. 
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3 Results 
3.1 Comparison of morpholino oligonucleotides 
In order to perform knockdown analysis in Xenopus, morpholino oligonucleotides, which block the 
protein translation, were designed. Three Brg1 morpholinos with different targeting sides were 
tested, which all target the homeologs in Xenopus laevis mRNA. In Figure 3.1 the alignment of both 
homeologs is shown. Whereas brg1.a (NCBI: AY762376) implies the whole coding sequence, the 
second allele brg1.b (NCBI: BG554361) contains only a partial coding sequence and the 5’UTR. The 
two sequences are 96% identical on nucleotide level. 
 
Figure 3.1: Partial cDNA sequence alignment of Xenopus homeologs brg1.a and brg1.b. Sequences of brg1.a 
(AY762376) and brg1.b (BG554361) are provided from NCBI. Shown are the 5’UTR and the first nucleotides of 
the coding region of both homeologs. In red the starting codon ATG is depicted. Differences in the two gene 
sequences are highlighted in gray. The alignment was generated by CLC workbench viewer. 
The morpholino targeting sites of all three morpholinos are shown in Figure 3.2 A. To compare their 
individual efficiency, a luciferase reporter gene assay was established. A ~ 700 bp fragment, reaching 
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from -77 bp - +617 bp of the Brg1 sequence, called BISH, was cloned into the pCS2+GW vector with a 
C-terminal luciferase tag. Xenopus laevis embryos were injected in the 2 cell stage with the indicated 
morpholino radially and in the 8 cell stage the 4 animal blastomeres were injected with synthetic 
BISH-luciferase mRNA. The embryos were cultivated until NF12 and luciferase activity was measured. 
The efficiency of translation blocking is displayed in Figure 3.2 B. All three morpholinos showed an 
inhibition efficiency of more than 50%. However a clear ranking can be made. BMO3 was the less 
efficient, with an inhibition up to 0.35%, BMO2 reduces the luciferase luminescence to 0.22% and 
BMO1 showed the best blocking efficiency with a reduction to 0.14%. Given that BMO1 inhibits the 
translation best, any further analysis in Xenopus laevis was executed with this morpholino. 
 
3.2 BMO1 reduces Brg1 protein level from MBT on 
As described in the introduction, the development up to midblastula in Xenopus is entirely regulated 
by maternal mRNA and protein. Furthermore transcription is blocked during this period. With the 
midblastula transition (MBT) this transcription blocking is abrogated and the zygotic gene 
transcription begins. To examine the time point when BMO1 is acting and Brg1 protein level is 
decreased, the protein level before MBT (NF7) and after MBT (NF9) was monitored. In Figure 3.3 A a 
Western Blot is depicted, showing that at preMBT the Brg1 protein level is not changed after BMO1 
injections. At late blastula stage (NF9), 3 hours later, the protein level of Brg1 is reduced under these 
conditions.  
 
Figure 3.2: Different morpholino targeting sites 
result in different translation blocking efficiencies. 
In A the ATG-region of brg1.a and brg1.b is shown 
and the three different morpholino targeting sites 
are depicted. B shows the result of the luciferase 
assay, in order to quantify the translation blocking. 
In each condition 25 pg of BISH-luciferase mRNA was 
coinjected with either CoMO or BMO1, BMO2 or 
BMO3, each 60 ng. The luciferase signal of all tested 
conditions was normalized to CoMO signal intensity. 
The mean of 3 independent experiments is shown. 
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Figure 3.3: BMO1 inhibits only newly synthesized Brg1 protein. In A one representative Western Blot out of 
three independent experiments is shown. Brg1 protein level was analyzed preMBT (NF7) and postMBT (NF9). 
As a reference α-tubulin protein level was measured and the knockdown efficiency was calculated. The protein 
level ratio was normalized to UI samples. Two different samples (#) of BMO1 were examined within one 
biological repeat. B shows one representative qRT-PCR analysis out of three independent experiments for MBT 
marker gs17, xnr5 and xnr6. In panel C a WMISH against xnr5 is shown under UI, CoMO and BMO1 conditions 
at NF7 and NF9. Shown is the vegetal pole. Numbers display the sum of 3 independent experiments. 
UI , uninjected. 
 
The pre- and postMBT correlation of the two conditions was confirmed by measuring mRNA levels of 
gs17, a gene known to become activated at the MBT Figure 3.3 B (Krieg & Melton, 1985). 
Interestingly, BMO1 injected embryos consistently express lower amounts of Gs17 mRNA than 
control embryos. In addition, the gene expression levels of xnr5 and xnr6 were monitored by 
qRT-PCR. These two genes are expressed at low levels already at preMBT (Blythe et al, 2010). Also 
these two genes show an upregulation after MBT but none of them showed a downregulation like 
gs17. This indicates that not all genes require Brg1 function for their activation at MBT. Furthermore 
it proves that morphant embryos are not delayed in development. 
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The xnr5 expression pattern was also analyzed in a WMISH analysis (see Figure 3.3 C). In 
more than 90% of the postMBT morphant embryos a slightly broader expression domain paired with 
stronger expression signal is observed. This slight upregulation of gene expression was not detected 
in preMBT embryos. In total these results show, that BMO1 blocks translation of Brg1 mRNA only 
from the time of MBT on. An explanation to this is that preMBT Brg1 protein is of maternal origin and 
therefore insensitive to morpholino inhibition.  
 
3.3 Morphological gain- and loss-of-function studies 
To obtain first information on Brg1 function during the development of Xenopus laevis, knockdown 
studies with BMO1 or overexpression with ectopic Brg1WT mRNA were performed. In Xenopus it is 
possible to distinguish the prospective dorsal from the prospective ventral side already at the 4 cell 
stage. This allows targeted injections and the independent investigation of Brg1 function in both 
entities of the developing embryo. 
 
3.3.1 Targeted loss-of-function analysis 
For the knockdown analysis, BMO1 was injected either in the dorsal-marginal zone (DMZ) or in the 
ventral-marginal zone (VMZ). 5 ng/blastomere CoMO or BMO1 were injected together with 
25 pg/blastomere lacZ mRNA for lineage tracing. Embryos injected with CoMO developed normal in 
93% (DMZ) or 87% (VMZ), respectively (Figure 3.4 A, E, D, G). However, a knockdown of Brg1 in the 
DMZ led in 80% of the embryos to severe perturbations of dorso-anterior structures (Figure 3.4 D) 
and only 20% developed normally. These morphant embryos displayed various phenotypes, ranging 
from a reduced eye size up to a complete loss of anterior structures. An example of a strong 
phenotype is shown in Figure 3.4 B. Besides the dorso-anterior impairments, also the 
antero-posterior body axis is shortened compared to controls. To ensure that this phenotype is 
specific and not the result of off-target effects, coinjections with human WT Brg1 mRNA were 
performed. Due to the Brg1 gene sequence divergence between human and Xenopus, the translation 
of the human Brg1 mRNA is not inhibited by BMO1. Indeed, under rescue conditions the phenotype 
of morphant embryos can be reduced to less than 18% (Figure 3.4 D). In Figure 3.4 C a rescued 
embryo is shown.  
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Figure 3.4: Embryonic morphology after targeted Brg1 knockdown. Panels A-C show lateral views of NF35 
embryos injected in the DMZ with either CoMO (5 ng/blastomere) (A), BMO1 (5 ng/blastomere) (B) or BMO1 
coinjected with 1 ng hBrg1WT mRNA (C). D-E’ show lateral views of NF35 embryos injected in the VMZ with 
either CoMO (5 ng/blastomere) (D) or BMO1 (5 ng/blastomere) (E, E’). In F and G the quantification of either 
DMZ- (F) or VMZ- (G) injections are shown. DMZ, dorsal marginal zone; VMZ, ventral marginal zone. 
 
VMZ-injected embryos displayed a different morphology. 68% of Brg1 morphant embryos developed 
wild type morphology (Figure 3.4 E and G). The remaining 32% developed normal heads and dorsal 
structures, but they failed to form a fin and their tails were bent and reduced (Figure 3.4 E’). 
Furthermore they apparently lost ventral cell mass. If this is due to apoptosis or reduced cell 
proliferation is not clear. From this result it can be concluded that Brg1 has an important role in axial 
patterning, which mainly occurs on the dorsal side of the embryo but to a less extent Brg1 is also 
required for proper ventral development. 
 
3.3.2 Targeted gain-of-function analysis 
The above described loss-of-function analysis uncovered a strong requirement for Brg1 in dorsal 
development. To complete the analysis of Brg1 impact on morphogenesis, similar targeted 
microinjections with exogenous xBrg1WT mRNA were performed, to test a possible effect under 
overexpression conditions. DMZ-overexpression of 500 pg xBrg1WT mRNA did not lead to a 
phenotype, the embryos developed normally (data not shown). Strikingly, an excess of Brg1 mRNA in 
one ventral blastomere produced partial secondary axis in 50% of the cases (Figure 3.5). The second 
body axes were anteriorly truncated and showed trunk tissue. This phenotype is reminiscent of axis 
induction by components of the wnt pathway, like Siamois or Chordin.  
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To validate the trunk character of the xBrg1WT mRNA induced axial structure, a WMISH with cardiac 
actin, a muscle-specific marker, was performed. All embryos tested in the WMISH, which exhibited a 
secondary axis also showed staining for skeletal muscle in the truncated body axis. Figure 3.5 G-I 
display such an embryo from lateral and dorsal view. The secondary axis typically branch off from the 
primary body axis, as shown in Figure 3.5 I’. This result indicates that an excess of Brg1 on the ventral 
side leads to a conversion of ventral mesoderm to dorsal mesoderm. Additionally it suggests a 
potential role of Brg1 in wnt signaling.  
 
 
Figure 3.5: Gain of function on the ventral side causes truncated secondary axes. A shows a VMZ lacZ 
(100 pg/blastomere) injected embryo in lateral view with normal shape. An overexpression of xBrg1WT mRNA 
(500 pg/blastomere) induced formation of a truncated secondary axis in 50% of the embryos (B). In C the 
quantification of 3 independent experiments is shown. D-I’ show WMISH embryos stained with cardiac actin. In 
D-F’ the lacZ injected embryos are displayed in lateral (D, E) and dorsal view (F). In F’ a higher magnification of F 
is shown. In G-I’ WMISH of xBrg1WT overexpressed embryos are shown in lateral (G; H) or dorsal (I) view. In I’ a 
close-up of the branching secondary axis is depicted. 
 
3.4 Wnt signaling is not affected in Brg1 morphants  
The results so far point to an involvement of Brg1 in axis formation and vertebrate embryogenesis, 
even though the mechanism Brg1 employs is not known. Whereas the ventral program is considered 
to be the ground state of the fertilized egg, the dorsal gene expression program has to be established 
de novo in the developing embryo (Robertis & Kuroda, 2004). One very important signaling pathway 
that induces dorsal genes is the canonical Wnt pathway. The findings raise the question, whether 
Brg1 acts directly on the pathway and its target genes. To resolve this issue an epistatis experiment 
was performed. 
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Figure 3.6: Loss of Brg1 on the ventral side does not inhibit axis induction by Siamois. A-D, A’-D’ and A’’-D’’ 
show the head of embryos either DMZ-injected (A-A’’; B-B’’) or VMZ-injected (C-C’’; D-D’’) under CoMO (A-A’’; 
C-C’’) or BMO1 (B-B’’; D-D’’) conditions in lateral or dorsal views. For both morpholinos a total of 5 ng/embryo 
was injected. In VMZ-injections 25 pg of Siamois mRNA was coinjected in order to create a secondary axis. In E 
the result of the displayed embryos is visualized in a graph. In F all tested conditions are listed. DMZ, dorsal 
marginal zone; VMZ, ventral marginal zone; + indicates injection site; n.a, not applicable; n.s., not specific; 
***, p ≤ 0.005; *, p = 0.52. 
 
Induction of a complete second embryonic axis by wnt signaling is achieved by injections of 
exogenous Siamois mRNA into one ventral blastomere (Lemaire et al, 1995). Coinjections of BMO1 
(5 ng/blastomere) should reveal if the loss of Brg1 blocks the forming of the ectopically induced 
secondary axis. For quantification, the embryos were cultivated until NF38 and classified according to 
the Dorso-Anterior-Index (DAI) (Kao & Elinson, 1988). When CoMO was coinjected together with 
Siamois mRNA, the embryos developed a secondary axis with an average DAI of 3.8 (see Figure 3.6 
C-C’’). This dose of Siamois mRNA was chosen in order not to saturate the embryo’s response, thus to 
provide a sensitive environment in which the BMO1 effect can be seen. This is the reason why some 
embryos did not develop a full secondary axis. In coinjections of BMO1 and Siamois mRNA the 
average DAI of the generated secondary axis was 3.38. A representative embryo is shown in Figure 
Results 
48 
3.6 D-D’’. Although on average the secondary axes are reduced, this reduction is statistically not 
significant. To control the morpholino-mediated translation blocking, 5 ng/total of BMO1 were 
injected into the DMZ and the DAI was examined. As expected the BMO1 DMZ-injected embryos 
displayed a reduction of dorso-anterio structures with an significant average DAI of 3.87 in 
comparison to a DAI of 4.9 in control embryos (Figure 3.6 F). A morphant embryo with a 
corresponding DAI is shown in Figure 3.6 B-B’’. This proves that BMO1 injections indeed were 
effective. This result is not in agreement to the results obtained from Nishant Singhal. Whereas his 
data indicated a positive coregulatory role for Brg1 within the wnt signaling pathway, the latter 
experiment rather suggests that Brg1 does not interfere in the dorsalizing program induced by Wnt 
signaling. This is demonstrates, at least, for the downstream events of Siamois. Nonetheless, it also 
does not exclude a broader role of Brg1 beyond or upstream of Siamois. 
 
3.5 Axis patterning genes are downregulated in neurula stage 
After completing the gross morphological analysis of Brg1 requirements, the underlying molecular 
causes of the morphant phenotype were investigated. Prominent candidates to analyze are genes 
that help to establish the vertebrate body plan. To investigate the antero-posterior patterning, 
control and morphant embryos were examined in a WMISH analysis at neurulation stage. Three 
markers were analyzed, which mark differing section along the AP body axis. 
 As an anterior marker pax2 was chosen. It is a paired box transcription factor and is 
expressed in the eye primordium and anterior head structures during neurula. In later stages pax2 
marks and is essential for proper pancreas development (Heller & Brandli, 1997). In unilateral BMO1 
injected embryos the expression pattern of pax2 on the injected side is perturbed and the 
knockdown led to an unstructured expression pattern in more than 20% of the embryos (Figure 3.7.B 
and C). This effect is dose-dependent, since the percentage in 20 ng BMO1 injected embryos 
increased to almost 50%. The reduction of pax2 expression was specific as the effect was less 
prominent if human Brg1 WT mRNA was coinjected. 
As a more posterior marker, the gene early growth response 2, egr2, was chosen. This gene, 
formerly known as krox20, is expressed in rhombomeres r3 and r5 (Giudicelli et al, 2001). Already 
with 10 ng BMO1 unilateral injections, 80% of the embryos showed a clear reduction in egr2 
expression (Figure 3.7 A-D and F). Noteworthy rhombomere 5 was more affected than rhombomere 
3. Again, a dose-dependency was seen as with 20 ng BMO1 almost 90% of the embryos responded 
with misexpression. Also this effect is specific for Brg1 because the penetrance could be reduced to 
54% upon coinjection of 1 ng human Brg1WT mRNA.  
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As a posterior marker, homeobox B9, hoxb9, was analyzed. This gene belongs to the 
hox-cluster and marks the posterior part of the chordal plate (Godsave et al, 1994). In 43% of the 10 
ng BMO1 injected embryos this gene is shifted posteriorly, meaning the expression area was not 
reaching as far anterior as its expression on the uninjected side (Figure 3.7 A’-C’). Upon 20 ng BMO1 
injections, 62% of the embryos were affected. This percentage could again be reduced to 36% when 
hBrg1 mRNA was coinjected (Figure 3.7 G). 
 
 
Figure 3.7: Antero-posterior axis markers are reduced in morphant embryos. A-A’; D-D’ show neurula 
embryos, unilateral injected with either 20 ng/blastomere CoMO (A, A’), 10 ng/blastomere BMO1 (B, B’), 20 
ng/blastomere BMO1 (C, C’) or 20 ng /blastomere BMO1 coinjected with 1 ng human Brg1WT (D, D’) in 
anterior (A-D) or dorsal (A’-D’) views. Three axis markers were analyzed simultaneously by WMISH: pax2, egr2 
and hoxb9. The quantification for each marker is shown in E-G and represents the mean of 3 biological repeats. 
+ indicates the injected site; *, p ≤ 0.05. 
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In total, this experiment shows that embryos deficient for Brg1, have a general impairment of the 
antero-posterior patterning through all analyzed AP-tissues. Further, it suggests a defective gene 
expression pattern rather than a shift of AP-tissue, since the gene expression is reduced but the 
pattern localization is comparable to the uninjected body half.  
 
3.6 Dorso-ventral patterning in gastrula embryos is perturbed 
In neurula stages the gene expression domains of antero-posterior marker genes were clearly 
reduced upon loss of Brg1. Nevertheless this alone cannot explain the severe phenotype seen in the 
morphological studies. Morphant tadpoles mainly showed a loss of dorso-anterior structures. These 
defects may originate from early gastrula stage, when the organizer instructs the germ layer and axes 
patterning. At the beginning of gastrulation, mesoderm cells of the organizer initiate the involution 
process. During gastrulation, the involuting cells secret proteins that counteract and inhibit the 
ventralizing proteins. This interplay between dorsalizing and ventralizing factors patterns the embryo 
in a very precise manner. Several dorsalizing and ventralizing factors were analyzed at mid gastrula to 
further investigate axis patterning defects. As organizer genes xnr3, otx2, foxa4, gsc and chordin 
were analyzed.  
Nodal-related 3 (xnr3) is an atypical member of the nodal family. In contrast to the other 
family members it is a direct wnt target gene and its expression domain locates in the animal 
hemisphere (Smith et al, 1995). During gastrulation it becomes expressed in the organizer territory 
and functions as a BMP-inhibitor (Hansen et al, 1997). Its expression at the blastoporus lip is reduced 
upon loss of Brg1 in 62% of the embryos, but only 3% of the CoMO injected embryos show reduced 
gene expression (Figure 3.8 A, A’). 
Another important organizer gene is orthodenticle homeobox2 (otx2). It starts to be 
expressed after MBT and marks the organizer field of early gastrula. At later stages it is expressed in 
anterior structures throughout all three germ layers (Pannese et al, 1995). Apart from superficial 
expression at the blastoporus lip also the involuted organizer can be visualized with otx2 WMISH 
probe. In morphant embryos, a robust reduction of gene expression could be observed in 81% of the 
morphant embryos. Even more interestingly, the size of the organizer region was diminished (Figure 
3.8 B, B’). This indicates a functional impairment of the organizer, which will promote ventralizing 
factors. 
Foxa4, formerly known as XFD1’, is also expressed in the organizer and its expression pattern 
was examined in gastrula embryos. This forkhead box gene is induced by Activin signaling and marks 
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the notochord in tadpole stages (Knochel et al, 1992). In 58% of the morphant embryos foxa4 is 
reduced (Figure 3.8 C, C’). 
Notably, not all organizer genes were misregulated in Brg1 morphants. Goosecoid (gsc), is 
one example. 90% of the morphant embryos formed a normal gsc gene expression pattern (Figure 
3.8 D, D’). The promoter region of gsc is well described and it contains a proximal binding site for the 
transcription factor Twin, which is regulated through wnt signaling and it contains a distal element 
for binding of Mixer, a nodal/TGF-ß transcription factor (Watabe et al, 1995).  
 
Figure 3.8: Loss of Brg1 disturbes the dorso-ventral patterning. Radially BMO1 (40 ng/embryo) injected 
embryos (A’-M’) showed an impaired dorso-ventral patterning at gastrula stage compared to CoMO 
(40 ng/embryo) injected ones (A-M). All embryos are shown from posterior with dorsal on the top and ventral 
on the bottom. Except for otx2 (B, B’) and vent2 (G, G’), in which a dorsal view is shown with anterior on the 
top and posterior on the bottom. The inserts in A; A’ show the lateral view of bisected embryos. The inserts in 
B, B’ and G, G’ show a posterior view of the embryo. In E, E’ the insert shows a dorsal view of the embryos. 
Each marker was analyzed in 2-4 independent biological repeats. The numbers of each gene expression profile 
is depicted in the graph next to the pictures. *, p ≤ 0.05.  
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Another interesting candidate is BMP-inhibitor Chordin. This gene is also expressed in the organizer 
and it was not altered upon loss of Brg1 (Figure 3.8 E, E’). Like goosecoid, also chordin receives 
multiple inductive signals. While the first induction wave is triggered by wnt signaling in the 
ectoderm of late blastula, it becomes induced in the mesoderm by nodal signaling from early gastrula 
onwards (Wessely et al, 2001). 
Taken together, these results indicate a weakening of the organizer in a selective manner, e.g. 
some but not all of its genes are expressed at lower level. The ventralizing genes are mainly under 
the control of BMP-signaling and vent1 and vent2 are direct target genes (Onichtchouk et al, 1998). 
In morphant embryos, both genes had a larger expression territory as in control embryos (Figure 3.8 
F, F’ and G, G’). In fact, their mRNAs were spreading into the organizer region. This is in particular 
seen for vent2. But among the ventralizing genes Brg1 specificity is seen as well. The expression of 
xenopus-posterior (xpo), another ventral-promoting gene, was not changed upon Brg1 knockdown 
(Figure 3.8 H, H’). 
As the majority of the tested markers are mesodermal genes, it was surprising that the 
pan-mesodermal marker xbra is unaffected (Figure 3.8 I, I’). Nevertheless, the skeletal muscle specific 
genes myoD (Figure 3.8 J, J’) and myf5 (Figure 3.8 K, K’) were both reduced at high frequency. 
In total, the selective reduction of gene expression at gastrula and neurula suggests that Brg1 
is not functionally coupled to a particular signaling pathway or gene network. However, it clearly 
shows that dorso-ventral patterning in morphant embryos is impaired and the embryos are 
ventralized already at gastrula stages. 
 
3.7 Brg1 knockdown affects gene expression already at blastula 
So far, the molecular imbalance in Brg1 morphant embryos was already visible at early as gastrula. 
The organizer is one major signaling center, which helps to pattern the embryo during this crucial 
developmental phase. But the first axis patterning signals are expressed even earlier than 
gastrulation. 
After the MBT, in which a burst of transcription is happening, two centers are established, 
which are important for later axis patterning. One is the dorso-animally located BCNE. In this tissue, 
the first wave of chordin gene expression is located. In addition, noggin, a gene induced by ß-catenin 
signaling, and xnr3, which was already shown to be downregulated in gastrula embryos, are 
coexpressed in this domain. In radially injected embryos all three genes were reduced in their gene 
expression pattern (Figure 3.9 A-C; A’-C’). Among these genes, chordin responds the most upon a loss 
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of Brg1 protein, as all morphant embryos were affected by the knockdown. This is a very interesting 
finding since it was shown in gastrula that chordin gene expression was not altered upon Brg1 
knockdown (Figure 3.8 E and E’). As mentioned above, the expression wave in gastrula embryos is 
driven by nodal signaling, whereas the first wave in late blastula is induced by ß-catenin signaling. 
Nevertheless, this reduction is Brg1 specific, because the gene expression of all three genes can be 
rescued with coinjections of human Brg1WT mRNA (Figure 3.9 A’’-C’’).  
 
Figure 3.9: BCNE genes are downregulated upon Brg1 knockdown. Shown are late blastula embryos with 
animal pole on top and vegetal pole on bottom. The embryos were radially injected with either CoMO or BMO1 
(both 60ng/total), followed by WMISH for BCNE genes. Chordin (A, A’), noggin (B, B’) and xnr3 (C, C’) showed 
reduction in gene expression. The reduction was partially rescued by coinjections of 1 ng hBrg1WT mRNA (A’’; 
B’’; C’’). Siamois (D, D’) was not altered in BMO1 injected embryos. A’’’-C’’’ illustrate the quantification of 4-5 
independent experiments of the indicated gene. E illustrates a scheme of blastula signaling centers and 
associated gene signature.*, p ≤ 0.05. 
 
Furthermore, siamois gene expression was investigated in late blastula embryos. Its gene expression 
is also dorsally located but more vegetally than the BCNE genes. Furthermore, siamois, as mentioned 
above, is a direct wnt/ß-catenin target gene. Interestingly, siamois gene expression was unaffected 
by the knockdown of Brg1 (Figure 3.9 D and D’). Because, the epistasis experiment suggested that 
Brg1 probably is upstream of siamois, this result was quite surprising. These findings refuse a general 
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requirement for Brg1 in canonical Wnt signaling but it has to have a gene specific role in and beyond 
wnt/ ß-catenin signaling. 
3.8 ß-catenin target gene siamois is not changed upon loss of Brg1 
The latter result revealed that siamois expression is not altered at late blastula stage after radial 
BMO1 injections. This result was unexpected and surprising for one particular reason. The reduction 
of dorso-anterior structures in the Brg1 knockdown embryos resembles a wnt defective 
morphological phenotype. Siamois is a very well described direct wnt target, which is known to 
mediate the hallmarks of wnt signaling during development: overrepresented on the ventral side it 
induces a complete secondary axis; reduced on the dorsal side, dorso-anterior structures and the 
AP-body axis are reduced (Bae et al, 2011; Lemaire et al, 1995). With the epistasis experiment, a Brg1 
role downstream of Siamois signaling was be ruled out. With the last experiment, also an upstream 
role for Brg1 is unlikely. To exclude that Brg1 and siamois are interconnected, one additional 
experiment was performed. As the injection scheme between the morphological phenotype and the 
blastula analysis differ, siamois expression was also investigated in targeted DMZ injections. 
Therefore the two dorsal blastomeres were injected at the 4 cell stage with either 2.5 or 
5 ng/blastomere BMO1. As lineage trace Alexa 488 was coinjected. Some embryos were collected at 
late blastula stage in order to perform a WMISH. At early gastrula, dorsal explants were isolated and 
RNA was extracted to perform a qRT-PCR. Additionally, some embryos were cultivated until tadpole 
stage in order to determine the strength of the morphant phenotype (see workflow Figure 3.10 A). 
Whereas the CoMO injected embryos developed normally, the ventralized phenotype of BMO1 
injected embryos was apparent already with 2.5 ng/blastomere and more severely in 5 ng 
blastomere BMO1 injections (Figure 3.10 C, D). In the qRT-PCR analysis, siamois gene expression in 
dorsal explants is indeed slightly downregulated but not in a dose-dependent manner as one would 
expect from the morphological phenotype (Figure 3.10H). 
The WMISH experiment underlines this result. Only 4% in the 2.5 pg/blastomere embryos 
showed a reduced siamois expression. In embryos injected with 5 ng/blastomere a minor fraction, 
namely 16% of the embryos, showed siamois reduction (Figure 3.10E-G). In total, this experiment 
testifies conclusively that morphant embryos display no severe alteration in siamois gene expression, 
independent of the mode of injections.  
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3.9 Exogenous chordin mRNA can compensate for the loss of Brg1 
From the last experiments a general interconnection between Brg1 and the ß-catenin signaling can 
be excluded. However, with the BCNE results it is obvious that the early wave of chordin, noggin and 
xnr3 is dependent on Brg1 protein level. In order to analyze if Brg1 acts in the same gene network, 
the most sensitive gene was chosen for a rescue experiment. It was examined if exogenous chordin 
mRNA can compensate for a loss of Brg1. Therefore, at 4 cell stage the DMZ of one dorsal blastomere 
Figure 3.10: BMO1 morphants display a ventralized phenotype 
with normal siamois expression. A shows the schematic workflow. 
Injections were targeted into the DMZ. 10 ng of CoMO, 5 ng or 
10 ng of BMO1 were injected in total. Alexa 488 was coinjected as 
lineage trace. At NF9, embryos were collected for WMISH. At NF10 
dorsal explants were dissected, followed by RNA extraction and 
relative qRT-PCR analysis. B-D show NF38 embryos in lateral view 
injected with either 10 ng CoMO (B) or 5ng BMO1 (C) or 10 ng 
BMO1 (D). The numbers display the sum of two independent 
experiments. B’-D’ show the Alexa fluorescence of the embryos 
shown in B-D. E-G show WMISH of NF9 embryos stained against 
siamois under indicated conditions. Animal pole is on the top. 
Numbers display the sum of two independent experiments E’-G’ 
show bisected WMISH embryos stained against siamois under 
indicated conditions. Animal pole is up. H shows siamois qRT-PCR 
result of dorsal explants under indicated conditions. Gene 
expression was correlated to h4 gene expression and normalized to 
CoMO dorsal explants. Shown is one representative analysis out of 
two independent experiments.  
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was injected with 5 ng/blastomere BMO1, with or without chordin mRNA. As a control, chordin 
mRNA was injected alone. To characterize the phenotype, the injected embryos were cultivated until 
NF38. For quantification the “Eye-Size-Index” (ESI) was measured, as the ratio of the morphant eye 
size divided by the uninjected eye size. In Figure 3.11 A the workflow of this experiment is shown.  
 
 
Figure 3.11: Exogenous chordin mRNA rescues the morphological BMO1 phenotype. A shows the workflow of 
the experiment. Embryos were injected in one DMZ at 4 cell stage. At NF38 the eye size (red dashed line) of the 
injected site and the uninjected site was measured and divided [injected/uninjected] in order to obtain the 
eye-size index (ESI). For uninjected embryos the ratio [left/right] was calculated. 5 ng of BMO1 was injected +/- 
exogenous chordin mRNA. 25 pg of lacZ mRNA was coinjected in every condition. In B-E lateral views of 
analyzed eyes are shown under indicated conditions. Numbers display the ESI of the shown embryos. In F the 
quantification of 3 biological replicates is shown. + marks the injected site; *, p <0.02-7. 
 
 As a control, the ESI of uninjected embryos was measured (Figure 3.11 B). In this case the left eye 
size was divided by the right eye size, leading to an expected average of almost 1, namely 0.973 
(Figure 3.11 F). In morphant embryos the eye of the injected site was diminished significantly to an 
average size of 0.7 (Figure 3.11C and F). As a control two chordin mRNA doses were chosen, 150 pg 
and 300 pg. Both mRNA doses lead to an ESI higher than 1 (ESI: 1.18). Given that an overexpression 
of chordin mRNA led to dorsalization, this result was expected (Sasai et al, 1994). In order to 
investigate whether chordin mRNA can compensate for a loss of Brg1, the chordin mRNA was 
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coinjected with BMO1. Indeed, both doses normalize the eye size of the morphant embryos. In panel 
Figure 3.11 E a rescued embryo with 300 pg chordin mRNA is shown. On average this dose is 
sufficient to rescue the eye size to 0.939. In total, this result underlines the interconnection between 
Brg1 and the early chordin expression in the BCNE.  
 
3.10 A Brg1 morphant BCNE causes loss of eye and brain structures 
In 2004, it was shown that a functional BCNE is essential for proper brain and eye development 
(Kuroda et al, 2004). Since all examined BCNE genes were reduced in Brg1 morphants, the question 
arose, whether the defective BCNE could cause the observed ventralization of the body plan. To test 
this hypothesis a transplantation assay was performed. The workflow is shown in Figure 3.12 A.  
 
 
Figure 3.12: A Brg1 morphant BCNE fails to form proper eye and brain structures. A illustrates transplantation 
assay workflow. For details see text. B-B’’ lateral and dorsal view of an NF35 embryo are shown with a WT 
BCNE transplant. The insert (bright-field/fluorescence merge) shows that the transplants contributed to dorsal 
structures. In C-C’’ an embryo with a morphant BCNE transplant is shown in lateral and dorsal view. Note that 
the overall shape of the embryo is comparable to the WT transplant. However, eyes were not detectable (white 
arrow). The phenotype of transplanted embryos was classified in “dorsal formation”, with normal eye and head 
structures or in “dorsal malformation”, in which eyes and brain are missing. The quantification of five biological 
replicates is shown in D.  
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At 2 cell stage, 40 ng of BMO1 was radially injected. Morphant and wild type embryos were 
cultivated until the 16 cell stage and the BCNE region was marked by Alexa 488 injections into two 
dorso-animal blastomeres. At blastula stage the BCNE of a wild type host embryo was removed and 
homotopic grafting with either a morphant or a wild type BCNE was performed. The embryos were 
cultivated until NF38 and the phenotype was characterized and quantified.  
Two-thirds of the transplanted WT BCNE formed a normal shaped embryo with eye and head 
structures (Figure 3.12 B-B’’; D). In the case of a transplanted morphant BCNE only a minor fraction, 
namely 12%, of the embryos developed eye structures. The residual 88% showed clear impairment of 
eye tissue and head structures, see panel Figure 3.12 C-C’’. This result indicates that the phenotype 
in morphant embryos results in part from the reduced gene expression within the BCNE region. 
Notably, the overall AP-axis of embryos transplanted with a morphant BCNE was less strong affected 
than the AP-axis of morphant embryos generated by DMZ injections (see Figure 3.4). This indicates 
that regions outside the BCNE contribute to axis formation such as anterior mesendoderm, which is 
formed by a combination of wnt and nodal signaling. 
 
3.11 Molecular analysis of BCNE transplants 
Already the morphological characterization of the transplanted embryos was very meaningful, but to 
gain a better understanding of the structural subdivisions of the brain, a WMISH with brain and eye 
marker was followed up. For this purpose otx2 was chosen, which marks the retina and the three 
brain sections forebrain, midbrain and hindbrain. In panel Figure 3.13 A and B a WT BCNE transplant 
is shown. In B lateral and dorsal views of the otx2 stain can be seen. In the lateral pictures the retina 
is nicely visible whereas in the dorsal view the forebrain with its olfactory patches, the midbrain 
between the eyes and the hindbrain is clearly structured. In panel Figure 3.13 D and E a partial 
morphant transplant is shown. As can be seen from the Alexa fluorescence, the BCNE was only 
partially removed in the host embryo. This is also displayed in the WMISH pattern of otx2. Whereas 
the right body site showed retina staining, the morphant left body site lacked this expression. More 
difficult to interpret was the brain expression of otx2. On the right body half otx2 staining was visible 
but the brain was not well structured. In the case of a complete BCNE transplant only diffuse otx2 
staining was observed and no distinct brain structures could be defined (Figure 3.13 F and G). In 
those embryos, the anterior proportion of the brain appeared reduced in size and lacked otx2 
expression. Since the green Alexa signal proved the survival of the transplanted cells, the abnormal 
brain structure had to be due to the lack of Brg1 protein in the BCNE region, leading to an incorrect 
differentiation. 
Results 
59 
 
Figure 3.13: Transplantation of morphant BCNE leads to a loss of eye tissue and malformation of brain 
structures. Shown are embryos transplanted with either a WT BCNE (A, B) or morphant BCNE (D-G). In the left 
row a merge of the bright-field and the fluorescence picture is depicted in a dorsal view either for a WT 
transplant (A) or two morphant transplanted embryos (D, F). In B, E and G the embryos shown in A, D and F are 
stained for otx2 expression and are shown in lateral and dorsal views. In the WT transplant the formation of 
the three brain structures: fore-, mid and hind-brain was distinguishable. Additionally otx2 was expressed in 
the retina. In D and E an unilateral morphant transplant is shown. In F and G the result of a complete morphant 
BCNE is shown. In H the quantification of the otx2 pattern is depicted. 17 WT transplants and 
24 Brg1-morphant transplants were analyzed. fb, forebreain; mb, midbrain; hb, hindbrain. *, p ≤ 0.05. 
 
Although the WT transplants also displayed problems in retinal and also brain formation, the 
malformation in morphant transplants was clearly more severe. In 75% of the morphant transplants 
no or only rudiments of retinal otx2 stain was observed. For all brain structures the malformation 
was around 50%. This finding underlines that morphant embryos did not only suffer from an eye 
defect but also brain tissue is unstructured and does not develop properly. 
 
3.12 Brg1 knockdown impairs the transcriptional readout of wnt-and nodal inducers 
In the last experiments the impact and necessity of the BCNE for later eye and brain development 
was analyzed and it was underlined that Brg1 plays a crucial role for gene expression of BCNE genes. 
Furthermore it revealed, that also other tissues outside the BCNE contribute to the full 
morphological phenotype, as the AP-axis was hardly reduced in the transplantation assay. The 
anterior mesendoderm, defined by a combination of wnt and nodal signaling, has a major impact on 
AP-axis establishment (Robertis & Kuroda, 2004). To investigate the effect of Brg1 knockdown on the 
two signal pathways, an animal cap assay was performed. For this purpose, embryos were radially 
injected with 40 ng BMO1 at the 2 cell stage. At the 8 cell stage either Wnt8 mRNA or Activin mRNA 
was injected into two animal blastomeres to induce wnt- or nodal- signaling, respectivley. The 
embryos were cultivated until blastula stage and then the animal part of the embryo was dissected 
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and cultured separately (Figure 3.14 A). When control embryos reached the gastrula stage (NF11) the 
animal caps were lysed for RNA preparation. The activation of two target genes per pathway was 
assessed by qRT-PCR. For both pathways two target genes were investigated, of which one 
responded upon Brg1 knockdown in vivo and one which did not respond (see Figure 3.8 and Figure 
3.9). For wnt induced animal caps siamois and xnr3 and for activin-induced animal caps gsc and foxa4 
for were examined. 
 
 
Figure 3.14: Loss of Brg1 leads to reduction of target genes after ectopical wnt and nodal induction in animal 
cap assay. Panel A shows the workflow of the animal cap assay. For details see Materials und Methods. In B 
and C qRT-PCR results of the titration for Wnt8 and Activin mRNA is shown. The mean of two independent 
experiments for each signal induction is shown. In D and E one representative qRT-PCR results out of 2-3 
experiments of the induction assay is depicted. Coinjections with BMO1 led to a reduced induction of all 
analyzed genes. Please note the different scale on the y-axes. 
 
From initial tests, two different doses of inducing RNA were chosen (see Figure 3.14 B and C). With 
regard to wnt signaling both target genes, xnr3 and siamois, showed decreased gene expression 
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upon knockdown of Brg1 in both induction dosages. The same was true for Activin induction of 
goosecoid and foxa4 transcription. This outcome was unexpected, since siamois as well as goosecoid 
transcription was not altered by reduced Brg1 protein level in vivo. Notably, the strength of the 
reduction differs among the two induction dosages. Xnr3 and foxa4 gene expression were halved in 
both inducing dosages. In contrast, the gene expression of gsc and siamois were halved in the lower 
induction dosages, but were less impaired in higher induction dosage. In total, these induction 
experiments indicate that Brg1 is required for the transcriptional readout of both, wnt and 
nodal-signaling. Presumably for some genes, a reduction can be overcome by stonger induction, 
which could explain the results of the in vivo analysis.  
 
3.13 Genes outside the BCNE are affected by Brg1 knockdown 
The data presented so far details crucial functions for Brg1 in brain and axes development. These 
functions can be traced back as early as blastula stage. Furthermore, Brg1 has a major impact on the 
BCNE, which is important for head development. As pointed out before, also other tissues are 
affected by Brg1 knockdown.  
It is known that the anterior endomesoderm is contributing in head formation (Robertis & 
Kuroda, 2004). This tissue is defined by a combination of wnt and nodal signaling, which in the latter 
experiment both showed a regulation by Brg1. The combination of the two pathways induce factors 
like Cerberus, which functions as a secreted wnt,- nodal- and BMP-inhibitor (Piccolo et al, 1999b). Its 
expression pattern is confined to early mesendoderm and is located in a signaling center vegetally of 
the BCNE. This second signaling center at blastula is called the “Nieuwkoop center” (Robertis & 
Kuroda, 2004). In order to examine whether Brg1 also has an impact on genes outside the BCNE, 
BMO1 injections were performed at the 8 cell stage in either the dorso-animal (DA; BCNE) or 
dorso-vegetal (DV; Nieuwkoop center) cells. Besides cerberus also hhex, hematopoietically expressed 
homeobox, was analyzed. To directly compare the DV injections with the former Brg1 knockdown in 
BCNE, DA injections were performed side by side and assessed again for chordin and noggin 
expression. 
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Figure 3.15: Dorso-vegetal genes do contribute to the observed phenotype in X. laevis. Embryos were 
injected at the 8 cell stage, either in the two dorso-animal blastomeres (DA) or the two dorso-vegetal 
blastomeres (DV) with 10 ng CoMO (A-K) or 10 ng BMO1 (A’-K’). To lineage-trace the injected cell progeny, 
25 pg lacZ mRNA was coinjected. Embryos were cultivated until late blastula stage and afterwards analyzed for 
BCNE markers chordin (A-B’) and noggin (D-E’). As Nieuwkoop center genes cerberus (G-H’) and hhex (J-K’) 
were analyzed. A-E’ show whole embryos, the animal pole is up. G-K’ show bisected embryos, the animal pole 
is up. Numbers indicate the sum of 3-4 independent experiments. In C, F, I, L the quantifications for the 
indicated gene is depicted. *, p < 0.05. 
 
In DA injections, chordin and noggin showed a clear reduction in gene expression, namely 50% or 
73%, respectively (Figure 3.15 A, A’; B, B’; C; F). This expected result underlines the requirement of 
Brg1 in BCNE gene expression. In DA injections cerberus as well as hhex expression were not altered 
(Figure 3.15 I; L), because of missing spatial overlap as revealed by the lacZ lineage tracing stain 
(Figure 3.15 G, G’ and J, J’). However, as the injections and the expression pattern of cerberus and 
hhex overlaped in DV injections, a loss of Brg1 caused a reduction in 55% and 69% of the embryos, 
respectively. This points out that Brg1 is required for gene transcription of distinct genes also in 
prospective mesendsoderm. Furthermore, when BCNE genes were analyzed in BMO1 DV injections, 
the embryos provided new informations. As the expression pattern perfectly matches with DV 
Results 
63 
injections, chordin and noggin mRNAs were tremendously reduced in the BCNE (Figure 3.15 B, B’; 
E, E’). For chordin, 80% of the injected embryos showed reduced gene expression. This was even 
higher as in DA-injections. Regarding noggin the percentage of embryos with reduced gene 
expression was comparable with DA-injections, namely 70%. These observations highlight a non 
cell-autonomous function for Brg1 protein, which is required for the transcription of Nieuwkoop 
center genes to unfold the RNA signature of the neighboring BCNE.  
These results can be summarized as follows. Embryonic patterning requires the BCNE and 
Nieuwkoop center signaling activities on the prospective dorsal side. Genes in both signaling centers 
become induced by wnt activity and Brg1 helps to induce many, but not all of them. Furthermore, 
autonomous and non-autonomous effects allow anterior neural differentiation of the head. Thus, 
Brg1 behaves as a pleiotropic regulator of gene activation from midblastula stage on.  
 
3.14 Brg1 knockdown in Xenopus tropicalis 
In search for a possible common denominator that explains Brg1’s target gene selectivity, a 
genome-wide transcriptome analysis was undertaken. For this approach, the related species Xenopus 
tropicalis is more suitable than Xenopus laevis for several reasons. First of all Xenopus tropicalis has a 
diploid genome in contrast to the allotetraploid Xenopus laevis. This makes it easier to accomplish 
protein knockdown in a reliable manner. A second big advantage offers the much better annotated 
genome resource of X. tropicalis, which increases the number of transcripts that can be scored and 
related to biological pathways depending on Brg1 function.  
A first prerequisite was to demonstrate a comparable and specific morphological phenotype 
upon Brg1 knockdown in X. tropicalis. BMO1 and BMO2 also fit to the Brg1 sequence of X. tropicalis 
(Figure 3.16 A). This allows using the same morpholinos, thereby increasing the comparability of the 
results obtained in the two species. For this purpose BMO1 and BMO2 were singly injected in one 
dorsal blastomere at the 4 cell stage. After cultivating until NF40, the Eye-Size-Index (ESI) was 
measured. The eye size was reduced and dorso-anterior structures were impaired upon both 
morpholino injections to a comparable extent like in X. laevis by BMO1. This argues that Brg1 has a 
similar role in X. tropicalis as in X. laevis. Again BMO1 was the more potent morpholino regarding the 
strength of the phenotype. To nearly abolish eye development, 2.5 ng/blastomere of BMO1 was 
sufficient whereas 10 ng/blastomere had to be injected in the case of BMO2 (Figure 3.16 B; E; D; G). 
Although, four fold higher than BMO1, the latter dose is within the recommended dose range for 
Xenopus (Heasman, 2002). In addition, both BMO1 and BMO2 were partially rescued by coinjections 
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of human Brg1 WT mRNA (Figure 3.16 C; F; D; G). These results provide the experimental grounds to 
investigate the genome wide contribution of Brg1 to the embryonic transcriptome.  
 
Figure 3.16: BMO targeting side and their effect on development. A shows the BMO targeting side in the 
X. tropicalis Brg1 mRNA sequence. In B, C, E, F lateral views of the morphological phenotype of BMO1 and 
BMO2 in X. tropicalis are shown. Embryos were injected in the DMZ of one dorsal blastomere at the 4 cell 
stage, cultivated until NF40 and the Eye-size-Index (ESI) were measured. In panel B, lateral views of a 
2.5 ng/blastomere BMO1 injected embryo is shown. The eye on the injected side was hardly developed (white 
arrow). This could be partially rescued by coinjections with 1 ng/blastomere hBrg1 WT mRNA (C). The 
penetrance of the BMO1 phenotype under the different conditions is shown in panel D. In panel E an embryo 
injected with 10 g/blastomere BMO2 in lateral view is shown. On the injected side the eye size was reduced. 
This could be partially rescued with coinjections of 1 ng/blastomere hBrg1 WT mRNA (F). In panel G the 
quantification of the ESI is shown. Numbers indicate the sum of 3 independent experiments. +, injected site; 
*, p ≤ 0.05. 
 
3.15 BMO1 and BMO2 reduce Brg1 protein level at blastula and cause embryonic lethality 
during gastrulation 
For the genome-wide transcriptome analysis, embryos were radially injected with either BMO1 or 
BMO2 oligonucleotide. Therefore a dose had to be defined that reduces the Brg1 protein levels as 
much as possible, while at the same time being non-toxic to the embryo. Since the studies in X. laevis 
indicate early functions for Brg1 from blastula stage onwards, the focus of the transcriptome analysis 
was set to the late blastula. This way, zygotic gene expression and transcriptional readout of early 
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signaling activities would be included. Titration experiments revealed for BMO1 a dose of 
30 ng/embryo and for BMO2 a dose of 60 ng/embryo being most efficient in Brg1 knockdown. Two 
criteria influenced these experiments: The survival of the embryos and the efficiency of the 
knockdown. In the case of BMO1 already 30 ng/embryo injected radially led to embryonic lethality 
during gastrulation. Almost 90% of the injected embryos did not finish the gastrulation, whereas the 
lethality until late blastula stage was comparable to the control embryos (Figure 3.17 A). From the 
morphological analysis it was not clear, why BMO1 injected embryos were not able to proceed 
further in development. The protein level in BMO1 injected embryos at late blastula was reduced to 
an average of 0.48 of the compared control morphants (Figure 3.17 B). This finding indicates that it is 
not possible to produce a null situation presumably due to the maternal Brg1 protein stores. For 
BMO2 injected embryos the situation was not as severe. Whereas almost 80% of the injected embryo 
survived gastrulation, almost 50% died during neurulation (Figure 3.17 A). The embryos displayed 
reduced dorso-anterior structures, followed by death. In terms of protein inhibition, BMO2 was 
somewhat less efficient. On average a knockdown of 0.6%, compared to control morphants was 
created (Figure 3.17 B). In the Western Blot analysis, displayed in Figure 3.17 B, also the maternal 
Brg1 level (see lane “egg”), the preMBT Brg1 protein level (see lane “4cell”) and the Brg1 protein 
level in late blastula uninjected embryos (see lane “UI”) was analyzed. With this titration and 
characterization of the protein level the first steps towards a genome-wide analysis are made. 
 
 
Figure 3.17: BMO1 and BMO2 injection decrease the Brg1 protein level at blastula stage but result in 
embryonic lethality. A shows the lethality rate of embryos injected with either 60 ng/embryo CoMO, 
30 ng/embryo BMO1 or 60 ng/embryo BMO2. Numbers represent the sum of 8 independent experiments. In 
panel B a representative Western Blot analysis out of 4 independent experiments, is shown. As loading control 
the protein level for α-tubulin was investigated.The knockdown efficiency is the ratio between Brg1 and 
alpha-tubulin protein level. The ratios were normalized to the CoMO ratio. M, marker. 
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3.16 Morphant embryos are not delayed in development and do not activate apoptosis  
After finding the right and tolerable dosages of the two morpholinos, some critical points had to be 
addressed. First of all it is important to determine that morphant embryos really pass beyond the 
MBT. To rule out that morphant embryos are not delayed, the MBT marker gene gs17 was analyzed 
in qRT-PCR analyses. The transcript levels of chordin and cerberus, shown to be reduced upon Brg1 
knockdown, were also examined in these experiments. The gene expression of these three genes was 
related to the housekeeping gene odc and normalized to control morphant samples. Upon both 
BMO1 injections gs17 was reduced, but still robustly induced compared to the preMBT transcript 
levels (see Figure 3.18 A “4cell”). About 40 minutes after collecting the embryos in late blastula stage 
control morphants and Brg1 morphant embryos started to gastrulate, as evident from the 
simultaneous appearance of the dorsal blastoporus lip.  
 
 
Figure 3.18: Morphant embryos are neither delayed in development nor do activate apoptosis. A shows one 
representative qRT-PCR analysis of NF9 embryos with MBT marker gs17, chordin and cerberus under the 
indicated conditions. Panel B-E display an ICC for activate Caspase-3. As positive control FADD-plasmid was 
injected in both dorsal blastomeres (DMZ) to ectopically induce apoptosis. CoMO, BMO1 and BMO2 injected 
embryos were radially injected. No activated Caspase-3 pattern was observed in morphant embryos. The 
dashed red line marks the area of active Caspase-3 staining in the positive control. The black dashed lines in the 
inserts depict the dorsal lip. The white asterisk indicates background staining in the blastocoel.  
 
The embryonic lethality following from the Brg1 protein knockdown raised the concern, if the 
embryos were still healthy at the onset of the gastrulation or if they activated the apoptotic program 
already. This was investigated by immunostaining for active Caspase-3. Beginning of gastrulation, 
radially injected morphant and control embryos were collected and stained for activate Caspase-3. 
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As a positive control 60 pg of FADD plasmid was injected into the DMZ 4 cell stage (Figure 3.18 B). 
Whereas the positive control showed an accumulation of apoptotic cells, neither the control 
morphants nor the BMO-injected embryos showed apoptotic cells (Figure 3.18 C-E).  
With these controls it can be stated that the embryos that are going to be analyzed in the 
genome-wide analysis have passed the MBT, are reduced in Brg1 protein level, show the typical 
reduction of chordin and cerberus, do not undergo apoptosis and are not delayed in development.  
 
3.17 Genome-wide transcriptome analysis of BMO1 morphant embryos 
For the genome-wide transcriptome analysis the Affymetrix GeneChip®Xenopus Tropicalis Genome 
Array was used. On this Chip over 59000 probe sets are spotted, which represent more than 25000 
genes in X. tropicalis. In total, 12 genome arrays were performed. For each condition - CoMO, BMO1 
and BMO2 - four biological replicates were analyzed. The quality of each RNA sample was tested on 
the Bioanalyzer. The RIN-values ranged between 8 and 8.6. The 12 RNA samples were handed over to 
the “Facility of functional genomics” at the Munich Gene Center, where the array hybridization was 
performed. The raw-data was sent to Dr. Tobias Straub, the head of the “Bioinformatics Core Unit” at 
the Adolf-Butenandt Institut, who performed the bioinformatic analysis described below. 
 
 
Figure 3.19: Brg1 knockdown causes minor changes in the transcriptome. A shows a pie chart of all 10216 
genes that were active at NF9 and their response to Brg1 knockdown. For more details see text. The list in 
panel B shows the 5 most significant GO-terms for the upregulated gene cohort. In list C 5 significant enriched 
GO-terms of all downregulated genes are shown. Exp Count, expected count. 
 
A cutoff was defined which binned the 25000 genes on the array in “active at late blastula” and 
“not-active at late blastula”. 10216 of the spotted genes were active at this early developmental 
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stage. For statistical reasons the local false discovery rate (lfdr) was set to ≤  0.2. After filtering, only 
872 genes remained as responding to Brg1 knockdown. This indicates that 9344 genes, i.e. 91.46% of 
all active genes at late blastula were statistically not changed upon BMO1 knockdown. From the 
872 altered genes 21 (2.07%) were upregulated and 661 (6.47%), were downregulated. These results 
are depicted in a pie chart of all active genes in Figure 3.19 A. This outcome was rather surprising, as 
a change in gene expression of only 8% of all genes obviously cause severe morphological 
phenotypes and embryonic lethality. 
In order to classify the responding genes, a Gene Ontology search was carried out. Within the 
upregulated gene cohort terms like “chromatin assembly” or “macromolecular complex assembly”, 
were overrepresented (Figure 3.19 B). Among the downregulated genes mainly developmental 
related genes were affected, like “nervous system development” and “pattern specification process” 
(Figure 3.19 C). This analysis leads to the conclusion that knockdown with BMO1 results rather 
selectively in changes on the transcription level but these changes are sufficient to perturb the 
embryonic program and cause embryonic lethality.  
 
3.17.1 Genes related to “nervous system development” are affected in Brg1 morphants 
Since the majority of misexpressed genes was downregulated and related to development, the focus 
was set on this gene cohort. First of all the most enriched sub-GO-term “nervous system 
development” was examined in detail. This GO-term lists 62 genes of which 19 were misregulated 
upon BMO1 injections. To validate the microarray results, another four independent biological 
replicates were performed and the gene expression of the 19 misregulated genes was re-investigated 
by quantitative RT-PCR. The results are shown in Figure 3.20. The gene expression levels of the 
analyzed genes were related to two house keeping genes, ornithin decarboxylase (odc) and 
glycerinaldehyd-3-phosphate-dehydrogenase (gapdh), and then normalized to control embryos. 
Genes that were downregulated more than 1.5 fold in the microarray analysis are depicted in red. 
From these 19 genes 15 could be verified to be significantly downregulated upon BMO1 injections, 
marked with the asterisk. This experiment underlines the significance of the microarray data and 
connects it to the morphological phenotype which was observed in DMZ targeted injections (see 
Figure 3.4).  
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3.17.2 BMO1 affects a broad range of genes throughout all germ layers 
The morphological analysis has identified a requirement for Brg1 in neuroectodermal differentiation, 
starting in the BCNE. Even though this requirement is underlined in the microarray analysis, it is not 
Brg1’s only function. This becomes particularly clear in the morphological phenotype of BMO1 
VMZ-injections. One third of these embryos displayed problems in the development of 
ventro-posterior structures (see Figure 3.4). This broader function is reflected in the microarray 
analysis, in which not only dorsal genes were affected but rather a broad range of general 
development related genes. In order to investigate the additional effects of BMO1 injections 
throughout germ layers, a selection of genes with broad functions in diverse developmental 
programs were further tested.  
As mentioned before, chordin, noggin, xnr3, siamois, twin and otx2 are expressed in the 
dorso-animal part of the embryo. Whereas chordin and noggin were significantly downregulated, 
xnr3 was upregulated. This is not in accordance with the WMISH pattern observed in X. laevis and 
might reflect a regulatory difference between the two species (Figure 3.9). Siamois in contrast, is not 
responding in X. laevis while the paralogous gene twin is upregulated in X. tropicalis upon BMO1 
injection. Otx2 was marginally reduced in the microarray and qRT-PCR analysis, while its WMISH 
pattern in X. laevis gastrula embryos revealed a prominently reduced expression domain (Figure 3.8).  
Follistatin, cerberus, bmp4 and sizzled are all located in the dorso-vegetal halve of the 
developing embryo. Whereas follistatin and cerberus are important to specify head structures, bmp4 
Figure 3.20: Genes in the GO-term 
“nervous system development” are 
highly affected upon BMO1 
knockdown. qRT-PCR analysis of 
the tested 19 genes that showed 
reduced expression in the BMO1 
morphant array. Genes which 
showed ≥ 1. 5 fold change in the 
morphant microarray analysis are 
depicted in red. 15 genes within this 
group showed a significant 
reduction in gene expression. 
Shown is the mean of 
eight  independent experiments. 
*,p ≤ 0.05.  
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supports ventro-posterior fate. Follistatin and bmp4 were reduced in their gene expression, whereas 
cerberus and sizzled did not respond to BMO1-mediated lower levels of Brg1 protein.  
Important for neuroectodermal differentiation are the genes zic1 and zic3. Both genes were 
downregulated upon knockdown of Brg1. In contrast, zic2, important for the maintenance of 
neuron-precursor genes, was not changed (Yan et al, 2009). Little information is available about 
sox21 but it is believed to promote neuroectodermal differentiation. It was one of the strongest 
responder to Brg1 ablation in the microarray analysis. In contrast, epidermal fate promoting gene 
foxi1 is upregulated upon Brg1 knockdown.  
 
 
Figure 3.21: A broad range of genes are affected by the BMO1 injections. Shown is a qRT-PCR analysis of 19 
genes, which are expressed in various tissues of the developing embryo and which define different germ layers. 
Shown is the mean of eight independent biological experiments. The asterisk marks statistical significance with 
p ≤ 0.05.  
 
The remaining genes that were investigated are all expressed in mesendodermal cells. Gata4, 
which is active in the dorsal and ventral mesendoderm, promotes differentiation of anterior 
mesoderm and was downregulated in morphant embryos. The gene early growth response 1, egr1, is 
transcribed mesodermal and later on also in posterior parts of neurula embryos. Even though this 
gene was upregulated in the microarray analysis, this result could not be verified by qRT-PCR. Xnr5 
and xnr6 are both targets of the wnt and nodal pathway and are already expressed preMBT. As it was 
shown earlier in Figure 3.3 the preMBT expression of the genes were not changed, but in late 
blastula the gene expression are slightly upregulated in morphant embryos. This could be verified in 
the microarray analysis.  
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All together, the responses of this set of functionally diverse genes, crystallizes the notion that 
a loss of Brg1 protein activity has a broad impact on gene expression in the embryo. Given that these 
requirements are already visible at approximately 40-50% of the normal Brg1 level suggests that the 
full extent of Brg1’s impact on gene transcription could be much larger and potentially even global.  
 
3.18 Brg1 knockdown by BMO2 recapitulates the major changes in gene expression 
To control for potential off target effects of the BMO1, the microarray analysis was repeated with a 
second morpholino, BMO2 (Figure 3.16 A). The pretest had indicated that the blocking efficiency of 
this morpholino was not as strong as BMO1, and consequently the morphological phenotype was 
milder.  
As expected from the lower translation-blocking efficiency less genes responded to BMO2 in 
the microarray analysis. From the 10241 active genes at late blastula, 259 genes, 2.53%, were 
upregulated upon BMO2 knockdown. A minor fraction, namely 190 genes, 1.86%, was 
downregulated. The remaining 9792 genes, 95.62% did not pass the statistical cutoff of lfdr ≤ 0.2. 
 
 
 
With both classes of responders, upregulated and downregulated, a search in Gene Onthology was 
performed, but no statistical overrepresentation was found. This is quite unusual but points towards 
a rather global function of Brg1 rather than a specific functional annotation.  
Despite the quite different outcome of BMO1 and BMO2 microarray data, also common 
responders were identified. As mentioned above in the BMO1 analysis various genes were chosen to 
be verified in qRT-PCR analysis. The same genes were tested also under BMO2 conditions. The result 
is displayed in Figure 3.23.  
Figure 3.22: Microarray analysis for BMO2 
injected embryos. Shown is a pie chart of all 
active genes at NF 9 and their response to Brg1 
knockdown by BMO2.  
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The BCNE genes chordin and noggin were only slightly downregulated in its gene expression 
but this reduction was not statistically significant over a mean of 7 independent biological replicates. 
In the dorso-animal group only twin was statistically reproduced among the two morpholino 
oligonucleotides. However, for all genes, except xnr3, the principal tendency was the same as with 
BMO1. 
 
Figure 3.23: BMO2 microarray validation via qRT-PCR. A broad range of genes from various cell tissues and 
germ layers were analyzed in qRT-PCR analysis. 8 genes could be verified as statistically significant. In general, 
the investigated genes showed a similar tendency of misregulation for both morpholinos. Shown is the mean of 
seven independent experiments. *, p ≤ 0.05. 
 
The dorso-vegetal genes showed a diverse pattern in comparison to the BMO1. Whereas follistatin 
was downregulated, albeit to less extent than in the BMO1 morphants, cerberus gene expression was 
severely downregulated. This result was already observed in previous experiments (Figure 3.18). The 
two ventral genes, bmp4 and sizzled are not changed upon BMO2 injections. 
Regarding the neuroectodermal genes, the two morpholinos achieved comparable result, 
although again gene responses were weaker with BMO2. Neurogenesis promoting genes zic1 and 
zic3 were downregulated, neuronal progenitor maintenance factor zic2 was unchanged, while sox21 
was severely reduced and epidermal fate promoting gene foxi1 was upregulated. 
Among the mesendodermal genes, only gata4 was reduced under BMO2 knockdown. Egr1 
and xnr6 were slightly upregulated but not in a statistically significant manner. Xnr5 was not changed 
in its gene expression.  
In total, the BMO2 morpholino displayed fewer changes on global gene expression level than 
BMO1. This was expected, because BMO2 also showed a lower translation blocking efficiency. 
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Finally, the validation of the same genes by qRT-PCR revealed similar tendencies. All together, the 
BMO2 data supports the results so far obtained for BMO1. 
3.19 Global transcription changes at midblastula transition 
The analysis revealed on morphological and molecular level that Brg1 is required especially during 
specification of dorsal structures. Nevertheless there is also evidence that Brg1 plays a role in ventral 
cell fate specification. Neither with the morphological features nor with the global transcriptome 
analysis a common denominator for Brg1 target genes has been revealed so far.  
Due to the fact, that the earliest responders among dorsoventral Brg1 target genes can be 
traced back to the MBT, this stage was reinvestigated with the goal to define a potential role for Brg1 
in zygotic genome activation. So far, only a few studies investigated the preMBT transcriptome in 
Xenopus (Blythe et al, 2010; Paranjpe et al, 2013; Yanai et al, 2011). The majority of the published 
analyses examined genome-wide data after the MBT (Akkers et al, 2009; Bogdanovic et al, 2011; 
Bogdanovic et al, 2012; Schneider et al, 2011). Since the transcriptome undergoes major global 
changes at MBT, a comparison between the expression levels of preMBT and postMBT embryos 
would be very informative regarding the molecular events happening at the MBT. A simplified 
scheme in Figure 3.24 illustrates these changes. 
In principal, three different classes of mRNAs are considered to be present at late blastula 
(NF9). One group of genes is maternally expressed and will be degraded with midblastula transition. 
This pool of RNA is depicted in blue. Other genes are already expressed maternally and with the MBT 
those gene transcripts get replaced with zygotic transcripts. Overall this pool of RNA, illustrated in 
green, may stay more or less constant in its abundance. The third class of mRNAs are the newly de 
novo gene transcripts, which are not present in the preMBT embryo. This class is shown in purple. In 
order to reveal a possible role for Brg1 in activating the newly zygotic genes, the purple class of 
mRNAs needs to be identified.  
 
 
Figure 3.24: Simplified scheme of RNA classes and 
their dynamics during early development. In blue 
the maternal RNA class is visualized. It is defined as 
maternally present and the expression decreases 
after MBT. Depicted in green is the RNA class that 
is maternally and zygotically expressed with little 
changes in expression level. In purple are the 
transcripts classified that are absent maternally 
and get de novo transcribed with transition at the 
midblastula.  
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To examine this question a second microarray analysis was performed. The experimental workflow is 
shown in Figure 3.25 A. Xenopus tropicalis wild type embryos were collected in three phases: at the 
4 cell stage; every 20 minutes over the MBT and in late blastula stage again every 20 minutes, until 
the pigmentation of the dorsal lip appeared. Then, to identify the preMBT sample closest prior to the 
MBT, the expression level of MBT marker gs17 was analyzed in qRT-PCR. In Figure 3.25 B a 
representative qRT-PCR analysis is shown. The gene expression level of gs17 was normalized to 4 cell 
stage embryos. Finally, the latest sample without gs17 transcript was chosen as the preMBT sample 
for analysis.  
The corresponding postMBT sample was the one collected ~40 minutes prior to appearance 
of the dorsal lip. This time point is in accordance to the time point of the BMO microarray analyses. 
To ensure the quality of the RNA the collected samples were run on the Bioanalyzer. The samples 
with the highest RIN score were chosen for the microarray analysis. In total, 3 pairs of independent 
pre- and postMBT samples were processed. 
 
Figure 3.25: Experimental workflow to determine pre-and postMBT samples for microarray analysis. A shows 
a scheme of the experimental workflow. X. tropicalis WT embryos were in vitro fertilized and samples were 
collected at the 4 cell stage, whilst over the MBT in 20 min intervals and in late blastula again in 20 min 
intervals until the appearance of the dorsal lip. RNA was extracted and gene expression of MBT marker gs17 
was investigated by qRT-PCR. B shows a representative qRT-PCR analysis of gs17 expression profile. The sample 
pair which was used for the microarray analysis is shown in red.  
 
3.20 Comparison of pre- and postMBT transcriptomes  
In the comparative microarray analysis, 10169 mRNAs from active genes were detected in either 
preMBT or postMBT. After setting the statistical cutoff of the “adjusted p-value” to ≤ 0.05, only 1357 
genes remained, that are significantly. From this gene cohort 596 genes (5.86%) showed an 
upregulation of transcription and 761 genes (7.48%) a reduction of transcription between MBT and 
the late blastula. This result is depicted in the pie chart in Figure 3.26 A.  
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In Figure 3.26 B the enriched GO-terms for the upregulated gene class are listed. Besides the 
expected term “regulation of RNA metabolic process” and “transcription, DNA-dependent” also 
developmentally relevant terms like “pattern specification process” and “developmental process” 
emerged. The pattern specification process is of particular interest, as it was overrepresented in the 
downregulated responder genes cohort of the BMO1 microarray data set (Figure 3.19). 
 
 
Figure 3.26: Gene expression changes of preMBT and postMBT embryos. A shows a pie chart with the three 
classes of RNA pools revealed from the comparative microarray analysis. In B the 5 most significant GO-terms 
for the “upregulated after MBT” cohort are shown. 
 
3.21 Highly upregulated genes at MBT need Brg1 protein 
As the GO-term “pattern specification process” was detected both in the downregulated GO-terms of 
the BMO1 morphant array and in the cohort of upregulated genes after MBT, this connection was 
further examined. The genes, present in this GO-Term, are listed in a heat map in Figure 3.27 
according to the magnitude of activation at MBT, strongly activated genes are on top; less strongly 
activated genes are at the bottom. These genes were now compared to the list of BMO1 responding 
genes (see Figure 3.19). The genes which showed a downregulation more than 1.5 fold change in the 
BMO1 microarray analysis are marked with a red asterisk. Interestingly, the majority of the marked 
genes were among the strongest activated ones at MBT. In the GO-term “nervous system 
development” this distribution can be seen as well (data not shown). The genes that undergo strong 
upregulation after the MBT were among the genes that depend strongly on Brg1 protein.  
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In the BMO2 morphant microarray analysis this observation is not that explicit, but the trend is also 
apparent (data not shown). To verify further the hypothesis that a loss of Brg1 mainly affects the 
strongest upregulated genes after MBT- the “MBT-burst” gene class- was examined in detail. Defined 
as “MBT-burst” are genes, that show an upregulation at MBT higher than 5.65 fold change and this 
class of genes was separately compared with the responding genes of the BMO1 and BMO2 array 
data sets. In Figure 3.28 two pie charts display the response of the “MBT-burst” genes either under 
BMO1 knockdown or BMO2 knockdown conditions. For BMO1 324 genes were listed and almost 50% 
of them were misregulated. 135 genes were significantly downregulated and 9 genes were even 
upregulated upon Brg1 knockdown. The remaining 180 genes were not statistically significant with a 
local false discovery rate (lfdr) ≥ 0 .2. Under BMO2 conditions, the same trend is seen, albeit less 
pronounced. 30 genes of the 352 “MBT-burst” genes showed a downregulation upon knockdown 
Figure 3.27: Heat map of GO-term “pattern 
specification process”. The genes related to 
“pattern specification” are listed upon their 
changes in gene expression preMBT relative to 
postMBT. The first two columns describe the 
gene expression preMBT and postMBT, 
respectively. The deeper the blue the higher is 
the gene expression. The ratio for each gene is 
depicted in the logFC column. The genes that 
underwent the strongest changes have a high 
logFC value and are listed on top and genes 
which underwent no changes or 
downregulation are displayed in the bottom of 
the list. The red asterisk marks the genes that 
were downregulated more than 1.5 fold in the 
BMO1 morphant array. 
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with BMO2 and 11 genes showed an additional upregulation. For the vast majority, namely 311 
genes, the changes in their expression level were not statistically significant. Nevertheless, the fact 
that more genes in this subset showed a downregulation rather than an upregulation is meaningful, 
because the overall trend of the transcriptome analysis upon BMO2 injections displayed rather an 
up- than a downregulation (Figure 3.22). This underlines the specificity of the finding that mostly 
genes that undergo a burst of transcription at the MBT require Brg1 protein. 
 
 
Figure 3.28: The “MBT-burst” genes require Brg1 protein function. The strongest upregulated genes at MBT 
were correlated to their gene expression upon either BMO1 knockdown (A) or BMO2 knockdown conditions (B) 
and visualized in a pie chart.  
 
After revealing a relation between strong induction of gene expression at MBT and the necessity for 
concomitant presence of Brg1 protein, this hypothesis was further analyzed. Therefore, the genes of 
the preMBT/postMBT microarray analysis were devided into two classes. One class contains all genes 
that showed an upregulation in transcription at the MBT and the other class represents all genes that 
were either not changed between pre and postMBT or were downregulated at MBT.  
Under both knockdown conditions, BMO1 and BMO2, the genes that underwent a 
upregulation at the MBT were reduced in their gene expression in comparison to the genes that did 
not undergo such a burst of transcription (Figure 3.29). The impairment of this transcriptional burst 
at MBT was more severe upon BMO1 knockdown than under BMO2 knockdown conditions. Given 
that BMO2 is less efficient in blocking the protein translation, this result is coherent. However, the 
tendency is clearly visible and statistically validated. 
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Figure 3.29: Brg1 protein function is needed for the transcriptional burst at MBT. In A the boxplot displays 
that genes which underwent an upregulation at MBT are strongly impaired in their expression level under 
BMO1 knockdown conditions in comparison to genes without an upregulation. B shows the same correlation 
under BMO2 knockdown conditions. w/o, without. 
 
From this data it can be concluded, that Brg1 protein function is required to ensure the 
transcriptional burst at MBT. Additionally, the fact that two different morpholino oligonucleotides, 
with a minimum of overlap, result in a comparable morphological phenotype showing the same 
trend of correlation in the microarray sets, underlines the specificity of the finding.  
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4 Discussion 
The development from a zygote to a multicellular organism is a profound process, which requires 
extensive arrangements on the cellular and genomic level. Each different cell type is the product of 
distinct signal gradients, inductive events or transcriptional restrictions in order to establish a unique 
transcriptional and cellular architectural state. Any developmental signal matters and even minor 
imbalances can lead to severe malformations up to embryonic lethality. Understandably, the earliest 
events in the life of an organism have to be tightly regulated and controlled. Chromatin modifying 
enzymes like methyltransferases or chromatin remodeling complexes have a pivotal role during 
these early events. By modulating the chromatin state, they cause changes on the transcriptional 
level, in particular stable on and off states ensuring a regulatory memory that stabilizes cell fates. 
In this PhD thesis a crucial role for the chromatin remodeling ATPase Brg1 protein function 
during early Xenopus development has been revealed. A requirement for Brg1 during differentiation 
of neurons was already suggested. An additional role during neurogenesis and dorso-ventral 
patterning at earlier time points was discovered in this study. With a morpholino-based knockdown 
approach it was shown that Brg1 protein is essential for embryogenesis, since a loss of Brg1 caused 
embryonic lethality during gastrulation. Furthermore, the first misregulated genes under knockdown 
conditions were found in late blastula stage. Mainly the BCNE signaling center was affected but not 
all genes were equally impacted, which suggests some target specificity. In addition, also genes 
outside the BCNE were affected. The transcriptome analysis of morphant embryos at blastula stage 
revealed rather minor changes, though it was informative in terms of gene specificity. Two major 
considerations led to the investigation of Brg1 function during zygotic genome activation. The 
activation of the zygotic genome presumably requires large rearrangements within the chromatin 
structure which takes place at the MBT, meaning shortly before the first effects upon Brg1 
knockdown were visible. Secondly, it was shown that Brg1 deficient mice die during implantation and 
that maternal Brg1 protein is needed for proper zygotic genome activation (Bultman et al, 2006). 
Taken this into consideration, the transcriptome of preMBT and postMBT wild type embryos were 
investigated and three different mRNA pools were defined. After comparing the mRNA subsets with 
the transcriptome analysis of Brg1 morphant embryos it became clear that the highly upregulated 
genes were specifically dependent on Brg1 activity. This suggests that Brg1 is required in Xenopus 
development for the burst of transcription at the MBT and that it is essential for a proper activation 
of zygotic genes, similar to what was shown in mouse development. 
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4.1 Morpholino efficiency and targeting behavior 
In order to perform morpholino-based knockdown analyses, three different morpholinos against 
Brg1 mRNA were designed. As shown in Figure 3.2 the target sides differed among the three 
morpholinos. BMO1 targets only the coding region, beginning with the ATG. BMO2 is designed a bit 
upstream in the 5’UTR but reaching into the coding sequence. BMO3 targets only the 5’UTR and 
shares 14 bases with the BMO2. Although the targeting sides are in close proximity, the luciferase 
assay revealed differences in the translation blocking efficiency (see Figure 3.2). The optimal 
morpholino target is a 25 base sequence that lies within the region from the 5’ cap to the first 25 
bases of the coding region (www.gene-tools.com). Even if the company meanwhile recommend 
testing 2-3 morpholinos for the same mRNA, such a difference in blocking efficiency is rather 
unusual. The Kroll lab used a Brg1 morpholino targeting even further upstream of the minor efficient 
BMO3 tested in this study. Taken this into consideration, this could explain why they did not observe 
an earlier effect upon Brg1 knockdown. Although they investigated the Brg1 protein level by western 
blot analysis and clearly saw a downregulation, one has to keep in mind that their analysis regards 
embryos in neural stages (Seo et al, 2005). Presumably their morpholino was not efficient enough to 
reduce the protein level already at blastula stage in order to observe a misregulation. In the 
literature a correlation between morpholino efficiency and targeting side was not suggested so far. 
One paper, which investigates morpholino knockdown efficiency by a luciferase-based assay, 
correlated the inhibition efficiency with the strength of the phenotype in zebrafish upon Chordin 
knockdown. Two Chordin morpholinos were independently injected and indeed the more upstream 
morpholino showed lower penetrance (Kamachi et al, 2008). Overall such a correlation would be 
interesting and could presumably be explained by possible secondary structures, which leave the 
ATG-region accessible for ribosomes, whereas the 5’UTR forms loops.  
In vivo, the Brg1 protein levels were examined in eggs, wild type 4 cell stage embryos and at 
late blastula stage in four different conditions: wild type, CoMO-, BMO1- and BMO2-injected. An 
increase in Brg1 protein level between eggs and 4cell stage was observed, whereas between the 
4 cell stage and the late blastula stage (NF9) the protein level is more or less constant. Under 
knockdown conditions, BMO1 reduced the Brg1 protein level to less than 50%, whereas BMO2 
reached a reduction up to 60%. Given that the time point of the genome-wide analysis is quite close 
to the MBT a complete reduction of Brg1 protein cannot be achieved, as the maternal Brg1 protein is 
still present. Though, a reduction only up to 40-50% already leads to embryonic lethality. 
 
Discussion 
81 
4.2 Phenotypic analysis of Brg1 morphant embryos 
4.2.1 Morpholino based knockdown analyses 
For genome-wide analysis Xenopus tropicalis embryos were radially injected. In BMO1 injections this 
led to embryonic lethality during gastrulation, while the majority of radial BMO2 injected embryos 
survived until neurulation. Most likely, this difference is explained by the different morpholino 
efficiencies. Regarding the embryonic lethality caused by BMO1 several mechanisms are possible 
that explain a unfinished gastrulation. First of all, SWI/SNF and Brg1 are known to be connected to 
cell cycle progression (Muchardt & Yaniv, 2001; Simone, 2006). A reduction of Brg1 therefore will 
lead to uncontrolled cell proliferation as some of the cell cycle check points are not functional 
anymore. This in turn leads to more and more DNA damages and especially in this early 
developmental stage the embryo cannot compensate for it, which in the end leads to developmental 
arrest. In case of BMO2 injected embryos the protein level is less reduced and probably sufficient to 
ensure in some degree a normal proceeding through gastrulation. Although an alteration within the 
cell cycle in Brg1 morphant embryos is valid, it is presumably not the cause of the embryonic 
lethality, as PMEFs deficient for Brg1 show no alterations in cell viability (Bultman et al, 2000). The 
second possible explanation is rather related to developmental specification processes, as it was 
revealed within this thesis that Brg1 is required for a proper transcriptional burst at the MBT. Among 
the genes, which were highly upregulated were mainly genes important for cell fate specification 
(Figure 3.19). Additionally, the germ layers and the body plan are specified during gastrulation. Given 
that after BMO injections the level of Brg1 was reduced, also the transcription of these genes was 
impaired and the specification process during gastrulation could not proceed in a proper way. In the 
case of BMO1, this was more severe than in BMO2 injections as the Brg1 protein level was lower and 
more genes were affected. This could be the cause of a cellular arrest as the cells lacked specific 
signals for differentiation. However, a tightly controlled study in morphant embryos investigating the 
morphological changes during gastrulation paired with apoptotic and proliferation markers would 
give further insight.  
In targeted knockdown studies two different injections were performed. The marginal zones of 
either dorsal or ventral blastomeres were injected. BMO injections into the dorsal marginal zone led 
to severe dorso-anterior malformation. The phenotype ranged from a mild reduction of the eye up to 
a near complete loss of dorso-anterior structures (Figure 3.4). In order to classify morphological 
phenotypes in Xenopus the Dorso-Anterior-Index (DAI) is often used (Kao & Elinson, 1988). On this 
scale, the DMZ injected embryos classified as DAI 2–DAI 4, which is associated with a reduction of 
dorsalizing factors. As already pointed out in the introduction, the dorsalizing activity in Xenopus 
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embryos is mediated via ß-catenin signaling. A physical interaction in HEK239T cells between ß-
catenin and Brg1 was already shown and a promoting function of Brg1 of wnt target genes was 
suggested. Additionally, a genetic interaction of Brahma and Armadillo was described in Drosophila 
(Barker et al, 2001). Furthermore, knockdown of maternal ß-catenin target genes, like siamois, twin 
or chordin, display similar dorso-anterior truncated phenotypes in Xenopus (Bae et al, 2011; Ishibashi 
et al, 2008; Kuroda et al, 2004). These described functions paired with the observation of the 
knockdown analysis of this study suggests a similar interconnection between ß-catenin and Brg1 also 
in Xenopus. This is a preferable explanation, but some results claim against it. The first experiment to 
verify such an interconnection was the secondary axis assay induced by Siamois. Although the 
secondary axis formation was minimally reduced on average, upon coinjections of BMO1, the 
DAI-value was not significantly reduced. This indicates that Brg1 is not essential to transmit the 
downstream dorsalizing activity of wnt target gene siamois. However, it does not exclude a genetic 
interaction between ß-catenin and Brg1 in Xenopus or a possible inducing feature of Brg1 on other ß-
catenin target genes. In the end, the result of this experiment remains inconclusive. To resolve this 
question a CoIP or even better a ChIP at ß-catenin target genes should be performed. Noteworthy 
only siamois was analysed in this epistatis experiment, but the secondary axis formation potential is 
known for many more ß-catenin target genes (Carnac et al, 1996; De Robertis, 2006; Lemaire et al, 
1995). A second hint that the role of Brg1 is beyond wnt/ß-catenin signaling suggested the animal 
cap assay (see Figure 3.14). Although both wnt-target genes, siamois and xnr3, were less induced by 
wnt8 mRNA in the presence of BMO1, the same is also true for the two nodal-signal genes goosecoid 
and foxa4. Upon coinjections of Activin mRNA and BMO1 also these two genes showed a reduced 
gene expression. This suggests a more general role for Brg1 as a transcriptional activator, rather than 
a specific role in the ß-catenin signaling pathway. Though, the strongest argument, that Brg1 has a 
role beyond the ß-catenin signaling, is the fact that no enrichment for wnt target genes was detected 
within the microarray analysis (see Figure 3.19). In total, these results points towards a more general 
role for Brg1 in gene induction, with no pathway but gene target specificity. 
BMO injections into the marginal zone of ventral blastomeres had a much weaker impact on 
development. About one third of the ventrally injected BMO1 morphants showed a malformed 
ventro-posterior development. Overall, it represented a mildly dorsalized phenotype, caused by a 
loss of ventral structures. Again there could be several explanations for that. Firstly, it could be that 
the outgrowth of the tail is impaired. However, this explanation is rather unlikely because in this late 
developmental stage Brg1 is restricted to neural structures and the outgrowth of the tail starts 
around NF27 (Beck & Slack, 2002; Seo et al, 2005). Loss of ventral tissue could also result from 
increased apoptotic cell death. As discussed above, Brg1 is connected to the cell cycle and a possible 
mechanism could be that a loss of Brg1 on the ventral side of the embryo causes uncontrolled cell 
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cycling. However, this would indicate different functions of Brg1 depending on its dorsal or ventral 
localization, which could be possible but is rather unlikely. As the phenotype looked like a mild 
dorsalized embryo, a further explanation could be that a loss of Brg1 leads to a reduction of ventral 
fate signaling. One possible candidate is Bmp4 protein. Bmp4 is hardly maternally expressed but is 
quickly upregulated at late blastula, peaking in early gastrula (Hemmati-Brivanlou & Thomsen, 1995). 
Broadly expressed in the ecto- and mesoderm, bmp4 expression is restricted during gastrulation to 
the ventrolateral marginal zone (Hemmati-Brivanlou & Thomsen, 1995). A knockdown study of Bmp4 
revealed a mild dorsalization phenotype with major perturbation on ventral fin development 
(Reversade et al, 2005). This phenotype is morphologically very similar to the one observed in this 
study. The microarray analysis showed that bmp4 indeed was reduced upon Brg1 knockdown (see 
Figure 3.21). Additionally, recently a physical interaction of Brg1 and Smad3 could be detected in 
several human cell lines. It was shown that the interaction between the two proteins promotes 
specific TGF-ß target genes (Xi et al, 2008). This study paired with the microarray data of this study 
suggests that Brg1 also positively affects the transcriptional level on the ventral side of the embryo, 
causing a loss of ventral factors in targeted morphant embryos. 
All together, the data indicates, that Brg1 acts predominantly as a transcriptional coactivator 
in both dorsal and ventral tissues. Nevertheless, it is quite surprising that a loss of Brg1 on the dorsal 
side led to a strong reduction of dorso-anterior structures and a loss on the ventral side caused only 
mild reduction.  
 
4.2.2 Overexpression of wild type Brg1 
While the loss-of-function analysis shows the requirements of the gene, gain-of-functions analysis 
reveals what the gene can do. The ectopic overexpression of wild type Brg1 in one DMZ did not 
produce a phenotype. Surprisingly, the overexpression of wild type Brg1 in one ventral blastomere 
caused a truncated secondary body axis. This feature is the hallmark of genes expressed in the 
dorsal-marginal zone of a developing amphibian embryo. The majority of these genes are under the 
control of the maternal ß-catenin signaling pathway (De Robertis, 2006). Genes like siamois and 
chordin are known to produce full secondary body axes when overexpressed on the ventral side of an 
embryo (Oelgeschlager et al, 2003). Although the secondary axis produced by Brg1 overexpression 
contains skeletal muscles, a complete secondary axis, containing head and eye structures, was not 
generated (Figure 3.5). A possible explanation is an induction of Brg1 towards ß-catenin target genes. 
But the fact that in ventral cells ß-catenin is predominantly excluded from cell nuclei, makes this 
argument difficult to hold on (Schneider et al, 1996). Furthermore, Brg1 overexpression only 
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produced truncated secondary axes. Interestingly, an overexpression of a dominant-negative BMP 
receptor on the ventral side also results in truncated secondary axis (Suzuki et al, 1994). This leads to 
the idea that an excess of Brg1 either directly inhibits BMP receptors, represses BMP signals, or 
activates ventrally expressed BMP inhibitors, like sizzled or “BMP and activin membrane-bound 
inhibitor”, bambi. Because Brg1 was also shown to be involved in transcriptional repression, a 
repression of positive regulating BMP signals could be possible (Murphy et al, 1999). In this scenario 
bmp4 is again the most likely candidate. As described above, it mediates the development of ventral 
fate. However, as the morphological phenotype of ventral BMO injections resembles the knockdown 
of Bmp4, presumably Brg1 acts as an activator on bmp4 rather as a repressor. A third hypothesis 
regards an activation of intrinsic BMP inhibitors. Bambi is a TGF-ß-family type I receptor lacking the 
intracellular kinase domain and therefore acts as a pseudoreceptor resulting in inhibiting BMP 
signaling (Onichtchouk et al, 1999). Moreover, Bambi is induced by BMP via the conserved 
BMP-responsive elements and via distinct Smad3 binding repeats and it is coexpressed with bmp4 in 
Xenopus development (Onichtchouk et al, 1999; Sekiya et al, 2004b). In human colorectal tumor cell 
lines, an aberrant high expression of Bambi was observed, which is regulated by ß-catenin–TCF4, 
suggesting that besides BMP and smad signaling also wnt/ß-catenin signaling is involved in the 
regulation of Bambi (Sekiya et al, 2004a). Additionally, Bambi was slightly reduced upon Brg1 
knockdown in the microarray analysis presented in this thesis. This makes Bambi a good candidate to 
be under a positive control of Brg1, which could be involved in forming a truncated secondary axis. 
 On the basis of the morphological phenotypes it is hard to define a clear role for Brg1 during 
development. A molecular marker screening after the various injections would have helped to 
identify the pathways through which Brg1 is acting. Especially in the gain-of-function experiment a 
WMISH at blastula or gastrula stage against either dorsalizing-promoting or BMP inhibitory genes 
would have given a better overview about the Brg1 mechanisms. However, in sum, the most feasible 
explanation points towards a general positive transcriptional regulation of Brg1 during development. 
This would explain all three morphological phenotypes generated in loss- and gain-of-function 
experiments. 
 
4.3 Genome-wide transcriptome analysis of Brg1 morphant embryos 
The embryonic lethality and the inconclusive morphological phenotype derived from targeted 
injections have led to an investigation of a genome-wide transcriptome analysis. The late blastula 
stage was chosen, because radial BMO1 and BMO2 injected embryos were still viable and the BMO1 
morpholino caused already a of reduction in Brg1 protein level. Most importantly, the misregulated 
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BCNE genes chordin, noggin and also cerberus testified that Brg1 is functioning at this time and thus 
increasing the likelihood to investigate direct transcriptional effects. Additionally, the transcriptional 
aspects of axes formation are executed during blastula and gastrula time periods. These facts made a 
global investigation at this early developmental stage feasible. To underline the result, two 
morpholinos were individually injected. The different outcome of the two morphant microarray data 
sets can result from the different translation blocking efficiencies of both morpholinos. If the 
phenotype has a rather composite genetic underpinning, then interactions among genes, which are 
more dependent on Brg1 than other targets, will generate multiple intermediate states of 
DV-patterning in Brg1 morphants, which could lead to an apparently non-overlapping microarray 
result. This could be tested, by comparing the two morpholinos under comparable Brg1 protein 
ablation, rather than maximally achievable depletion conditions. Furthermore, many responder 
genes may show up as a mixture of maternal and zygotic transcripts, thus the real effect is masked by 
their maternal contributions. Therefore it is still possible that each morpholino generates a specific 
phenotype due to unknown off target effects. They are, however, not the major cause of the 
phenotypes, since both BMO1 and BMO2 effects were rescued by coinjections of human wild type 
Brg1 mRNA (see Figure 3.16). 
 A very helpful tool to classify such big data sets is the Gene Onthology analysis (GO). The 
group of responders, which are upregulated upon BMO1 injections, showed an enrichment for terms 
like “chromatin assembly” (GO:0031497), “cellular component assembly” (GO:0022607) or 
“macromolecular complex assembly” (GO:0065003). Even though the output of this analysis was 
rather small, it is obvious that the cell somehow tried to compensate the loss of a chromatin 
remodeling activity to keep up chromatin integrity. Interestingly, neither brahma nor any other 
chromatin remodeling ATPase subunit was upregulated upon Brg1 knockdown. This is in accordance 
with the results Nishant Singhal generated in his PhD thesis. Namely, the malformation of dorso-
anterior structures upon Brg1 depletion were not rescued by coinjections of either hBrahma wild 
type mRNA or xISWI wild type mRNA. This indicates that other ATPase subunits cannot compensate a 
loss of Brg1 and it underlines the importance of Brg1 protein during early development. Notably, also 
none of the BAF proteins were upregulated upon loss of Brg1.  
 In contrast, the genes, which are downregulated upon BMO1 injections, were quite various. 
More than 50 GO-terms were enriched in the responders, whereof the majority is related to 
developmental processes. The most prominent terms are “nervous system development” 
(GO:0007399), “system development” (GO:0048731) and “pattern specification process” 
(GO:0007389). Interestingly, no distinct developmental signal pathway was found. This indicates that 
Brg1, as presumed, is not cooperating with one particular pathway, but rather has a role within 
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various developmental pathways. A loss of Brg1 affects many regulatory genes, whose misregulation 
lead to a dramatic malformation of the embryo and ultimately to its death.  
 
4.4 Brg1 and its role in axes determination 
4.4.1 Antero-posterior axis 
The targeted Brg1 morphant embryos clearly were shorter along the antero-posterior body axis in 
comparison to control morphant embryos (Figure 3.4). In order to have a better estimation about the 
perturbed fragmentation, three AP-axis markers were examined in unilateral BMO1 injected 
embryos. The time point after neurulation was chosen as at this stage the AP-axis is determined. 
Surprisingly, a shift of one AP-segment was not observed. 
The anterior marker pax2 was reduced in a dose-dependent manner after BMO1 injections. If 
this reduction is direct or indirect is not known. Recently, it has been suggested that Pax2 interacts 
with Pax5 to induce the midbrain marker engrailed2. Therefore it is considered essential for brain 
formation in Xenopus (Koenig et al, 2010). In zebrafish a feedback mechanism between Eng2 and 
Pax2 was characterized in which the eng2 gene is activated by Pax2, while Eng2 protein binds then to 
the pax2 promoter region to maintain pax2 gene expression (Picker et al, 2002). In the same year 
another study in Xenopus embryos revealed that orthodentricle homoebox 2, Otx2 directly activates 
pax2 expression (Tour et al, 2002). From these studies it can be suggested that pax2 is under the 
control of otx2, a gene which is already expressed in the organizer territory during gastrulation 
(Fletcher & Harland, 2008). A closer look at the microrarray data sets revealed that otx2 was 
downregulated upon Brg1 knockdown in both morpholino injections up to 1.4 fold change, albeit this 
could not be significantly verified in the qRT-PCR analysis afterwards. In contrast, pax2 is not yet 
expressed in late blastula stages, as the microarray data indicate. This result paired with the WMISH 
gastrula analysis, in which the territory of otx2 was diminished, makes it very likely that a loss of Brg1 
results in reduction of otx2 and consequently pax2 is not fully induced. 
Egr2, the second analyzed marker, is induced by a combination of Noggin protein and Fgf2 
(fibroblast growth factor 2, formerly known as bFGF) at the start of gastrulation. Interestingly, Fgf2 
induction alone induces posterior marker hoxb9 in early gastrula embryos and Fgf2 alone is sufficient 
to induce krox20 in late gastrulation embryos (Lamb & Harland, 1995). In essence, the Fgf2 signal 
helps to specify gene domains along the AP axis, but other factors, like Noggin, are needed at the 
right time to refine the AP-patterning. Unfortunately the Affymetrix microarray does not contain a 
noggin probe set, but in the qRT-PCR analysis noggin was reduced in both BMO1 and BMO2 
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morphants. Furthermore, it was shown that chordin gene expression regulates egr2 expression in 
Xenopus neural explants. Upon Chordin knockdown, the neural explants did not express egr2 
anymore (Kuroda et al, 2004). This is not surprising, as noggin and chordin are coexpressed and both 
function as BMP inhibitors (Bachiller et al, 2000; Kuroda et al, 2004). A study in mice suggested that 
Egr2 not only induces cell segregation but also cell specification, as rhombomere r3 and r5 acquire 
the fates of neighboring rhombomeres in Egr2 depleted embryos (Voiculescu et al, 2001). Why 
rhombomere 5 was more prone to be reduced in comparison to rhombomere 3 upon loss of Brg1 in 
Xenopus is absolutely unclear. One suggestion is that during segmentation, r3 receives additional 
factors which stabilize the expression, while these are missing in rhombomere 5. In total, the results 
indicate that egr2 is reduced in Brg1 morphant embryos by indirect effects, probably through 
reduced noggin gene expression.  
As posterior marker hoxb9 was analyzed. All Hox genes, which are expressed at this stage, 
are coexpressed in a similar pattern as the pan-mesodermal marker xbra. Besides Fgf2, also 
FGF-target gene Xbra is capable to induce hoxb9 expression in Xenopus animal cap assays and hoxb9 
is reduced in Xbra downregulated embryos (Lamb & Harland, 1995; Wacker et al, 2004). 
Furthermore, Bmp4 obviously also has a regulatory effect on the Hox gene cluster, as a constitutive 
Bmp4 receptor leads to an expansion of posterior Hox gene expression, like hoxb9 (Wacker et al, 
2004). Given that Brg1 morphant embryos showed morphologically a ventralized phenotype, it was 
really surprising to see also hoxb9 being reduced. Nevertheless, the positive interconnection 
between Brg1 and Bmp4, led to reduced bmp4 expression in morphant embryos. This could explain 
why hoxb9 expression was diminished, in particular because fgf2 gene expression was not changed 
upon Brg1 knockdown.  
Taken together, the outcome of this experiment is surprising, because an overall reduction of 
the all three analyzed tissues was observed. Conversely, in ventral targeted BMO injections a 
reduction of ventral structures was observed as well. This result underlines again a positive role of 
Brg1 in gene expression and that a knockdown of Brg1 results in reduced gene expression, which 
leads to a composite molecular phenotype. 
 
4.4.2 Dorso-ventral patterning 
The establishment of dorso-ventral patterning can be divided into 2 phases. The first phase takes 
place already in the blastula, in which the BCNE and the Nieuwkoop center are established. The 
second phase is the balancing between organizer and non-organizer signaling centers, a process 
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called dorsalization (Figure 3.8) (Dale & Slack, 1987; Forman & Slack, 1980). To gain an overview of 
this process in Brg1 morphants, both developmental stages were investigated by WMISH analyses.  
The BCNE and Nieuwkoop center both are formed after the transcriptional burst at the MBT on the 
dorsal side of the embryo. Here, the expression of BCNE genes chordin, noggin and xnr3 were 
investigated plus the more vegetal expressed siamois. All four genes are under the control of 
maternal wnt/ß-catenin signaling and the BCNE genes are characterized as BMP-inhibitors and 
required for neural differentiation (Kuroda et al, 2004; Wessely et al, 2001). Among the BCNE genes, 
chordin gave the strongest response to Brg1 knockdown, in WMISH analysis and in both microarray 
datasets. As mentioned above, also noggin gene expression was reduced upon Brg1 knockdown. In 
contrast to its WMISH pattern, xnr3 was not reduced in the microarray analysis of BMO1 and BMO2, 
but rather showed a slight upregulation (see Figure 3.21 and Figure 3.23). However, one has to keep 
in mind that xnr3 was the less responsive BCNE marker in the WMISH analyses and it was performed 
in X. laevis, whereas the microarray data was performed in X. tropicalis. A study, which investigated 
the differences in the gene profiles between these two related species, came to the conclusion that 
differences are rare, but if there are differences, they most likely appear during very early 
development (Yanai et al, 2011). The fact that siamois gene expression was not changed upon BMO1 
and BMO2 injections is in perfect accordance to the earlier discussed results (see Figure 3.9 and 
Figure 3.10).  
Another interesting observation was made in the targeted 8 cell injections (see Figure 3.15). 
DA-injections with BMO1 resulted in a reduction of chordin and noggin gene expression, which was 
expected. Surprisingly, also the Brg1 knockdown in DV-cells reduced the gene expression of these 
two genes. So far the dorsal A and B-blastomeres in Xenopus were thought to solely give rise to the 
BCNE tissue (Bauer et al, 1994; Kuroda et al, 2004). But with this analysis, it is shown that also 
C-blastomeres contribute to the formation of the BCNE and its gene expression, in a 
non-cell autonomously manner. This is at least true for late blastula stages embryo, in which the 
epiboly movements have shifted the BCNE more vegetally (Bauer et al, 1994). 
The investigation of the Nieuwkoop center was represented by the genes cerberus and hhex. 
The BMO1 DA-injections did not interfere with gene expression of both genes, as expected because 
the expression domain and the injections did not overlap, visualized by the lacZ stain (Figure 3.15). 
This suggests a cell-autonomy behavior of the two genes. In the DV-injections, however, both genes 
are severely reduced upon Brg1 knockdown. This reduction was partially validated by the microarray 
analysis and qRT-PCR data. Under BMO1 and BMO2 conditions, hhex gene expression was reduced in 
the microarray analysis. This is different for cerberus. In the microarray and the qRT-PCR, cerberus 
gene expression was hardly changed upon BMO1 injections. However, its expression was significantly 
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reduced upon Brg1 knockdown generated by BMO2. But since cerberus expression has several 
different induction signals, it could well be that for cerberus, like in the case of xnr3, the differences 
between the two morpholinos and the two species stand out (Heasman, 2006; Yamamoto et al, 
2003).  
In summary, these analyses emphasize that Brg1 is needed as early as blastula stage to 
ensure proper dorso-ventral patterning. This is in particular visible in the BCNE and the Nieuwkoop 
center. Since the organizer develops from these two signaling centers on the dorsal side of the 
embryo, this perturbed expression is carried on to later stages.  
In gastrula embryos, the gene expression domains of otx2 and vent2 are an exemplary 
couple, which represents the distribution of dorsal and ventral territories. Upon CoMO injections a 
clear organizer territory was seen in both expression patterns. Otx2 was expressed in a broad area of 
the involuting mesoderm, the organizer, whereas vent2 was expressed around the blastoporus but 
excluded from the organizer region (Figure 3.8). Upon BMO1 injections the organizer was diminished, 
shown by a reduced otx2 expression and a much broader vent2 gene expression. In essence, it can be 
stated: the organizer is weakened and the counteracting ventral factors expand into the organizer 
region. This shows that Brg1 morphant embryos were molecularly ventralized from this stage on. 
This behavior is seen in other tested genes as well. Xnr3 and foxa4 for example are both expressed at 
the dorsal lip and in the involuted mesodermal organizer region and were reduced upon BMO1 
injections. In contrast, ventral gene vent1, coexpressed with vent2, was expanded in BMO1 injected 
embryos. This expansion fits perfectly to the morphological phenotype, but both genes are regulated 
by BMP-signaling and their expression is reduced in the microarray analysis upon Brg1 knockdown 
(Gawantka et al, 1995; Hata et al, 2000; Robertis & Kuroda, 2004). The only possible explanation for 
this discrepancy can be found within the different techniques. The microarray and qRT-PCR display 
the absolute quantification and the WMISH displays the distribution of the transcripts and 
quantitative information has to be taken with caution. Additionally, one has to keep in mind that the 
developmental stage, investigated in the two analyses, are different. Two possibilities arise from this 
data. Either, bmp4 and the vent genes are not properly induced in late blastula and compensatory 
effects rescue the reduction until midgastrulation stage, or the absolute gene expression is still 
lowered in gastrula embryos, but the pattern spans a broader area compared to control embryos.  
 Vent1/vent2 and goosecoid homeobox genes are expressed in presumptive non-organizer 
and organizer territories, respectively, and have been shown to mutually repress each (Sander et al, 
2007). The goosecoid promoter region is well described and it contains a wnt-signaling binding site, 
which is mediated through Twin and a nodal binding site, which in turn is mediated through Mixer 
(Watabe et al, 1995). Even though goosecoid is expressed in the organizer and is partially under the 
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control of the wnt signaling it seems not to be a target of Brg1, because the expression was not 
altered in gastrula morphant embryos (see Figure 3.8). Another explanation could be that 
compensatory effects between the two inducing pathways ensure a stable goosecoid expression in 
Brg1 morphants. In order to clarify this question more experiments have to be performed.  
 A similar phenomena is seen with chordin, which is expressed at the dorsal lip in gastrula 
embryos. In the case of a ventralized embryo, Chordin as a BMP-inhibitor should be reduced. But in 
BMO1 injected morphant gastrula embryos chordin expression was not altered. This is even more 
surprising since its expression was strongly reduced at blastula stages. However, similar to goosecoid, 
also chordin is induced by wnt/ß-catenin pathway and nodal signaling. During blastula stages chordin 
is expressed in the BCNE through maternal ß-catenin signaling but at gastrulation the induction and 
maintenance is mediated by nodal signaling, probably through Xnr1 (Reid et al, 2012; Wessely et al, 
2001). In the microarray analysis of BMO1 injected embryos twin is upregulated, whereas xnr1 is not 
changed. Presumably, some inducing signals were still present or even slightly overrepresented and 
this ensured a normal expression pattern of chordin at gastrula stage.  
The panmesodermal marker xbra was not changed in WMISH analysis upon BMO1 injections, 
but was slightly reduced in the microarray analysis. Probably this has to do with Xbra’s autocatalytic 
loop and its various regulatory factors. The primary induction may be lowered by a loss of Brg1 but 
the feedback loop and other inductive signals may compensate for a possible reduction (Loose & 
Patient, 2004). Two other genes that were investigated in gastrula morphant embryos are muscle-
specific myoD and myf5. Both genes wre slightly reduced in gene expression, but in a very high 
penetrance, suggesting some compensatory effects, which ensured muscle formation in Brg1 
morphant embryos. 
 
4.5 Brg1 and its role in neurogenesis 
Besides the function of Brg1 in axes patterning, the results obtained in this thesis and the so far 
published data on Brg1  also suggest a special impact of Brg1 during neurogenesis (Seo et al, 2005).  
One of the strongest responder upon Brg1 knockdown at blastula was the BMP-inhibitor 
chordin. Furthermore, the early wave of chordin and cerberus in the blastula stage was shown to be 
important for later brain development (Kuroda et al, 2004). Two experiments underline first of all its 
early requirement for chordin gene expression and secondly the necessity of Brg1 to induce chordin 
gene expression: The morphological rescue with exogenous Chordin mRNA (Figure 3.11) and the 
transplantations assay (Figure 3.13). The morphological rescue with exogenous Chordin mRNA 
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implicates two findings. First, that Chordin is downstream of Brg1 and second that indeed the early 
chordin wave is important for later brain development. In the transplantation assay, a Brg1 deficient 
BCNE was transplanted into a wild type background and the embryos developed hardly eye tissue 
and had malformed brain structures. This proves in addition the requirement of Brg1 in the very 
early steps of specification and its role in brain development. Furthermore, this indicates that a wild 
type environment could not alleviate the differentiation capacity of the Brg1 morphant BCNE, which 
argues for a requirement of the BCNE in a cell-autonomous manner. Furthermore, a delay in neural 
tube closure was detected in the morphant transplants, even though it was not quantified.  
Another aspect of Brg1 function in neurogenesis was revealed from the microarray data sets. 
Many genes important for “nervous system development” were significantly downregulated upon 
BMO1 injections. One of the severely reduced genes is meis3. Meis homeobox 3 was first identified 
as a hindbrain marker and regulator downstream of the zic genes (Dibner et al, 2001; Gutkovich et al, 
2010) In knockdown studies it was shown that meis3 is important for the induction of several 
posterior Hox genes, like hoxD1 during gastrulation. Additionally, in neural stages a loss of meis3 
causes a loss of primary neuron markers and neural crest cells (Gutkovich et al, 2010; In der Rieden 
et al, 2011). From the literature so far, an earlier role than during gastrulation was not shown. 
Nevertheless, a reduction already in late blastula stages could lead to a delay of target genes 
expression and successively lead to malformed brain structures or a defective Hox code, especially in 
the posterior part.  
Another interesting candidate within the GO-term “nervous system development” was the 
gene foxd5. During recent years, a key regulatory function for foxD5 in the neural differentiation 
network was suggested (Neilson et al, 2012; Yan et al, 2009). Furthermore is it expressed at blastula 
stages on the dorsal side of the embryo (Fetka et al, 2000). The regulatory network of foxD5 is very 
complex and modulated depending on the developmental stage. This suggests that also other factors 
contribute to the network (Yan et al, 2009). At early gastrula stages loss of foxD5 reduces the level of 
zic1, zic3, sox2. Other targets like geminin and zic2 are not reduced in their expression, possibly 
because they are activated by maternal Foxd5 protein stores (Yan et al, 2009). The microarray data 
matched well with the proposed regulatory network. Whereas geminin and zic2 were not changed 
upon loss of Brg1, the downstream neural differentiation genes like zic1, zic3 and sox2 were reduced. 
Presumably, this prevention of initial induction led later on to a composite effect and to the failure of 
cell differentiation. Even though it is known that the zic genes are expressed at MBT, very little is 
known about their function in these early stages. One major hint into this direction regards the 
balance between epidermal specification marker and neuroectodermal marker already at blastula 
stage. Whereas zic1 and zic3 were downregulated in Brg1 morphant embryos, their epidermal 
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antagonist foxi1 was upregulated. This interdependence suggests that the zic genes help to 
prepattern the embryo already at blastula stage. 
The Brg1 morphant phenotype described in the literature so far mainly affects an expansion of sox2 
domain in mid-neurula stages. Sox2 maintain the cells in a neuronal precursor state and inhibits 
further differentiation. Since different stages were investigated in this analysis, due to the higher 
degree of Brg1 depletion and the resulting embryonic lethality, it is difficult to compare or draw any 
conclusion from their finding. Based on the results obtained in this thesis, other explanations like a 
reduction of BCNE genes, are more likely to cause the impaired dorso-anterior development. In total, 
it seems that the neurogenic phenotype upon Brg1 knockdown consists rather of multiple additive 
effects. 
 
4.6 Brg1 and its role during zygotic genome activation 
The detailed analysis presented here indicates that Brg1 is required as early as the blastula stage. 
Upon its loss an imbalance in DV- and AP-patterning is generated. This led in mild phenotypes to a 
ventralized, antero-dorsal truncated embryo up to embryonic lethality in strongly affected specimen. 
In search for a common denominator that helps to understand the complex consequences of Brg1 
depletion, its impact on the newly zygotic transcripts was examined. The newly transcribed gene 
pool was chosen, because the genome-wide analysis was performed in late blastula stage embryos, 
approximately only 3 hours after MBT’s burst of transcription. In addition, the microarray data sets 
revealed a high impact of Brg1 on developmental required genes, of which the majority is highly 
upregulated at the MBT. In order to reveal the zygotic transcripts a further genome-wide analysis in 
wild type embryos was investigated. One study is published so far, in which the transcriptome 
preMBT and postMBT was investigated. However, this study focuses on the differences between 
X. laevis and X. tropicalis (Yanai et al, 2011). The analysis in this thesis is the first study, which puts a 
special focus on comparing the transcriptome of preMBT embryos with the transcriptome of 
postMBT embryos. With this data set it is possible to reveal which maternal genes will be degraded 
after MBT, which genes are upregulated and which genes do not change in their expression level. 
The data of the three different RNA pools paired with the information gained from the two 
morphant microarray analysis suggests a common denominator for the Brg1 requirement in 
development: Genes, which are highly upregulated at MBT are sensitive to a loss of Brg1 in a 
dose-dependent manner. This indicates that the burst of transcription happening at the MBT 
requires Brg1 protein function as transcriptional activator (see Figure 4.1). Since several genes 
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important for embryonic development and pattern specification were among these highly 
upregulated genes, also the phenotypes that arose upon loss of Brg1 can be explained by this finding.  
 
 
Figure 4.1: The MBT burst of transcription is diminished in Brg1 morphants. In A the wild type situation is 
shown. The matured Xenopus egg contains only active ventral promoting activity (depicted in green). With the 
sperm entry the cortex of the zygote is shifted and maternal dorsal promoting activity is activated on the 
prospective dorsal side (depicted in blue). At blastula stage the zygotic genome is activated and a 
transcriptional burst of ventralizing and dorsalizing factors is induced, so that the two counteracting entities 
shape the embryo. A normal tadpole develops. In B the Brg1 morphant situation is shown. The first steps are 
not affected, as the morpholino does not target maternal Brg1 protein. At blastula, the zygotic genome 
activation occurs but upon loss of zygotic Brg1 protein the transcriptional burst is impaired. This leads to lower 
dorsalizing but also to lower ventralizing activity. In the end this results in an imbalance between dorsal and 
ventral promoting activities and the DV pattern is shifted towards ventral fate. The embryo will develop a 
ventralized phenotype. MBT, midblastula transition 
Presumably, the embryonic lethality is a result of an absence of inducing signals. During gastrulation, 
the germ layers and body axes are specified. If signals that are important for the specification process 
are lowered or absent, the embryo is not able to proceed in development. This fact also points out 
that not only dorsal-specific genes were reduced upon a loss of Brg1 but also ventral fate factors. If 
only dorsalizing factors would be missing the embryo would be strongly ventralized, like it is the case 
of UV-treated embryos (Kao & Elinson, 1988). But among the highly upregulated genes also 
ventralizing genes are identified, like Bmp4, which was upregulated 8 fold after MBT. As mentioned 
before, Bmp4 is an essential ventralizing factor and was reduced in BMO injected embryos. 
Apparently, the combined downregulation of dorsal and ventral specification factors led to 
embryonic death, probably by a developmental arrest during the gastrulation process. In the case of 
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targeted injections or milder knockdown conditions, an overall perturbation is not achieved and the 
morphant embryos succeeded to go on with development, although at the expense of teratogenic 
malformations. In those embryos, the misbalance between ventral to dorsal fate is shifted towards 
the ventral fate, i.e. the default state of the embryo prior to the MBT. 
The secondary axes arising from ventral injections of Brg1 mRNA are more difficult to explain. 
As Brg1 acts independently from particular pathways but as a transcriptional activator, a 
combinatory effect is the most likely reason for the second body axis induction. As discussed above, 
also on the ventral side a transcriptional burst drives gene expression after MBT. Included in this 
burst is for example sizzled, a BMP-inhibitor, which was upregulated 27 fold. An overexpression of 
Brg1 could lead to an even stronger upregulation and thereby leading to a BMP-inhibitory effect 
which causes the secondary axis. However, sizzled is mildly upregulated upon Brg1 knockdown, 
which indicates, that sizzled is no direct target of Brg1. In the end two possibilities arise. Either, bmp4 
is upregulated upon Brg1 overexpression and thereby indirectly intrinsic BMP-inhibitors will be 
upregulated or Brg1 induces ectopically dorsalizing genes on the prospective ventral side during the 
burst of MBT.  
 
4.7 Possible Brg1 mechanism at the burst of transcription 
With the analysis of this thesis a new role for the chromatin remodeling ATPase Brg1 during early 
Xenopus development was revealed. The data presented here suggest a positive role of Brg1 on 
highly upregulated gene expression at MBT, which implies an additional selectivity of Brg1 to these 
genes. Nishant Singhal, a former PhD student who started the characterization of Brg1 during 
Xenopus development also investigated the capability of other remodeling ATPase to compensate for 
a loss of Brg1. He tested xISWI and hBrahma mRNAs, which both were not able to rescue the 
morphological phenotype generated by Brg1 knockdown (Singhal, 2005). This raised the question, 
what determines the Brg1 specificity to its target genes. One possibility could be a histone mark, 
which recruits Brg1 containing SWI/SNF complexes. A recent paper showed that the promoter of 
genes, which burst at the MBT are decorated with H3K16ac at preMBT stage (Blythe et al, 2010). This 
could be a recruiting signal for Brg1, since Brg1 contains a bromo-domain, which binds to acetylated 
histone tails. But for which purpose is Brg1 needed at these genes? In order to gain further 
information about the impact of the catalytic activity of Brg1, a dominant-negative protein can be 
used in loss-of-function studies. To investigate this, Nishant Singhal also performed this kind of 
loss-of-function approach. He mutated the catalytic domain of the ATPase and observed a 
comparable morphological phenotype as seen in morpholino injected embryos. From this data it can 
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be concluded that the enzymatic function of Brg1 is required for Xenopus development. (Singhal, 
2005). This indicates that not only the presence of Brg1 is needed at MBT, but in particular the 
catalytic function is required for its role during the burst of transcription at MBT. One major function 
of chromatin remodeling complexes is the sliding of nucleosomes along the DNA. Furthermore, a 
hallmark of transcription is the nucleosome-free region at promoters of transcribed genes (Iyer, 
2012). As the research of nucleosome sliding in the picture of development is poorly investigated, 
this fact leaves room for speculation. A mechanism by which Brg1 is recruited to promoters to open 
up or keep the TSS open, is likely. The mechanism of the upregulation of several hundred genes in a 
synchronous manner was investigated in Drosophila over the last years. Recently, several papers 
were published, which deal with genome-wide data at the onset of zygotic genome transcription. In 
the course of this, a common motif in the promoter region of the newly transcribed genes was 
revealed and shortly after, the transcription factor Zelda, was found (Harrison et al, 2011; Liang et al, 
2008). Additionally, by genome-wide data in Drosophila it was shown that the synchrony of gene 
transcription in various tissue is accomplished by RNA polymerase II pausing (Lagha et al, 2013). 
Another recent study revealed that Brg1 in human cell lines is needed to overcome a nucleosomal 
barrier during RNA polymerase II elongation (Subtil-Rodriguez & Reyes, 2010). A hypothesis, which 
combines these studies and the findings presented here, could be: Genes, which undergo a burst of 
transcription, are marked preMBT with the acetlyation of H3K16. Maternal Brg1 protein, which is not 
targeted by the morpholino injections binds to it and recruits additional transcription factors. By this, 
RNA polymerase II is recruited and starts with a minimal transcription, causing a poising of these 
genes. With the onset of the zygotic transcription, maternal Brg1 or a recruited factor helps to 
release the paused RNA polymerase II in order to ensure proper transcription. To assure such a high 
transcriptional upregulation, which is needed at MBT, the promoter has to be kept open, additional 
RNA polymerase II has to be recruited and the genes have to be rapidly transcribed. Presumably, 
these steps are under the control of zygotic Brg1 and are impaired upon BMO injections in Xenopus. 
 
4.8 Conclusions and future directions 
It is shown, that Xenopus Brg1 protein is needed much earlier in development than described before, 
namely as early as the blastula stage. Furthermore, it was revealed that Brg1 has a gene specific role 
as transcriptional activator during the onset of the zygotic genome transcription. A loss of zygotic 
Brg1 leads to a reduced transcriptional burst at the MBT, which leads to the reduction of patterning 
signals resulting in embryonic lethality during gastrulation. Upon milder knockdown conditions or in 
targeted injections, a misbalance between dorsal and ventral signals impairs development, since the 
majority of the high upregulated genes at MBT are dorsalizing factors.  
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Nevertheless, further experiments are necessary to describe Brg1 function during early 
vertebrate development. It would be interesting to know, which genes are directly regulated by Brg1 
and which genes are indirectly affected by Brg1. Therefore, an experiment with Cycloheximide would 
be appropriated. It inhibits the protein translation and in combination with Brg1 overexpression only 
the direct target genes are expressed. The experiment goes hand in hand with the examination of 
the truncated secondary axes. Is this mediated by an upregulation of dorsalizing genes or an 
upregulation of intrinsic BMP-inhibitors? To further prove gene specificity, a ChIP-qPCR could be 
performed. Especially, as ChIP-Seq data of a chromatin remodeling factor is rather difficult to obtain 
as it has so many functions which are carried out over large fractions of the genome.  
Experiments, which reveal the mechanism behind Brg1 function at MBT would be very 
important. First of all, deletion mutants of Brg1 could show, if Brg1 is targeted via the H3K16ac 
histone mark to its target genes. ChIP-Seq data of paused RNA polymerase II at the MBT could show 
if the highly upregulated genes are really poised and whether Brg1 is colocalized. Furthermore, an 
investigation of other SWI/SNF complex proteins is necessary to reveal if Brg1 needs the presence of 
other complex components in order to function properly. In the same line it would be interesting, if 
at MBT a special SWI/SNF complex is present, like it was shown for ES-cells (Ho et al, 2009).  
Another profound data set, which was generated within this thesis, is the genome-wide 
transcriptome analysis, comparing pre and postMBT embryos. These data sets reveal insights into the 
tremendous changes on the transcriptional level and underline the necessity of a spatial and tight 
regulation to ensure embryonic patterning and development in Xenopus. 
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Abbreviations 
AP-axis antero-posterior axis 
AP-buffer alkaline phosphatase buffer 
Baf brahma associated factors 
Bambi BMP and Activin Membrane-Bound Inhibitor 
BCIP 5-Bromo-4-chlor-3-indoxylphosphat 
BCNE blastula Chordin- and  Noggin-expression center 
BMO Brg1-morpholino 
BMP bone morphogenic protein 
Brg1 brahma related gene 1 
Brm brahma 
bzw. beziehungsweise 
cDNA complementary DNA 
CHD chromodomain helicase DNA-binding 
ChIP chromatin immunoprecipitation 
ChIP-Seq ChIP-DNA sequencing 
CNS central nervous system 
CoIP Co-immunoprecipitation 
CoMO control morpholino 
DA dorso-animal 
DAI Dorsal-Anterior-Index 
dig-labeled digoxigenin-labeled 
DNA deoxyribonucleic acid 
DMZ dorsal marginal zone 
DV dorso-vegetal 
e.g. exempli gratia 
egr2 early growth response 2 
esBAF embryonic stem cell BAF complex 
ES cells Embryonic stem cells 
ESI eye-size-index 
EtOH ethanol 
FADD Fas-Associated protein with Death Domain 
foxa4 forkhead box A4 
gapdh glyceraldehyde-3-phosphate dehydrogenase 
gs17 gastrula specific 17 
gsc goosecoid 
GO Gene onthology 
h hour 
hCG human chorionic gonadotropin 
HDAC histone deacytelase 
hhex hematopoietically expressed homeobox 
hoxb9 homeobox B9 
ICC immunocytochemistry 
i.e. id est 
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ISWI Imitation SWI 
lfdr local false discovery rate 
MBS Modified Barth Solution 
MBT Midblastula transition 
MEMFA MEM Formaldehyde 
MeOH methanol 
min minute 
mRNA messengerRNA 
nBAF neuron-specific BAF-complex 
NBT Nitro Blue Tetrazolium 
NF Nieuwkoop and Faber stage 
NuRD Nucleosome Remodeling Deacetlyase 
odc ornithine decarboxylase 
o/n over night 
otx2 orthodenticle homeobox 2 
pax2 paired box 2 
PBS Phosphate Buffered Saline 
PMEF primary mouse embryonic fibroblast 
Pol II Polymerase II 
PRMT protein arginine methyltransferase 
PTM posttranslational modification 
RNA ribonucleic acid 
rpm revolutions per minute 
RT room temperatur 
SSC Saline-sodium citrate 
SWI/SNF SWItch/Sucrose NonFermentable 
TGF-ß transforming growth factor beta 
TSS transcriptional startside 
UI uninjected 
UTR untranslated region 
UV ultra-violett 
VMZ ventral marginal zone 
WMISH whole mount in situ hybridization 
w/o without 
WT wild type 
xnr xenopus nodal-related 
ZGA zygotic genome activation 
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Appendix 
BMO1 microarray analysis 
Listed are all genes, upreglulated ≥ 1.5 fold change and with a local false discovery rate ≤ 0.2. 
Set-probe number 
 fold 
change 
[log2] 
gene name symbol 
StrEns.5201.1.S1_s_at 3,719 WNT1-inducible-signaling pathway protein 3-like LOC100488354 
Str.40271.2.S1_a_at 3,227 Hypothetical protein LOC550005 LOC550005 
Str.9570.1.S1_at 3,080 ribophorin II rpn2 
Str.27732.1.S1_at 2,895 GTP binding protein 5 (putative) gtpbp5 
Str.20978.1.S1_at 2,344 Hypothetical protein LOC100158502 LOC100158502 
Str.51787.1.S1_at 2,153 histone cluster 1, H2ah hist1h2ah 
Str.51882.1.S1_at 2,094 chromosome 20 open reading frame 29 c20orf29 
Str.40271.1.S1_at 2,005 Hypothetical protein LOC549623 TGas006m08.1 
Str.16459.1.S1_at 1,698 
hect (homologous to the E6-
AP (UBE3A) carboxyl 
terminus) domain and RCC1 
(CHC1)-like domain (RLD) 1 
herc1 
Str.3409.1.A1_at 1,583 GTP binding protein 2 gtpbp2 
Str.24465.1.S1_at 1,562 mal, T-cell differentiation protein 2 mal2 
Str.1273.1.S1_at 1,499 histone H4-like LOC100496593 
StrJgi.934.1.S1_s_at 1,452 
protein kinase (cAMP-
dependent, catalytic) 
inhibitor gamma 
pkig 
Str.18904.1.S1_at 1,433 junctophilin 1 jph1 
Str.27312.1.S1_at 1,356 histone cluster 2, H2ab hist2h2ab 
Str.2030.1.A1_at 1,250 Frizzled homolog 3 fzd3 
StrEns.12239.1.S1_s_at 1,230 hypothetical protein  hypothetical protein  
LOC100491313 
LOC100496030 
Str.5781.1.A1_at 1,199 Hypothetical protein MGC147532 MGC147532 
Str.25548.1.A1_at 1,150 amyloid protein-binding protein 2-like LOC100487715 
StrEns.8996.1.S1_a_at 1,142 hypothetical protein LOC100496030 LOC100496030 
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Str.41102.1.S1_at 1,047 CCAAT/enhancer binding protein (C/EBP), delta cebpd 
Str.37449.1.A1_at 1,007 
poly (ADP-ribose) 
polymerase family, member 
4 
parp4 
Str.8423.1.S1_at 1,004 chromosome 6 open reading frame 211 c6orf211 
Str.3950.1.S2_at 0,989 integrin alpha-5-like LOC100492002 
Str.8642.1.S1_at 0,987 trans-1,2-dihydrobenzene-1,2-diol dehydrogenase dhdh 
StrAffx.105.1.S1_s_at 0,975 synaptotagmin 7 syt7 
Str.6540.2.A1_at 0,967 Vac14 homolog vac14 
Str.51459.1.S1_at 0,966 neurobeachin nbea 
Str.16785.2.S1_at 0,954 oxidase (cytochrome c) assembly 1-like oxa1l 
Str.50909.1.S1_at 0,953 activating transcription factor 7 atf7 
Str.14144.2.A1_at 0,934 zinc finger and BTB domain containing 5 zbtb5 
Str.21484.1.A1_s_at 0,907 
pyruvate dehyrogenase 
phosphatase catalytic 
subunit 1 
pdp1 
Str.11152.1.S2_at 0,904 cornichon homolog 4 cnih4 
Str.10066.1.S1_at 0,904 mesendoderm nuclear factor, gene 1 menf.1 
Str.2681.1.S1_at 0,897 
SMG1 homolog, 
phosphatidylinositol 3-
kinase-related kinase 
smg1 
Str.36162.1.A1_at 0,848 hypothetical protein LOC100498210 LOC100498210 
Str.31142.1.S1_at 0,847 transmembrane protein, adipocyte asscociated 1 tpra1 
Str.14124.1.S2_at 0,846 sestrin 1 sesn1 
StrEns.6148.1.S1_a_at 0,842 peptide chain release factor 1, mitochondrial-like LOC100486280 
Str.101.1.S1_at 0,833 replication factor C (activator 1) 5, 36.5kDa rfc5 
Str.564.1.S1_at 0,824 DNZDHHC/NEW1 zinc finger protein 11 dnz1 
Str.33322.1.S1_at 0,818 chromosome 16 open reading frame 68 c16orf68 
Str.11519.1.S2_at 0,815 spermine oxidase smox 
Str.9548.3.A1_at 0,806 28S ribosomal protein S25, mitochondrial-like LOC100494871 
Str.4065.1.S1_at 0,805 ATG4 autophagy related 4 homolog A atg4a 
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Str.27290.1.S1_at 0,804 ribonuclease H2, subunit A rnaseh2a 
Str.33694.1.S1_at 0,801 round spermatid basic protein 1 rsbn1 
Str.2504.2.S1_at 0,797 RNA binding motif protein 6 rbm6 
Str.40497.1.S1_at 0,794 
ras-related C3 botulinum 
toxin substrate 3 (rho 
family, small GTP binding 
protein Rac3) 
rac3 
Str.20705.2.A1_a_at 0,789 uncharacterized protein C8orf41-like LOC100487242 
Str.40433.1.S1_at 0,789 vasoactive intestinal polypeptide receptor-like LOC100497291 
Str.8281.1.S1_at 0,763 
small subunit of serine 
palmitoyltransferase A-B-
like 
LOC100495839 
Str.27561.1.S1_at 0,758 TSPY-like 2 tspyl2 
Str.32322.1.S1_at 0,755 nucleosome assembly protein 1-like 4 nap1l4 
Str.31445.1.S1_at 0,753 inhibitor of growth family, member 1 ing1 
Str.28870.1.S1_at 0,752 Hypothetical protein LOC779512 LOC779512 
Str.27848.1.S1_at 0,750 egl nine homolog 3 egln3 
Str.25272.1.S1_at 0,726 retinoid X receptor, gamma rxrg 
Str.7571.2.S1_a_at 0,726 
hypothetical LOC100491590  
hypothetical LOC100491682  
hypothetical LOC100493923 
LOC100491590 
LOC100491682 
LOC100493923 
Str.5120.1.S1_at 0,719 adaptor-related protein complex 2, sigma 1 subunit ap2s1 
Str.27693.1.S1_at 0,701 SCY1-like 3 scyl3 
Str.10400.2.S1_at 0,696 
biogenesis of lysosomal 
organelles complex-1, 
subunit 1 
bloc1s1 
Str.27324.1.S2_at 0,695 ras-related protein ras-dva ras-dva 
Str.849.2.A1_at 0,686 Hypothetical protein MGC75957 MGC75957 
Str.39705.1.S1_s_at 0,677 integrator complex subunit 12 ints12 
Str.30835.3.S1_a_at 0,671 Interleukin-15 il-15 
Str.2145.1.S1_at 0,668 laminin, gamma 1 lamc1 
Str.26914.1.S1_at 0,666 UTP11-like, U3 small nucleolar ribonucleoprotein utp11l 
Str.13906.1.S1_a_at 0,657 
low molecular weight 
neuronal intermediate 
filament 
nif 
Str.51698.1.S1_at 0,650 zinc finger protein 64 homolog zfp64 
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Str.29188.1.S1_at 0,647 chromosome 1 open reading frame 89 c1orf89 
Str.32445.1.S1_at 0,644 tubulin alpha-1D chain-like  MGC97820 protein 
LOC100487867  
MGC97820 
Str.3482.1.S1_at 0,640 dual specificity phosphatase 22 dusp22 
Str.27186.1.S1_s_at 0,637 histone H3.2-like LOC100496129 
Str.44813.1.S1_s_at 0,632 oligophrenin 1 ophn1 
Str.27520.1.A1_at 0,629 dedicator of cytokinesis 3 dock3 
Str.31215.1.S1_s_at 0,625 septin 12 Sep 12 
Str.216.1.S1_at 0,624 Hypothetical protein MGC76116 MGC76116 
Str.26671.2.A1_a_at 0,624 similar to candidate tumor suppressor OVCA2 ovca2 
Str.18325.1.A1_at 0,619 leucine rich repeat neuronal 1 lrrn1 
Str.42318.1.A1_at 0,611 GH3 domain-containing protein-like LOC100488130 
Str.22588.1.S1_at 0,610 chromosome 11 open reading frame 2 c11orf2 
Str.10971.1.S1_at 0,609 OTU domain-containing protein 1-like LOC100493984 
Str.40156.1.S1_at 0,608 probable tubulin polyglutamylase TTLL1-like LOC100495095 
Str.37703.1.S1_at 0,608 transportin 1 tnpo1 
StrJgi.4435.1.S1_s_at 0,606 DnaJ (Hsp40) homolog, subfamily C, member 27 dnajc27 
Str.16298.1.S1_at 0,602 nucleotide binding protein-like nubpl 
Str.52172.1.S1_at 0,600 
procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 
3 
plod3 
Str.8414.1.S1_at 0,590 nucleoporin 85kDa nup85 
Str.38351.1.S1_at 0,590 acyl-CoA synthetase family member 3 acsf3 
Str.42612.1.S1_at 0,590 
ATPase, H+ transporting, 
lysosomal 34kDa, V1 subunit 
D 
atp6v1d 
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Listed are all genes downregulated ≥ 1.5 fold change with a local false discovery rate ≤ 0.2. 
Set-probe number 
 fold 
change 
[log2] 
gene name symbol 
Str.1716.1.S1_x_at -3,945 purinergic receptor P2Y, G-protein coupled, 2 p2ry2 
Str.5336.1.S1_at -2,985 symplekin sympk 
Str.31377.1.S1_at -2,793 microsomal triglyceride transfer protein, gene 2 mttp.2 
Str.27013.1.S1_a_at -2,699 uroplakin 3B upk3b 
Str.11165.7.S1_at -2,579 sarcoplasmic/endoplasmic reticulum calcium ATPase 2-like LOC100489059 
Str.4354.1.S1_at -2,467 
signal transducing adaptor 
molecule (SH3 domain and ITAM 
motif) 2 
stam2 
StrEns.8369.1.S1_at -2,460 growth/differentiation factor 2-like LOC100485289 
Str.13147.1.A1_at -2,432 zinc finger protein 219-like LOC100495520 
StrEns.7683.1.S1_at -2,365 zona pellucida sperm-binding protein 4-like LOC100494768 
Str.15007.1.S1_at -2,343 gastrula-specific protein 17 gs17 
Str.19278.2.S1_at -2,318 hypothetical protein LOC100491368 LOC100491368 
Str.5826.1.S1_at -2,272 non-metastatic cells 2, protein (NM23B) expressed in nme2 
Str.6718.1.S1_at -2,204 hypothetical LOC100494381 LOC100494381 
Str.9193.1.A1_a_at -2,189 UPF0632 protein C2orf89-like LOC100491951 
Str.2177.1.A1_a_at -2,181 sphingosine-1-phosphate receptor 5 s1pr5 
Str.21595.1.A1_at -2,172 cyclin-dependent kinase 5 cdk5 
Str.5015.1.A1_at -2,168 
neural precursor cell expressed, 
developmentally down-regulated 
9 
nedd9 
Str.16322.1.S1_at -2,131 Sp9 transcription factor homolog sp9 
Str.31367.1.A1_at -2,128 coronin-7-like LOC100492934 
Str.21613.1.S1_a_at -2,121 Calponin 2 cnn2 
Str.17625.1.S1_at -2,107 hypothetical LOC100495344 LOC100495344 
Str.8191.1.S2_at -2,082 phospholipase A2, group XIIB pla2g12b 
Str.6681.1.S1_a_at -2,071 keratin krt 
Str.9958.1.S1_at -2,051 chromosome 7 open reading frame 11 c7orf11 
Str.7434.3.S1_at -2,050 La ribonucleoprotein domain family, member 1 larp1 
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Str.10944.1.S1_at -2,038 Zic family member 1 (odd-paired homolog) zic1 
Str.1956.1.S1_at -2,019 eukaryotic translation initiation factor 3, subunit H eif3h 
Str.11087.1.S1_at -1,993 distal-less homeobox 5 dlx5 
Str.15072.2.A1_a_at -1,975 delta-like 1 dll1 
Str.40060.1.S1_at -1,923 
solute carrier family 25 
(mitochondrial carrier, 
phosphate carrier),    member 25 
slc25a25 
Str.24376.1.S1_at -1,867 heart and neural crest derivatives expressed 2 hand2 
Str.1920.1.S2_a_at -1,864 hypothetical protein LOC549355 LOC549355 
Str.6151.1.S1_at -1,826 ATPase, Na+/K+ transporting, beta 2 polypeptide atp1b2 
Str.10072.1.S2_at -1,802 Solute carrier family 2 (facilitated glucose transporter), member 2 slc2a2 
Str.34177.1.A1_s_at -1,774 tumor necrosis factor receptor superfamily, member 21 tnfrsf21 
Str.15669.1.S1_at -1,764 nuclear receptor subfamily 2, group F, member 1 nr2f1 
Str.1093.1.S1_at -1,757 ADP-ribosylation factor-like 4C arl4c 
Str.30624.1.S1_at -1,746 ephrin-A3 efna3 
Str.20569.1.S1_at -1,740 Hypothetical protein LOC100127613 LOC100127613 
Str.8471.1.S1_at -1,739 oxysterol binding protein-like 11 osbpl11 
Str.16419.1.S1_at -1,732 DNA-damage-inducible transcript 3 ddit3 
Str.643.1.S1_a_at -1,728 hypothetical LOC100486597 LOC100486597 
Str.8459.1.S1_at -1,726 baculoviral IAP repeat-containing 2 birc2 
Str.4773.2.S1_s_at -1,716 hypothetical protein LOC100488209 LOC100488209 
Str.6630.1.S2_at -1,710 X-box binding protein 1 xbp1 
Str.29344.1.S1_at -1,706 neurogenin 3 neurog3 
Str.26164.1.S1_at -1,705 protocadherin 18 pcdh18 
Str.7073.1.S1_at -1,648 iroquois homeobox 2 irx2 
Str.11719.1.S1_at -1,644 tissue factor-like LOC100489511 
Str.6889.1.A1_at -1,631 vav 2 oncogene LOC733982 
Str.11302.1.S1_at -1,631 forkhead box D3 foxd3 
Str.16957.1.S2_at -1,623 fused in sarcoma fus 
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Str.20470.1.S2_at -1,609 cyclin E2 ccne2 
Str.49050.1.S1_at -1,590 Fast skeletal myosin light chain 2 TNeu107a14.1 
StrEns.3882.1.S1_at -1,583 forkhead box protein D5-C-like LOC100485983 
Str.21868.1.S1_at -1,582 
macrophage stimulating 1 
receptor (c-met-related tyrosine 
kinase) 
mst1r 
Str.10727.1.S1_at -1,579 deoxyribonuclease gamma-like LOC100497175 
StrEns.9993.1.S1_at -1,573 
succinate dehydrogenase 
complex, subunit B, iron sulfur 
(Ip) 
sdhb 
Str.9762.1.S1_at -1,571 stimulated by retinoic acid gene 6 homolog stra6 
Str.10076.1.S1_at -1,571 angiomotin like 2 amotl2 
Str.954.1.S1_at -1,555 
potassium channel 
tetramerisation domain 
containing 15 
kctd15 
Str.15587.1.S1_at -1,554 hypothetical protein LOC100487200 LOC100487200 
Str.2103.1.S1_at -1,546 anaphase promoting complex subunit 11 anapc11 
Str.6201.1.S1_at -1,546 SRY (sex determining region Y)-box 2 sox2 
Str.10659.1.S1_at -1,544 
transcription factor AP-2 epsilon 
(activating enhancer binding 
protein 2 epsilon) 
tfap2e 
Str.6731.1.S1_at -1,525 zinc finger protein 750 znf750 
Str.18694.2.S1_x_at -1,525 hypothetical protein LOC100498107 LOC100498107 
Str.3344.1.S1_at -1,520 novel protein similar to hatching enzymes LOC594901 
Str.34138.1.A1_at -1,518 WD repeat domain 24 wdr24 
Str.14655.1.S2_at -1,517 LIM homeobox 5 lhx5 
Str.16688.1.S1_at -1,513 RNA pseudouridylate synthase domain containing 3 rpusd3 
Str.12012.1.S1_at -1,490 ankyrin repeat domain 10 ankrd10 
Str.29569.1.S1_at -1,486 Meningioma (disrupted in balanced translocation) 1, gene 1 mn1.1 
Str.15223.4.S1_a_at -1,463 eukaryotic translation initiation factor 4A2 eif4a2 
Str.6185.1.S1_at -1,463 cornifelin homolog cnfn 
Str.21522.1.S1_at -1,449 uroplakin 2 upk2 
Str.49514.1.S1_at -1,419 T-box 3 tbx3 
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Str.23519.2.S1_a_at -1,416 Death inducer-obliterator 1 dido1 
Str.7428.1.S2_at -1,408 centromere protein N cenpn 
Str.51988.1.S1_at -1,397 serine/arginine-rich splicing factor 11 srsf11 
Str.37707.1.A1_at -1,396 fibronectin-like LOC100492420 
Str.27213.1.S1_a_at -1,391 
myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
homolog); translocated to, 4 
mllt4 
Str.5401.1.S1_at -1,381 retinal pigment epithelium-specific protein 65kDa rpe65 
Str.1047.1.S1_at -1,379 prohibitin 2 phb2 
Str.6900.1.S2_s_at -1,378 
ER degradation enhancer, 
mannosidase alpha-like 1 /// 
angiopoietin-related protein 1-
like 
edem1 /// 
LOC100491105 
Str.39270.1.A1_at -1,373 bone morphogenetic protein 15-like LOC100485893 
Str.10293.1.S1_at -1,363 SEC22 vesicle trafficking protein-like 2 (S. cerevisiae) sec22l2 
Str.125.1.S1_at -1,361 cytochrome b-561 cyb561 
Str.3124.1.S1_at -1,358 UbiA prenyltransferase domain containing 1 ubiad1 
Str.7820.2.S1_a_at -1,358 immediate early response gene 2 protein-like LOC100491464 
Str.16252.1.S1_at -1,356 SRY (sex determining region Y)-box 1 sox1 
Str.44939.1.A1_s_at -1,354 RAN binding protein 3 ranbp3 
Str.784.1.A1_at -1,353 rap1 GTPase-GDP dissociation stimulator 1-A-like LOC100486041 
Str.21559.2.S1_at -1,352 Y box binding protein 2 ybx2 
Str.15005.1.S1_at -1,349 hairy and enhancer of split 3, gene 1 hes3.1 
Str.51845.1.A1_at -1,337 hypothetical protein MGC69473 MGC69473 
Str.10716.1.S1_at -1,315 forkhead box D4-like 1, gene 1 foxd4l1.1 
Str.37993.1.S1_at -1,315 uncharacterized protein KIAA0319-like LOC100492839 
Str.14504.1.S1_at -1,314 rho GTPase-activating protein 39-like LOC100485974 
Str.27681.1.S1_at -1,313 protease, serine 27 prss27 
Str.11402.1.A1_at -1,298 
protein phosphatase 1, 
regulatory (inhibitor) subunit 3C, 
gene 1 
ppp1r3c.1 
Str.40874.1.S1_at -1,293 ring finger protein 222 rnf222 
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Str.15297.1.S1_at -1,292 
glyoxylate 
reductase/hydroxypyruvate 
reductase, gene 2 
grhpr.2 
Str.1890.1.S1_at -1,288 39S ribosomal protein L10, mitochondrial-like LOC100496025 
Str.18694.1.S1_at -1,269 uncharacterized protein ywlC-like LOC100497798 
Str.3160.2.S1_a_at -1,256 serine/arginine-rich splicing factor 6 srsf6 
Str.30747.1.A1_at -1,254 regulator of G-protein signaling 16 rgs16 
Str.8142.1.A1_at -1,245 TSC22 domain family, member 3 tsc22d3 
Str.3146.2.A1_at -1,243 hypothetical LOC100491246 LOC100491246 
Str.11483.1.S1_at -1,231 
leucine-rich repeat-containing 
protein 8C-like  leucine rich 
repeat containing 8 family,   
member C 
LOC100488426 
lrrc8c 
Str.18694.2.S1_a_at -1,221 uncharacterized protein  ywlC-like                   
LOC100497798 
LOC100498107 
Str.21593.1.S1_at -1,209 H1 histone family, member X h1fx 
Str.916.1.S1_at -1,205 lin-28 homolog A (C. elegans) lin28a 
Str.24820.1.S1_at -1,202 regulator of nonsense transcripts 1 upf1 
Str.1440.1.S2_at -1,190 
solute carrier family 25 
(mitochondrial carrier; 
peroxisomal membrane protein, 
34kDa), member 17 
slc25a17 
StrJgi.4201.1.S1_s_at -1,188 
mitogen-activated protein-
binding protein-interacting 
protein-like /// roadblock 
domain containing 3 
LOC100489368 
/// robld3 
AFFX-Str-gapdh-M_at -1,186 glyceraldehyde-3-phosphate dehydrogenase gapdh 
Str.420.1.S1_at -1,185 
ABO blood group (transferase A, 
alpha 1-3-N-
acetylgalactosaminyltransferase; 
transferase B, alpha 1-3-
galactosyltransferase) 
abo 
Str.38280.1.S1_at -1,185 leucine rich repeat containing 24 lrrc24 
Str.15044.1.S1_at -1,183 bolA homolog 2 bola2 
Str.17465.2.S1_a_at -1,181 hypothetical LOC100493277 LOC100493277 
Str.52067.1.S1_s_at -1,180 zinc finger protein 568 znf568 
Str.1183.1.S1_at -1,180 transmembrane protein 127 tmem127 
Str.6117.1.S1_at -1,174 max interactor 1 mxi1 
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Str.7447.2.A1_at -1,173 Heterogeneous nuclear ribonucleoprotein D-like hnrpdl 
Str.10535.1.S1_at -1,165 hypothetical LOC100495377 LOC100495377 
Str.13720.1.S1_at -1,162 GTP-binding protein 10 (putative) gtpbp10 
Str.6659.1.S1_at -1,160 nerve growth factor receptor ngfr 
Str.3502.1.S1_at -1,158 roadblock domain   containing 3 robld3 
Str.10455.1.S1_at -1,156 hypothetical LOC100495538 LOC100495538 
Str.14040.1.A1_at -1,151 hypothetical LOC100490704 LOC100490704 
Str.52193.1.S1_at -1,150 High-mobility group nucleosomal binding   domain 2 TEgg003n10.1 
Str.24811.1.S2_at -1,148 myelin expression factor 2 myef2 
Str.9615.1.A1_at -1,147 tyrosine kinase, non-receptor, 2 tnk2 
Str.5386.1.S1_at -1,143 phosphoglucomutase 1 pgm1 
Str.16319.2.S1_at -1,138 hypothetical protein LOC100489354 LOC100489354 
Str.51828.1.S1_a_at -1,129 ribosomal protein L9 rpl9 
Str.11288.1.S1_at -1,128 hypothetical LOC100486074 LOC100486074 
Str.303.1.S1_at -1,125 G protein-coupled receptor, family C, group 5, member C gprc5c 
Str.7693.2.S1_at -1,118 VENT homeobox 1, gene 1 ventx1.1 
Str.51981.1.S1_s_at -1,114 formin binding protein 4 LOC734003 
Str.12750.1.A1_at -1,107 LIM homeobox 1 lhx1 
Str.7116.1.S1_at -1,104 succinate-CoA ligase, alpha subunit suclg1 
Str.4741.1.S1_at -1,101 peroxisomal biogenesis factor 11 beta pex11b 
Str.17679.1.S1_at -1,097 chromosome 13 open reading frame 15 c13orf15 
Str.10984.1.S1_at -1,096 S100 calcium binding protein A11 s100a11 
Str.15740.1.A1_at -1,093 MAP kinase interacting serine/threonine kinase 2 mknk2 
Str.17253.1.S1_at -1,093 DnaJ (Hsp40) homolog, subfamily C, member 5 gamma dnajc5g 
Str.6879.1.A2_at -1,084 myeloid cell leukemia sequence 1 (BCL2-related) mcl1 
StrJgi.784.1.S1_s_at -1,083 retinoblastoma-like 1 (p107) rbl1 
StrJgi.5287.1.S1_s_at -1,076 kin of IRRE like 2 kirrel2 
Str.43062.1.A1_at -1,074 hypothetical LOC100135121 LOC100135121 
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Str.24440.1.S2_at -1,052 transcription factor 7-like 1 (T-cell specific, HMG-box) tcf7l1 
Str.27418.2.A1_at -1,050 DENN/MADD domain containing 2C dennd2c 
Str.6578.1.S2_a_at -1,047 serine/arginine-rich splicing factor 1 srsf1 
Str.2004.1.S1_at -1,043 frizzled homolog 2 fzd2 
Str.27441.1.S1_at -1,041 dyslexia susceptibility 1 candidate 1 dyx1c1 
Str.8403.1.S1_at -1,040 ribosomal RNA processing 12 homolog rrp12 
Str.10058.1.S2_at -1,035 syntaxin 19 stx19 
Str.37908.1.S1_a_at -1,030 DNA-directed RNA polymerase, mitochondrial-like LOC100488061 
Str.26578.1.S1_a_at -1,029 
Cbp/p300-interacting 
transactivator, with Glu/Asp-rich 
carboxy-terminal domain, 4 
cited4 
Str.5673.1.S1_at -1,028 high density lipoprotein binding protein (vigilin) hdlbp 
Str.10008.1.S1_at -1,022 hypothetical protein LOC100487199 LOC100487199 
Str.10236.1.S1_at -1,021 receptor-interacting serine-threonine kinase 4 ripk4 
Str.10362.1.A1_at -1,018 hypothetical LOC100493109 LOC100493109 
Str.37633.1.S1_at -1,015 aminopeptidase-like 1 npepl1 
Str.2049.3.S1_a_at -1,007 
solute carrier family 25 
(mitochondrial carrier; 
phosphate carrier), member 3 
slc25a3 
Str.28803.2.S1_a_at -1,005 hypothetical LOC100486098 LOC100486098 
Str.1861.3.S1_s_at -1,005 DEAD (Asp-Glu-Ala-Asp) box polypeptide 6 ddx6 
Str.20062.1.S1_at -0,997 phosphoglycerate dehydrogenase phgdh 
Str.52227.2.A1_a_at -0,993  hypothetical protein  
LOC100484994 
LOC100486020 
LOC100489931 
LOC100490293 
LOC100492588 
LOC100498560 
Str.22118.1.S1_at -0,992 hypothetical protein LOC100038295 LOC100038295 
Str.1881.1.S1_at -0,990 hypothetical protein LOC100497165 LOC100497165 
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Str.1933.1.S1_at -0,990 mitochondrial ribosomal protein L12 mrpl12 
Str.6229.1.A1_at -0,989 POU class V protein oct-25 Oct25 
Str.22855.1.S1_at -0,988 pleckstrin homology-like domain, family A, member 1 phlda1 
Str.15274.1.S1_at -0,985 Meis homeobox 3 meis3 
Str.11630.1.A1_s_at -0,985 XPA binding protein 2 xab2 
Str.6222.1.S1_at -0,984 annexin A2 anxa2 
Str.79.2.S1_at -0,984 POU domain, class 5, transcription factor 1.2-like LOC100498076 
Str.20248.1.S1_at -0,980 
sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3F 
sema3f 
Str.10351.1.S1_at -0,977 G protein-coupled receptor 161 gpr161 
Str.21546.1.S1_at -0,976 chromosome 14 open reading frame 179 c14orf179 
Str.8453.1.S1_at -0,975 chromatin modifying protein 1A chmp1a 
Str.6874.1.S1_at -0,974 RAB11A, member RAS oncogene family rab11a 
Str.3045.1.S1_at -0,972 musashi homolog 1 msi1 
Str.7693.2.S1_a_at -0,967 VENT homeobox 1, gene 1  VENT homeobox 1, gene 2 
ventx1.1 
ventx1.2 
Str.9076.1.S1_at -0,967 mitochondrial ribosomal protein S2 mrps2 
Str.3002.1.A1_at -0,965 Hypothetical protein LOC779546 LOC779546 
Str.37570.1.S1_at -0,964 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 3 
slc7a3 
Str.51678.1.S1_at -0,962 ribosomal protein S17 rps17 
Str.6544.1.S1_at -0,961 DEP domain containing 7 depdc7 
Str.51323.1.S1_at -0,960 hairy and enhancer of split 2 hes2 
Str.7709.1.S2_at -0,957 RCD1 required for cell differentiation1 homolog rqcd1 
Str.37157.1.S1_at -0,956 phosphatidylinositol 4-kinase type 2 alpha pi4k2a 
StrEns.4639.1.S1_s_at -0,951 arachidonate 5-lipoxygenase-activating protein alox5ap 
Str.17801.1.A1_at -0,951 hypothetical protein LOC100488783 LOC100488783 
Str.7111.1.S1_at -0,949 nucleophosmin/nucleoplasmin 2 npm2 
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Str.27139.1.S1_at -0,945 PR domain containing 1, with ZNF domain prdm1 
Str.37891.2.S1_at -0,939 hypothetical protein LOC100498385 LOC100498385 
Str.7002.1.S1_at -0,935 hypothetical LOC100497373 LOC100497373 
StrJgi.754.1.S1_s_at -0,931 G2/M-phase specific E3 ubiquitin protein ligase g2e3 
Str.19642.1.S1_at -0,923 ATG16 autophagy related 16-like 1 atg16l1 
Str.51307.2.S1_s_at -0,922 hypothetical protein LOC100485101 LOC100485101 
Str.5058.1.S1_at -0,916 rhabdoid tumor deletion region gene 1 rtdr1 
Str.6021.1.S1_at -0,915 hypothetical protein MGC75753 MGC75753 
StrJgi.6490.1.S1_s_at -0,913 nischarin nisch 
Str.27191.2.S1_at -0,912 putative ferric-chelate reductase 1-like LOC100489839 
Str.16697.1.S1_at -0,912 nuclear receptor subfamily 1, group D, member 1 nr1d1 
Str.10814.1.S1_a_at -0,910 T, brachyury homolog t 
Str.15841.2.S1_at -0,905 ras homolog gene family, member V rhov 
Str.10791.1.S1_at -0,901 F-box protein 5 fbxo5 
Str.29354.1.A1_at -0,896 integrator complex subunit 4-like LOC100498633 
Str.4240.1.S1_at -0,896 catechol-O-methyltransferase comt 
Str.37794.1.S1_at -0,895 lysophosphatidic acid receptor 6 lpar6 
Str.8913.1.S3_at -0,890 C-terminal binding protein 2 ctbp2 
Str.5871.1.S1_at -0,888 cyclin-dependent kinase inhibitor xic1 cdknx 
Str.11206.1.S1_a_at -0,885 hypothetical LOC100496939 LOC100496939 
Str.42508.1.A1_at -0,882 v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog kit 
Str.6167.1.S1_at -0,880 phosphorylase, glycogen, muscle pygm 
Str.41326.1.S1_s_at -0,875 hairy and enhancer of split 6, gene 1 hes6.1 
StrEns.3083.1.S1_s_at -0,873 angel homolog 2 angel2 
Str.27368.1.S1_at -0,864 HCLS1-associated protein X-1-like LOC100485912 
Str.42404.1.A1_at -0,864 Smg-5 homolog, nonsense mediated mRNA decay factor smg5 
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Str.10780.1.S1_at -0,860 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, delta 
subunit 
atp5d 
Str.50368.2.S1_at -0,858 retinoic acid receptor gamma-A-like LOC100485387 
StrEns.6535.1.S1_s_at -0,857 hormonally up-regulated Neu-associated kinase hunk 
StrAffx.22.1.S1_at -0,855 
hypothetical protein 
LOC100486038 /// hypothetical 
protein LOC100487146 
LOC100486038 
/// 
LOC100487146 
Str.6401.1.S1_a_at -0,854 cullin 4B cul4b 
Str.292.1.S1_at -0,853 KIAA0907 kiaa0907 
Str.4669.1.S1_at -0,851 hypothetical protein LOC100494135 LOC100494135 
Str.4856.1.S1_at -0,846 folate receptor 1 (adult) folr1 
Str.538.2.A1_at -0,844 chordin chrd 
StrJgi.4129.1.S1_at -0,844 ATPase inhibitory factor 1 atpif1 
Str.169.2.S1_a_at -0,840 sal-like 1 sall1 
Str.24427.1.A1_at -0,838 ran-binding protein 3-like LOC100498481 
Str.14235.1.S1_at -0,835 coenzyme Q10 homolog B coq10b 
Str.16683.1.A1_at -0,834 phosphatidylinositol 4-kinase, catalytic, alpha pi4ka 
Str.19092.2.A1_at -0,830 RAB11 family interacting protein 1 (class I) rab11fip1 
Str.511.2.S1_at -0,829 activating transcription factor 5 atf5 
Str.31799.1.S1_at -0,829 hypothetical protein LOC100124772 LOC100124772 
Str.38847.3.S1_at -0,827 chromosome 19 open reading frame 66 c19orf66 
Str.31289.2.S1_at -0,825 oocyte zinc finger protein XlCOF7.1-like LOC100496553 
Str.50363.2.S1_at -0,825 
COX10 homolog, cytochrome c 
oxidase assembly protein, heme 
A: farnesyltransferase 
cox10 
Str.10916.1.S1_at -0,823 
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex 
4 
ndufb4 
Str.11181.1.S1_at -0,823 transmembrane protein 49 tmem49 
Str.471.1.S1_a_at -0,822 ubiquitin-conjugating enzyme E2I (UBC9 homolog) ube2i 
Str.15327.1.S1_at -0,821 chromosome 3 open reading frame 32 c3orf32 
Str.37502.1.S1_at -0,820 lipase A, lysosomal acid, cholesterol esterase lipa 
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Str.10764.1.S1_a_at -0,811 transmembrane protein 183A tmem183a 
Str.27547.1.S3_at -0,810 hypothetical protein LOC550042 LOC550042 
Str.24913.1.S1_at -0,810 CLPTM1-like clptm1l 
Str.488.1.S1_at -0,802 hypothetical protein MGC76328 MGC76328 
Str.3639.2.S1_s_at -0,797 ankyrin repeat domain 11 ankrd11 
Str.26831.1.S1_s_at -0,791 bone morphogenetic protein 4 bmp4 
Str.4537.1.S1_at -0,788 alpha-ketoglutarate-dependent dioxygenase alkB homolog 3-like LOC100495476 
Str.8680.1.S1_at -0,786 lactate dehydrogenase B ldhb 
Str.26963.1.S1_at -0,782 Hypothetical protein LOC100145127 LOC100145127 
Str.3361.1.S1_at -0,780 MAK16 homolog mak16 
Str.4965.1.S1_at -0,777 minichromosome maintenance complex component 6 mcm6.2 
StrEns.171.1.S1_s_at -0,776 phosphatidic acid phosphatase type 2B ppap2b 
Str.6623.1.S1_at -0,774 hypothetical protein LOC733945 LOC733945 
Str.6018.1.S1_at -0,774 hairy and enhancer of split 4 hes4 
Str.15770.1.S1_at -0,773 prostaglandin-endoperoxide synthase 2  ptgs2 
Str.15499.1.S1_at -0,772 oxysterol binding protein osbp 
Str.24757.1.S1_at -0,764 nipsnap homolog 3A nipsnap3a 
Str.1347.1.A1_at -0,761 integrin-linked kinase ilk 
Str.24893.1.S1_at -0,760 SPRY domain-containing SOCS box protein 4-like LOC100496912 
Str.10257.1.S1_at -0,756 28S ribosomal protein S18b, mitochondrial-like LOC100489063 
Str.10270.1.S1_at -0,755 hydroxysteroid (17-beta) dehydrogenase 12 hsd17b12 
StrEns.9037.1.S1_s_at -0,755 WD repeat domain 91 wdr91 
Str.16160.1.S1_at -0,755 forkhead box I4, gene 2 foxi4.2 
Str.21592.1.S1_at -0,754 Rho/Rac guanine nucleotide exchange factor (GEF) 2 arhgef2 
Str.1370.1.S1_s_at -0,752 zinc finger, HIT-type containing 1 znhit1 
Str.51820.1.S1_at -0,749 cyclin F ccnf 
Str.34332.1.A1_s_at -0,744 heme oxygenase (decycling) 2 hmox2 
Str.2761.1.S1_at -0,739 CD81 molecule cd81 
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Str.49437.1.S1_at -0,737 Hypothetical protein LOC100144964 LOC100144964 
Str.10129.1.S1_at -0,736 
Novel solute carrier family 18 
(vesicular monoamine) slca18 
protein 
LOC733714 
Str.43415.1.S1_at -0,731 Coiled-coil domain containing 92 ccdc92 
Str.10123.1.S1_at -0,731 glucose-fructose oxidoreductase domain containing 1 gfod1 
Str.16503.1.S1_at -0,729 adaptor-related protein complex 2, alpha 2 subunit ap2a2 
StrEns.6699.1.S1_at -0,729 tRNA pseudouridine synthase-like 1-like LOC100497905 
Str.46269.1.A1_s_at -0,728 chromosome 19 open reading frame 60 c19orf60 
Str.19440.1.S1_a_at -0,728 B-cell translocation gene 5 btg5 
Str.381.2.A1_a_at -0,727 ubiquilin 4 ubqln4 
Str.34312.1.A1_at -0,725 hypothetical protein LOC100492765 LOC100492765 
Str.50958.1.S1_s_at -0,721 THAP domain containing 4 thap4 
Str.2540.1.S1_at -0,714 SMAD family member 6 smad6 
Str.22075.1.S1_at -0,711 mitochondrial ribosomal protein L33 mrpl33 
Str.37581.1.S1_at -0,708 hypothetical protein LOC100489670 LOC100489670 
Str.31764.1.A1_at -0,706 neurofilament, light polypeptide nefl 
Str.5440.1.S1_at -0,705 
ariadne homolog, ubiquitin-
conjugating enzyme E2 binding 
protein, 1 
arih1 
Str.49709.1.A1_s_at -0,704 intraflagellar transport 52 homolog ift52 
Str.6196.1.S2_at -0,704 hypothetical protein MGC75626 MGC75626 
Str.11467.1.S1_at -0,703 ferredoxin reductase fdxr 
Str.34173.3.S1_s_at -0,703 chromosome 2 open reading frame 42 c2orf42 
Str.27369.1.S2_at -0,702 homeobox B3 hoxb3 
Str.6282.1.A1_x_at -0,702 filamin C, gamma flnc 
Str.18831.1.S1_at -0,701 zinc finger protein 567-like LOC100495895 
Str.563.1.S1_at -0,700 inositol-3-phosphate synthase 1 isyna1 
Str.10174.1.A1_at -0,698 
single-strand-selective 
monofunctional uracil-DNA 
glycosylase 1 
smug1 
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Str.3944.1.S1_at -0,695 hypothetical protein LOC733539 LOC733539 
StrEns.1418.1.S1_s_at -0,695 Bloom syndrome, RecQ helicase-like blm 
Str.10015.1.S1_at -0,694 transmembrane protein 41B tmem41b 
Str.27247.1.S2_s_at -0,692 serine peptidase inhibitor, Kunitz type, 2 spint2 
Str.29917.1.A1_at -0,689 HMG box-containing protein hbcx 
Str.7564.2.S1_a_at -0,689 diazepam binding inhibitor (dbi) dbi 
Str.9089.2.S1_a_at -0,688 trans-2,3-enoyl-CoA reductase tecr 
Str.15911.1.A1_at -0,688 hypothetical protein MGC145685 MGC145685 
Str.6712.1.S1_s_at -0,681 ribosomal protein S2 rps2 
Str.6262.1.A1_at -0,681 phosphatase and actin regulator 4 phactr4 
Str.51838.1.S1_at -0,680 leucine-rich repeats and WD repeat domain containing 1 lrwd1 
Str.20309.1.A1_at -0,677 cyclin-dependent kinase 6 cdk6 
StrAffx.136.1.S1_s_at -0,674 family with sequence similarity 160, member B2 fam160b2 
Str.24290.1.S1_at -0,674 hypothetical protein MGC147490 MGC147490 
Str.32043.1.A1_at -0,670 hypothetical protein MGC147507 MGC147507 
Str.2514.1.S1_a_at -0,668 NIMA (never in mitosis gene a)-related kinase 2 nek2 
Str.21553.1.S1_at -0,667 zinc finger protein 740 znf740 
Str.862.1.S1_at -0,664 transcription factor CP2 tfcp2 
Str.1699.1.S1_at -0,664 malate dehydrogenase 2, NAD (mitochondrial) mdh2 
StrJgi.162.1.S1_at -0,663 serine palmitoyltransferase, long chain base subunit 3 sptlc3 
Str.15129.1.S1_at -0,660 alkB, alkylation repair homolog 5 alkbh5 
Str.8533.1.A1_s_at -0,655 caveolin 2 cav2 
Str.7025.2.S2_at -0,654 hypothetical LOC100496454 LOC100496454 
Str.5456.2.A1_s_at -0,653 arsA arsenite transporter, ATP-binding, homolog 1 (bacterial) asna1 
Str.28989.1.A1_at -0,651 72 kDa inositol polyphosphate 5-phosphatase-like LOC100486470 
Str.7586.3.S1_a_at -0,650 MAPK scaffold protein 1 mapksp1 
Str.6355.1.S1_at -0,648 RAD51 associated protein 1 rad51ap1 
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Str.10998.1.S1_at -0,644 CNDP dipeptidase 2 (metallopeptidase M20 family) cndp2 
Str.464.1.S1_at -0,643 radial spoke head 9 homolog rsph9 
Str.11870.1.S1_at -0,643 collagen, type IX, alpha 3 col9a3 
Str.17125.1.S1_at -0,643 Rho family GTPase 3 rnd3 
Str.17056.1.S1_a_at -0,643 H3 histone, family 3B (H3.3B) h3f3b 
Str.28075.1.S1_s_at -0,642 translocator protein (18kDa) tspo 
Str.8911.1.S1_at -0,642 hippocampus abundant transcript 1 hiat1 
Str.5375.2.S1_a_at -0,640 uridine monophosphate synthetase umps 
Str.3.1.S1_a_at -0,633 nanos homolog 1 nanos1 
Str.24671.1.S1_a_at -0,633 tubulin tyrosine ligase-like family, member 4 ttll4 
Str.11129.1.S1_at -0,631 ubiquitin-conjugating enzyme E2B (RAD6 homolog) ube2b 
Str.26863.1.S1_at -0,631 mitochondrial ribosomal protein L40 mrpl40 
Str.8957.1.A1_at -0,630 ATG2 autophagy related 2 homolog A atg2a 
Str.21719.1.S1_at -0,627 mitochondrial ribosomal protein L52 mrpl52 
Str.6511.1.S1_at -0,624 transmembrane protein 11 tmem11 
Str.52134.1.S1_s_at -0,620 PQ loop repeat containing 3 pqlc3 
Str.31657.1.S1_at -0,619 hypothetical protein LOC100494403 LOC100494403 
Str.10064.2.S1_a_at -0,618 MTERF domain containing 1 mterfd1 
StrJgi.4070.1.S1_s_at -0,616 
glycoprotein-N-
acetylgalactosamine 3-beta-
galactosyltransferase 1-like 
LOC100487794 
Str.15041.1.S1_at -0,616 
regulator of chromosome 
condensation (RCC1) and BTB 
(POZ) domain containing protein 
2 
rcbtb2 
Str.8025.1.S1_a_at -0,615 keratin 18 krt18 
Str.16910.1.S1_at -0,615 
activating transcription factor 4 
(tax-responsive enhancer 
element B67) 
atf4 
Str.1806.1.S1_at -0,614 Hypothetical protein MGC146711 MGC146711 
Str.37447.1.S1_at -0,613 hypothetical protein LOC100487171 LOC100487171 
Str.4820.1.S2_at -0,610 eukaryotic translation elongation factor 1 alpha 1, oocyte form eef1a1o 
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Str.21822.1.S1_at -0,610 AFG3 ATPase family gene 3-like 2 (S. cerevisiae) afg3l2 
Str.2054.1.S1_at -0,610 YTH domain family, member 1 ythdf1 
Str.6670.1.S1_at -0,609 aldolase A, fructose-bisphosphate aldoa 
Str.11968.1.A1_at -0,606 RAS, dexamethasone-induced 1 rasd1 
Str.6981.1.S1_at -0,606 growth arrest and DNA-damage-inducible, gamma gadd45g 
Str.7658.1.S1_at -0,603 maternal embryonic leucine zipper kinase melk 
Str.2080.1.S1_at -0,601 ribonuclease P 14kDa subunit rpp14 
Str.27246.1.S1_at -0,600 SRY (sex determining region Y)-box 11 sox11 
Str.1379.1.S1_at -0,598 cell division cycle  associated 7 cdca7 
StrEns.9103.1.S1_at -0,598 zinc finger homeobox protein 3-like LOC100489378 
StrEns.8056.1.S1_at -0,598 solute carrier family 45 member 3-like LOC100496642 
Str.52196.1.S1_at -0,598 enolase-phosphatase 1 enoph1 
Str.10330.1.S2_at -0,596 sprouty homolog 1, antagonist of FGF signaling spry1 
AFFX-Str-ef1a-5_at -0,594 eukaryotic translation elongation factor 1 alpha 1 eef1a1 
Str.27580.1.S1_at -0,594 
cat eye syndrome chromosome 
region, candidate 5 homolog 
(human) 
cecr5 
Str.5136.1.S1_at -0,592 TGFB-induced factor homeobox 1 tgif1 
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BMO2 microarray analysis 
Listed are all genes, upreglulated ≤ 1.5 fold change and with a local false discovery rate ≤ 0.2. 
Set-probe number 
 fold 
change 
[log2] 
gene name symbol 
Str.9570.1.S1_at 3,814 ribophorin II rpn2 
Str.37672.2.S1_at 3,324 LON peptidase N-terminal domain and ring finger 3 lonrf3 
Str.27732.1.S1_at 3,160 GTP binding protein 5 (putative) gtpbp5 
Str.21604.1.S1_at 2,113 5'-nucleotidase, cytosolic III nt5c3 
Str.11279.1.S1_at 2,102 unc-45 homolog B unc45b 
Str.51882.1.S1_at 2,061 chromosome 20 open reading frame 29 c20orf29 
Str.4820.1.S2_at 1,858 
eukaryotic translation 
elongation factor 1 alpha 1, 
oocyte form 
eef1a1o 
Str.7641.1.S3_at 1,754 B-cell translocation gene 1, anti-proliferative btg1 
Str.11402.1.A1_at 1,747 
protein phosphatase 1, 
regulatory (inhibitor) 
subunit 3C, gene 1 
ppp1r3c.1 
Str.27919.1.A1_at 1,669 nuclear factor, interleukin 3 regulated nfil3 
Str.52226.1.S2_at 1,613 chromosome 1 open reading frame 93 c1orf93 
Str.21588.1.S1_at 1,548 T, brachyury homolog, gene 2 t2 
Str.8423.1.S1_at 1,484 chromosome 6 open reading frame 211 c6orf211 
Str.16459.1.S1_at 1,483 
hect (homologous to the E6-
AP (UBE3A) carboxyl 
terminus) domain and RCC1 
(CHC1)-like domain (RLD) 1 
herc1 
Str.51692.1.S1_at 1,305 novel protein-like LOC733728 
Str.37449.1.A1_at 1,273 
poly (ADP-ribose) 
polymerase family, member 
4 
parp4 
Str.2357.1.S1_at 1,204 forkhead box I1 foxi1 
Str.20514.1.S1_at 1,180 FBJ murine osteosarcoma viral oncogene homolog fos 
Str.52097.1.S1_at 1,169 ATPase type 13A5 atp13a5 
Str.25548.1.A1_at 1,161 amyloid protein-binding protein 2-like LOC100487715 
Str.11288.1.S1_at 1,105 hypothetical LOC100486074 LOC100486074 
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Str.16957.1.S2_at 1,071 fused in sarcoma fus 
Str.21032.2.S1_a_at 1,069 MGC89871 protein MGC89871 
Str.3485.1.S1_at 1,067 rho GTPase-activating protein 11A-like LOC100495220 
Str.49500.1.S2_at 1,056 stearoyl-CoA desaturase (delta-9-desaturase) scd 
Str.16732.1.S2_at 1,046 
v-myc myelocytomatosis 
viral related oncogene, 
neuroblastoma derived 
mycn 
Str.11260.1.S1_at 1,045 hairy and enhancer of split 5, gene 1 hes5.1 
Str.21086.2.S1_s_at 1,038 
glutamate receptor, 
ionotropic, N-methyl D-
aspartate-like 1A 
grinl1a 
Str.6857.1.S2_at 1,004 eukaryotic translation termination factor 1 etf1 
Str.17056.1.S1_a_at 0,980 H3 histone, family 3B (H3.3B) h3f3b 
Str.5851.1.S1_at 0,978 PDZ binding kinase pbk 
Str.27186.1.S1_s_at 0,955 histone H3.2-like LOC100496129 
Str.22588.1.S1_at 0,950 chromosome 11 open reading frame 2 c11orf2 
Str.14144.2.A1_at 0,946 zinc finger and BTB domain containing 5 zbtb5 
Str.21295.1.S1_a_at 0,901 
nudix (nucleoside 
diphosphate linked moiety 
X)-type motif 16 
nudt16 
Str.51420.1.S1_at 0,895 iron-sulfur cluster assembly 2 homolog isca2 
Str.27913.1.S1_at 0,867 acidic repeat containing acrc 
Str.1999.1.S1_at 0,863 superoxide dismutase 1, soluble sod1 
Str.27324.1.S2_at 0,858 ras-related protein ras-dva ras-dva 
Str.27848.1.S1_at 0,848 egl nine homolog 3 egln3 
Str.15757.1.S1_at 0,836 dihydrofolate reductase dhfr 
Str.27290.1.S1_at 0,816 ribonuclease H2, subunit A rnaseh2a 
Str.17024.1.S1_at 0,809 
X-ray repair complementing 
defective repair in Chinese 
hamster cells 3 
xrcc3 
Str.51912.1.S1_at 0,806 S100P binding protein s100pbp 
Str.15137.1.S1_at 0,804 ADP-ribosylation factor-like 6 interacting protein 1 arl6ip1 
Str.51459.1.S1_at 0,798 neurobeachin nbea 
Str.51053.2.A1_s_at 0,789 
human immunodeficiency 
virus type I enhancer binding 
protein 2 
hivep2 
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Str.40497.1.S1_at 0,785 
ras-related C3 botulinum 
toxin substrate 3 (rho family, 
small GTP binding protein 
Rac3) 
rac3 
Str.51787.1.S1_at 0,782 histone cluster 1, H2ah hist1h2ah 
StrEns.3693.1.S1_s_at 0,766 
hypothetical protein                         
EGF-like module-containing 
mucin-like hormone 
receptor-like 1-like 
LOC100490769 
LOC100490939 
StrEns.6148.1.S1_a_at 0,763 peptide chain release factor 1, mitochondrial-like LOC100486280 
Str.8101.1.S1_at 0,758 ferritin, heavy polypeptide 1 fth1 
Str.20232.1.S1_at 0,757 Hypothetical protein LOC100144290 LOC100144290 
Str.37700.1.S1_at 0,751 
nuclear factor of kappa light 
polypeptide gene enhancer 
in B-cells inhibitor, zeta 
nfkbiz 
StrAffx.238.1.S1_at 0,740 integrator complex subunit 12 ints12 
Str.15265.1.S1_at 0,725 novel helix-loop-helix DNA binding domain protein LOC733709 
Str.17731.1.S1_at 0,724 general transcription factor 3A gtf3a 
Str.6900.1.S2_s_at 0,717 
ER degradation enhancer, 
mannosidase alpha-like 1 
angiopoietin-related protein 
1-like 
edem1  
LOC100491105 
Str.13001.1.S1_at 0,717 MAD2 mitotic arrest deficient-like 1 mad2l1 
Str.24585.1.S1_at 0,713 apolipoprotein O apoo 
Str.32445.1.S1_at 0,706 tubulin alpha-1D chain-like  MGC97820 protein 
LOC100487867 
MGC97820 
Str.31142.1.S1_at 0,704 transmembrane protein, adipocyte asscociated 1 tpra1 
Str.101.1.S1_at 0,703 replication factor C (activator 1) 5, 36.5kDa rfc5 
Str.27997.1.S1_at 0,701 hypothetical protein LOC100498215 LOC100498215 
Str.21484.1.A1_s_at 0,701 
pyruvate dehyrogenase 
phosphatase catalytic    
subunit 1 
pdp1 
Str.7662.1.S1_at 0,700 fatty acid 2-hydroxylase fa2h 
Str.34983.1.A1_s_at 0,698 Hypothetical protein LOC779512 LOC779512 
Str.39187.1.S1_at 0,697 mTERF domain-containing protein 3, mitochondrial-like LOC100485703 
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Str.26008.1.S1_at 0,688 hypothetical protein LOC100498571 LOC100498571 
Str.38888.1.S1_at 0,679 transcription factor AP-1-like LOC100493911 
Str.40052.1.S1_at 0,677 promethin-A-like LOC100486925 
Str.40271.2.S1_a_at 0,674 Hypothetical protein LOC550005 LOC550005 
Str.52018.1.S1_at 0,673 zinc finger protein 16 znf16 
Str.45299.1.A1_s_at 0,670 hypothetical LOC548351 LOC548351 
Str.26767.1.S1_at 0,663 dual serine/threonine and tyrosine protein kinase dstyk 
Str.37936.1.A1_at 0,660 fibroblast growth factor 20 fgf20 
Str.15499.1.S1_at 0,649 oxysterol binding protein osbp 
Str.18904.1.S1_at 0,646 junctophilin 1 jph1 
StrEns.10243.1.S1_at 0,642 thyrotropin subunit beta-like LOC100496349 
Str.9548.3.A1_at 0,639 28S ribosomal protein S25, mitochondrial-like LOC100494871 
Str.13245.1.S1_at 0,633 heat shock 70kDa protein 9 (mortalin) hspa9 
Str.25272.1.S1_at 0,626 retinoid X receptor, gamma rxrg 
Str.27358.1.S1_at 0,622 transmembrane protease, serine 11F tmprss11f 
Str.7160.3.A1_at 0,618 
ubiquinone biosynthesis 
methyltransferase COQ5, 
mitochondrial-like 
LOC100495452 
Str.29780.1.A1_at 0,617 Fanconi anemia, complementation group D2 fancd2 
Str.20243.1.S1_at 0,607 SET and MYND domain containing 4 smyd4 
Str.31445.1.S1_at 0,606 inhibitor of growth family, member 1 ing1 
Str.28441.1.S1_at 0,605 SNF related kinase snrk 
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Listed are all genes, downreglulated ≤ 1.5 fold change and with a local false discovery rate ≤ 0.2. 
Set-probe number 
 fold 
change 
[log2] 
gene name symbol 
Str.24244.1.S1_at -1,344 SRY (sex determining region Y)-box 21 sox21 
Str.24947.1.S1_at -1,308 ADP-ribosylation factor 4 arf4 
Str.11939.1.S1_at -1,303 l-amino-acid oxidase-like LOC100496394 
Str.5401.1.S1_at -1,235 retinal pigment epithelium-specific protein 65kDa rpe65 
Str.15587.1.S1_at -1,230 hypothetical protein LOC100487200 LOC100487200 
Str.11165.7.S1_at -1,206 sarcoplasmic/endoplasmic reticulum calcium ATPase 2-like LOC100489059 
Str.6222.1.S1_at -1,120 annexin A2 anxa2 
Str.10362.1.A1_at -1,111 hypothetical LOC100493109 LOC100493109 
Str.15223.9.A1_at -1,110 14 kDa phosphohistidine phosphatase-like LOC100497662 
Str.10659.1.S1_at -1,110 
transcription factor AP-2 epsilon 
(activating enhancer binding 
protein 2 epsilon) 
tfap2e 
Str.17388.1.S1_at -1,078 hypothetical LOC100495861 LOC100495861 
Str.42272.1.A1_at -1,035 Zinc finger, CCHC domain containing 2 zcchc2 
StrEns.6291.1.S1_s_at -1,029 nucleoporin 155kDa nup155 
Str.21950.1.S1_at -1,021 hypothetical LOC100488570 LOC100488570 
Str.420.1.S1_at -1,008 
ABO blood group (transferase A, 
alpha 1-3-N-
acetylgalactosaminyltransferase; 
transferase B, alpha 1-3-
galactosyltransferase) 
abo 
StrEns.8369.1.S1_at -0,961 growth/differentiation factor 2-like LOC100485289 
Str.6623.1.S1_at -0,953 hypothetical protein LOC733945 LOC733945 
Str.7820.2.S1_a_at -0,952 immediate early response gene 2 protein-like LOC100491464 
StrEns.12689.1.S1_s_at -0,910 ERGIC and golgi 2 ergic2 
StrJgi.8475.1.S1_s_at -0,908 SNAP-associated protein snapin 
Str.8913.1.S3_at -0,905 C-terminal binding protein 2 ctbp2 
Str.27847.1.A1_at -0,899 hypothetical protein LOC100493690 LOC100493690 
Str.12012.1.S1_at -0,894 ankyrin repeat domain 10 ankrd10 
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Str.31510.1.S1_at -0,894 Hypothetical protein MGC146314 MGC146314 
Str.4321.1.S1_at -0,888 RNA pseudouridylate synthase domain containing 4 LOC734064 
Str.21559.2.S1_x_at -0,868 Y box binding protein 2 ybx2 
Str.36616.1.A1_at -0,844 haloacid dehalogenase-like hydrolase domain containing 3 hdhd3 
Str.10535.1.S1_at -0,841 hypothetical LOC100495377 LOC100495377 
Str.6659.1.S1_at -0,820 nerve growth factor receptor ngfr 
Str.11483.1.S1_at -0,808 
leucine-rich repeat-containing 
protein 8C-like  leucine rich 
repeat containing 8 family,   
member C 
LOC100488426 
lrrc8c 
Str.643.1.S1_a_at -0,792 hypothetical LOC100486597 LOC100486597 
Str.26763.1.S1_at -0,779 chromosome 15 open reading frame 44 c15orf44 
Str.51988.1.S1_at -0,771 serine/arginine-rich splicing factor 11 srsf11 
Str.21643.1.S1_at -0,767 serpin peptidase inhibitor, clade I (neuroserpin), member 1 serpini1 
StrJgi.1740.1.S1_at -0,764 Na+/H+ exchanger domain containing 2 nhedc2 
Str.27583.2.S1_at -0,763 COX assembly mitochondrial protein homolog cmc1 
Str.1431.1.S1_at -0,753 hypothetical protein LOC100124857 LOC100124857 
Str.21898.1.S1_at -0,710 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 11, 14.7kDa 
ndufa11 
Str.21613.1.S1_a_at -0,705 Calponin 2 cnn2 
Str.39270.1.A1_at -0,694 bone morphogenetic protein 15-like LOC100485893 
Str.1984.1.S1_at -0,689 
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 1 
slc9a3r1 
Str.3624.1.S1_at -0,682 
APEX nuclease 
(apurinic/apyrimidinic 
endonuclease) 2 
apex2 
Str.17660.1.S1_at -0,679 interferon-related developmental regulator 1 ifrd1 
Str.15669.1.S1_at -0,673 nuclear receptor subfamily 2, group F, member 1 nr2f1 
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Str.10016.1.S1_at -0,661 cdc42 effector protein (Rho GTPase binding) 4 cdc42ep4 
Str.51981.1.S1_s_at -0,659 formin binding protein 4 LOC734003 
Str.39300.1.S2_at -0,657 MGC97787 protein MGC97787 
Str.27368.1.S1_at -0,653 HCLS1-associated protein X-1-like LOC100485912 
Str.5388.1.S1_a_at -0,652 calcium homeostasis modulator 2 calhm2 
Str.5015.1.A1_at -0,638 
neural precursor cell expressed, 
developmentally down-regulated 
9 
nedd9 
Str.37633.1.S1_at -0,635 aminopeptidase-like 1 npepl1 
StrJgi.1688.1.S1_at -0,626 hypothetical protein LOC100495013 LOC100495013 
Str.8618.1.S1_a_at -0,620 ATPase, H+ transporting, lysosomal 14kDa, V1   subunit F atp6v1f 
Str.21553.1.S1_at -0,613 zinc finger protein 740 znf740 
Str.27567.1.S2_at -0,606 polymerase (RNA) III (DNA directed) polypeptide E (80kD) polr3e 
Str.1806.1.S1_at -0,605 Hypothetical protein MGC146711 MGC146711 
Str.28803.2.S1_a_at -0,603 hypothetical LOC100486098 LOC100486098 
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Pre/postMBT microarray analysis 
Listed are all genes, upreglulated ≥ 5.65 fold change and with an adjusted p-value ≤ 0.05. 
Set-probe number 
 fold 
change 
[log2] 
gene name symbol 
Str.14985.1.S1_at 11,53 eomesodermin eomes 
Str.20300.1.S1_a_at 11,38 mix-like endodermal regulator mixer 
Str.1534.1.S1_at 11,09 hypothetical LOC100487344 LOC100487344 
Str.6030.1.S1_at 11,09 forkhead box A4 foxa4 
Str.15007.1.S1_at 10,74 gastrula-specific protein 17 gs17 
Str.10688.1.S1_at 10,28 
hypothetical protein 
LOC100170595            putative 
nuclease HARBI1-like 
LOC100170595 
LOC100492963 
Str.37794.1.S1_at 10,24 lysophosphatidic acid receptor 6 lpar6 
Str.112.1.S1_at 10,12 
Brachyury-inducible homeobox 
1, gene 1 homeobox protein 
Mix.1-like 
bix1.1 
LOC100491743 
Str.10234.1.S2_at 10,10 Zic family member 3 (odd-paired homolog) zic3 
Str.10066.1.S1_at 10,07 mesendoderm nuclear factor, gene 1 menf.1 
Str.113.1.S1_at 10,02 mix1 homeobox mix1 
Str.30719.1.A1_s_at 9,97 ras homolog gene family, member V rhov 
Str.11884.1.S1_at 9,86 anti-dorsalizing morphogenic protein admp 
Str.17224.1.S1_at 9,83 Zic family member 1 (odd-paired homolog) zic1 
Str.10058.1.S1_at 9,62 syntaxin 19 stx19 
Str.6151.1.S1_at 9,50 ATPase, Na+/K+ transporting, beta 2 polypeptide atp1b2 
Str.447.1.S1_at 9,48 ATPase, H+/K+ transporting, nongastric, alpha polypeptide atp12a 
Str.41254.1.S1_s_at 9,47 SRY (sex determining region Y)-box 2 sox2 
Str.6141.1.S1_a_at 9,39 
glycine amidinotransferase (L-
arginine:glycine 
amidinotransferase) 
gatm 
Str.7025.2.S2_at 9,36 hypothetical LOC100496454 LOC100496454 
StrJgi.4169.1.S1_s_at 9,32 hypothetical protein LOC100488209 LOC100488209 
Str.7482.2.S1_a_at 9,31 protocadherin 8, gene 2 pcdh8.2 
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Str.4932.1.S1_a_at 9,17 
hypothetical protein 
LOC100494704               VENT 
homeobox 2, gene 1 
LOC100494704 
ventx2.1 
Str.15097.1.S1_a_at 9,15 hypothetical protein    hypothetical protein  
LOC100497333 
LOC100498266 
Str.538.2.A2_at 9,14 chordin chrd 
Str.6229.2.S1_at 9,12 ephrin-B2 efnb2 
Str.2980.2.A1_a_at 9,05 
transcription factor AP-2 alpha 
(activating enhancer binding 
protein 2 alpha) 
tfap2a 
Str.6718.1.S1_at 8,97 hypothetical LOC100494381 LOC100494381 
Str.11206.1.S1_a_at 8,93 hypothetical LOC100496939 LOC100496939 
Str.20278.2.A1_a_at 8,90 hypothetical protein LOC100489209 LOC100489209 
StrJgi.7797.1.S1_s_at 8,84 hyaluronan synthase 2 has2 
Str.15369.1.S1_at 8,76 hypothetical protein LOC100127584 LOC100127584 
Str.10804.1.S2_s_at 8,76 keratin 5, gene 7 krt5.7 
Str.79.2.S1_at 8,75 POU domain, class 5, transcription factor 1.2-like LOC100498076 
Str.114.1.S1_at 8,74 SRY (sex determining region Y)-box 17 alpha sox17a 
Str.1955.1.S1_at 8,73 hypothetical protein LOC100491352 LOC100491352 
Str.20147.1.S1_at 8,73 fibroblast growth factor 8 (androgen-induced) fgf8 
Str.42150.1.S1_at 8,64 novel zinc finger protein LOC733912 
Str.10814.1.S1_a_at 8,56 T, brachyury homolog t 
Str.7018.1.S1_at 8,56 frizzled-related protein frzb 
Str.10716.1.S1_at 8,55 forkhead box D4-like 1,   gene 1 foxd4l1.1 
Str.4900.1.S1_at 8,53 zinc finger protein 470 znf470 
Str.51679.2.S3_a_at 8,52 hypothetical protein LOC100498064 LOC100498064 
StrJgi.754.1.S1_s_at 8,48 G2/M-phase specific E3 ubiquitin protein ligase g2e3 
Str.51679.2.S1_a_at 8,41 hypothetical protein LOC100498497 LOC100498497 
Str.14655.1.S2_at 8,39 LIM homeobox 5 lhx5 
Str.7693.2.S1_at 8,37 VENT homeobox 1, gene 1 ventx1.1 
Str.52227.2.A1_a_at 8,31 
hypothetical LOC100484994          
hypothetical LOC100486020     
hypothetical LOC100489931      
hypothetical LOC100490293    
hypothetical LOC100492588        
hypothetical LOC100498560 
LOC100484994 
LOC100486020 
LOC100489931 
LOC100490293 
LOC100492588  
LOC100498560 
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Str.7447.2.A1_at 8,30 Heterogeneous nuclear ribonucleoprotein D-like hnrpdl 
Str.15963.1.S1_at 8,29 tyrosine aminotransferase tat 
Str.7571.1.S1_a_at 8,29 hypothetical LOC100491682 LOC100491682 
Str.15754.1.S1_s_at 8,26 fibronectin leucine rich transmembrane protein 3 flrt3 
Str.2944.1.S1_at 8,26 cone-rod homeobox crx 
Str.490.1.S2_at 8,20 bone morphogenetic    protein 4 bmp4 
Str.2572.2.S1_x_at 8,20 hypothetical protein LOC100487243 LOC100487243 
Str.14828.1.S1_at 8,18 left-right determination factor lefty 
Str.7571.2.S1_a_at 8,16 
hypothetical LOC100491590 
hypothetical LOC100491682 
hypothetical LOC100493923 
LOC100491590 
LOC100491682 
LOC100493923 
Str.31317.1.S1_at 8,14 hypothetical protein LOC100487186 LOC100487186 
Str.6731.1.S1_at 8,14 zinc finger protein 750 znf750 
Str.51845.1.A1_at 8,00 hypothetical protein MGC69473 MGC69473 
Str.1534.1.S2_a_at 7,96 hypothetical protein LOC100495042 LOC100495042 
Str.2572.4.A1_a_at 7,94 hypothetical LOC100488588 LOC100488588 
Str.10455.1.S1_at 7,86 hypothetical LOC100495538 LOC100495538 
Str.7017.1.S1_at 7,86 SRY (sex determining region Y)-box 17 beta, gene 2 sox17b.2 
Str.15027.1.S1_at 7,85 wingless-type MMTV integration site family, member 8A wnt8a 
Str.1702.1.S1_at 7,78 secreted frizzled-related protein 2 sfrp2 
Str.52227.1.S1_a_at 7,76 hypothetical protein LOC100492588 LOC100492588 
Str.17465.2.S1_a_at 7,67 hypothetical LOC100493277 LOC100493277 
Str.3072.1.S1_at 7,65 grainyhead-like 3 grhl3 
Str.6681.1.S1_a_at 7,60 keratin krt 
Str.6282.1.A1_x_at 7,59 filamin C, gamma flnc 
Str.6185.1.S1_at 7,58 cornifelin homolog cnfn 
Str.7693.2.S1_a_at 7,50 VENT homeobox 1, gene 1  VENT homeobox 1, gene 2 
ventx1.1  
ventx1.2 
Str.740.1.S1_at 7,44 chromosome 3 open reading frame 54 c3orf54 
Str.10337.1.S1_at 7,37 dual specificity phosphatase 6 dusp6 
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Str.27989.2.A1_s_at 7,34 piggyBac transposable element-derived protein 4-like LOC100494255 
Str.21559.2.S1_x_at 7,25 Y box binding protein 2 ybx2 
Str.30372.1.S1_x_at 7,15 Nucleolar protein 5A (56kDa with KKE/D repeat) TEgg001j23.1 
Str.27186.1.S1_at 7,15 histone cluster 2, H3c hist2h3c 
Str.36384.1.S1_at 7,15 nodal homolog 2-A-like LOC100491883 
Str.6900.1.S2_s_at 7,14 
ER degradation enhancer, 
mannosidase alpha-like 1  
angiopoietin-related protein 1-
like 
edem1  
LOC100491105 
Str.10803.1.S1_at 7,13 goosecoid homeobox gsc 
Str.15.1.S1_at 7,13 cell division cycle 25 homolog B cdc25b 
Str.49496.1.S1_s_at 7,11 apelin receptor aplnr 
Str.27467.1.S1_at 7,11 zinc finger protein 350 znf350 
Str.10021.1.S1_at 7,11 orthodenticle homeobox 2 otx2 
Str.11939.1.S1_at 7,06 l-amino-acid oxidase-like LOC100496394 
Str.30175.1.S1_at 7,04 VENT homeobox 3, gene 2 ventx3.2 
Str.6981.1.S1_at 7,04 growth arrest and DNA-damage-inducible, gamma gadd45g 
Str.8142.1.A1_at 7,03 TSC22 domain family, member 3 tsc22d3 
Str.23268.1.A1_at 6,99 peptidase M20 domain containing 1 pm20d1 
Str.37312.1.S1_x_at 6,95 hypothetical protein LOC100145106 LOC100145106 
Str.10236.1.S1_at 6,94 receptor-interacting serine-threonine kinase 4 ripk4 
Str.7735.3.S1_a_at 6,91 
nodal homolog 3-B-like  nodal 
homolog                nodal homolog 
3, gene 2 
LOC100491713 
nodal     
nodal3.2 
Str.25552.1.S2_at 6,90 lysophosphatidic acid receptor 2 lpar2 
Str.7693.1.S1_at 6,79 VENT homeobox 1, gene 2 ventx1.2 
Str.7073.1.S1_at 6,79 iroquois homeobox 2 irx2 
Str.16160.1.S1_at 6,79 forkhead box I4, gene 2 foxi4.2 
Str.8390.1.S2_at 6,75 GATA binding protein 4 gata4 
Str.16319.2.S1_at 6,68 hypothetical protein LOC100489354 LOC100489354 
Str.11968.1.A1_at 6,63 RAS, dexamethasone-induced 1 rasd1 
Str.10727.1.S1_at 6,63 deoxyribonuclease gamma-like LOC100497175 
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Str.10803.1.S1_s_at 6,62 goosecoid homeobox  hypothetical LOC100135186 
gsc 
LOC100135186 
Str.12750.1.A1_at 6,62 LIM homeobox 1 lhx1 
Str.1716.1.S1_x_at 6,58 purinergic receptor P2Y, G-protein coupled, 2 p2ry2 
Str.27405.1.A1_at 6,47 WNT1 inducible signaling pathway protein 3 wisp3 
Str.15223.4.S1_a_at 6,42 eukaryotic translation initiation factor 4A2 eif4a2 
Str.8895.3.S3_at 6,42 GATA-binding factor 2-like LOC100487142 
StrEns.9366.1.S1_a_at 6,38 oocyte zinc finger protein XlCOF6-like LOC100495878 
Str.36919.1.S1_at 6,37 VENT homeobox 3, gene 1 ventx3.1 
Str.1534.1.S2_at 6,35 
hypothetical protein   
hypothetical protein 
hypothetical protein  
LOC100489830 
LOC100494885  
LOC100495042 
Str.15023.1.S1_a_at 6,33 dickkopf 1 dkk1 
Str.1273.1.S1_at 6,28 histone H4-like LOC100496593 
Str.52067.1.S1_s_at 6,28 zinc finger protein 568 znf568 
Str.51804.1.S1_at 6,27 chemokine (C-X-C motif) receptor 7 cxcr7 
Str.27170.2.A1_x_at 6,27 hypothetical protein LOC100145554 LOC100145554 
Str.488.1.S1_at 6,26 hypothetical protein MGC76328 MGC76328 
Str.16849.2.S1_at 6,25 histidine ammonia-lyase, gene 1 hal.1 
Str.27139.1.S1_at 6,22 PR domain containing 1, with ZNF domain prdm1 
Str.27989.1.S1_at 6,21 hypothetical protein LOC100493710 LOC100493710 
Str.8101.1.S1_at 6,19 ferritin, heavy polypeptide 1 fth1 
Str.6630.1.S2_at 6,18 X-box binding protein 1 xbp1 
Str.17625.1.S1_at 6,14 hypothetical LOC100495344 LOC100495344 
Str.4744.1.S1_at 6,11 dual specificity phosphatase 5 dusp5 
Str.6659.1.S1_at 6,11 nerve growth factor receptor ngfr 
Str.8646.3.S1_a_at 6,11 
inhibitor of DNA binding 3, 
dominant negative helix-loop-
helix protein 
id3 
Str.21522.1.S1_at 6,10 uroplakin 2 upk2 
Str.42133.2.A1_at 6,09 hypothetical LOC100486754 LOC100486754 
Str.27583.3.S1_at 6,07 MGC89648 protein MGC89648 
Str.266.1.S1_at 6,06 chemokine (C-X-C motif) receptor 4 cxcr4 
Str.42133.1.S1_x_at 6,02 zinc finger protein 33A znf33a 
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Str.51679.2.S2_at 6,00 hypothetical protein   hypothetical protein  
LOC100498064 
LOC100498497 
Str.51828.3.S1_s_at 5,99 hypothetical protein LOC100489130 LOC100489130 
Str.3160.2.S1_a_at 5,97 serine/arginine-rich splicing factor 6 srsf6 
Str.26882.1.S1_at 5,96 siamois homeodomain 1 sia1 
Str.10008.1.S1_at 5,90 hypothetical protein LOC100487199 LOC100487199 
Str.12012.1.S1_at 5,88 ankyrin repeat domain 10 ankrd10 
Str.27186.1.S1_s_at 5,84 histone H3.2-like LOC100496129 
Str.52193.1.S1_at 5,83 High-mobility group nucleosomal binding   domain 2 TEgg003n10.1 
StrJgi.8558.1.S1_s_at 5,81 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein  
LOC100486020 
LOC100488381 
LOC100493631  
LOC100494089 
LOC100498455 
Str.43435.1.A1_s_at 5,81 heart and neural crest derivatives expressed 2 hand2 
StrEns.11954.1.S1_a_at 5,79 hypothetical protein LOC100494960 LOC100494960 
Str.9440.1.S1_at 5,77 activated leukocyte cell adhesion molecule alcam 
Str.37384.1.S1_at 5,69 frizzled homolog 8 fzd8 
Str.33.1.S1_at 5,67 
protein kinase domain 
containing, cytoplasmic 
homolog, gene 1 
pkdcc.1 
StrEns.171.1.S1_s_at 5,65 phosphatidic acid phosphatase type 2B ppap2b 
Str.50024.1.S1_at 5,64 serine dehydratase sds 
Str.49462.1.S1_at 5,60 T-box 2 tbx2 
Str.30427.1.S1_at 5,57 StAR-related lipid transfer (START) domain containing 13 stard13 
Str.48764.1.A1_at 5,56 Mdm2 p53 binding protein homolog mdm2 
Str.11235.2.S1_at 5,52 hypothetical protein LOC100145165 LOC100145165 
Str.31298.1.S1_at 5,50 iroquois homeobox 1 irx1 
Str.10459.1.A1_at 5,49 Ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog) ube2d3 
Str.6149.1.S1_at 5,47 glutamine--fructose-6-phosphate transaminase 1 gfpt1 
Str.51121.1.S1_at 5,45 Kruppel-like factor 17 klf17 
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Str.23519.2.S1_a_at 5,44 Death inducer-obliterator 1 dido1 
Str.6018.1.S1_at 5,43 hairy and enhancer of split 4 hes4 
Str.26907.1.S1_at 5,43 nodal homolog 1 nodal1 
Str.6304.1.S2_at 5,42 calponin 1, basic, smooth muscle cnn1 
Str.36162.1.A1_at 5,41 hypothetical protein LOC100498210 LOC100498210 
Str.20470.1.S2_at 5,38 cyclin E2 ccne2 
StrAffx.22.1.S1_at 5,37 hypothetical protein   hypothetical protein  
LOC100486038 
LOC100487146 
Str.21783.1.S1_at 5,36 Sec61 alpha 1 subunit (S. cerevisiae) sec61a1 
Str.41326.1.S1_s_at 5,33 hairy and enhancer of split 6, gene 1 hes6.1 
Str.1865.1.S1_at 5,30 cerberus 1, cysteine knot superfamily cer1 
Str.18694.2.S1_x_at 5,29 hypothetical protein LOC100498107 LOC100498107 
Str.2177.1.A1_a_at 5,26 sphingosine-1-phosphate receptor 5 s1pr5 
Str.20538.3.A1_at 5,24 hypothetical protein LOC100497342 LOC100497342 
Str.17388.1.S1_at 5,24 hypothetical LOC100495861 LOC100495861 
Str.27013.1.S1_a_at 5,22 uroplakin 3B upk3b 
Str.37201.1.S1_at 5,18 melanopsin-B-like LOC100495677 
Str.27847.1.A1_at 5,16 hypothetical protein LOC100493690 LOC100493690 
Str.27924.1.S1_at 5,14 zinc finger protein ZIC 4-like LOC100493609 
Str.48741.1.S1_x_at 5,13 Peptidyl-prolyl isomerase G (cyclophilin G) ppig 
Str.16957.1.S1_at 5,12 fused in sarcoma fus 
Str.11165.7.S1_at 5,10 sarcoplasmic/endoplasmic reticulum calcium ATPase 2-like LOC100489059 
StrJgi.6845.1.S1_x_at 5,08 oocyte zinc finger protein XlCOF7.1-like LOC100495340 
Str.20538.1.S2_a_at 5,07 
KH domain containing, RNA 
binding, signal transduction 
associated 1 
khdrbs1 
Str.420.1.S2_a_at 5,07 
ABO blood group (transferase A, 
alpha 1-3-N-
acetylgalactosaminyltransferase; 
transferase B, alpha 1-3-
galactosyltransferase) 
abo 
Str.37703.1.S1_at 5,04 transportin 1 tnpo1 
StrEns.4645.1.S1_at 5,04 nodal homolog 4-A-like LOC100497218 
Appendix 
144 
Str.24746.1.S1_at 5,04 solute carrier family 43, member 1 slc43a1 
StrEns.8996.1.S1_a_at 5,03 hypothetical protein LOC100496030 LOC100496030 
Str.10535.1.S1_at 4,98 hypothetical LOC100495377 LOC100495377 
Str.8191.1.S2_at 4,96 phospholipase A2, group XIIB pla2g12b 
StrJgi.784.1.S1_s_at 4,95 retinoblastoma-like 1 (p107) rbl1 
Str.5015.1.A1_at 4,95 
neural precursor cell expressed, 
developmentally down-regulated 
9 
nedd9 
Str.37936.1.A1_at 4,92 fibroblast growth factor 20 fgf20 
Str.111.1.S1_at 4,91 hematopoietically expressed homeobox hhex 
Str.16175.1.S1_a_at 4,90 growth differentiation   factor 3 gdf3 
Str.9391.1.A1_at 4,90 Hypothetical protein LOC549444 LOC549444 
Str.50563.1.A1_at 4,90 Hypothetical protein LOC100216216 LOC100216216 
Str.6578.1.S2_a_at 4,86 serine/arginine-rich splicing factor 1 srsf1 
Str.6723.1.S1_x_at 4,84 pinhead pnhd 
Str.154.1.S1_at 4,84 frizzled homolog 10 fzd10 
Str.18694.1.S1_at 4,84 uncharacterized protein ywlC-like LOC100497798 
Str.20533.6.S1_x_at 4,83 hypothetical LOC100486606 LOC100486606 
Str.28734.1.A1_at 4,81 hypothetical protein LOC100489967 LOC100489967 
Str.40271.2.S1_a_at 4,80 Hypothetical protein LOC550005 LOC550005 
Str.16161.1.S1_at 4,80 sizzled szl 
Str.11217.1.S1_at 4,78 MGC89906 protein MGC89906 
Str.10785.1.S1_at 4,77 hypothetical LOC100497479 LOC100497479 
Str.1843.1.S1_at 4,76 v-ski sarcoma viral oncogene homolog ski 
Str.10305.2.S1_at 4,74 hypothetical protein LOC100216037 LOC100216037 
Str.18775.1.S1_at 4,69 
CKLF-like MARVEL 
transmembrane domain 
containing 8 
cmtm8 
Str.3002.1.A1_at 4,67 Hypothetical protein LOC779546 LOC779546 
Str.43058.1.S1_at 4,60 zinc finger protein LOC100337651 
Str.1183.1.S1_at 4,56 transmembrane protein 127 tmem127 
Str.6139.1.S2_at 4,55 GATA binding protein 6 gata6 
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Str.7077.1.A1_at 4,55 hormonally up-regulated Neu-associated kinase hunk 
Str.7705.5.S1_at 4,51 odd-skipped related 2 osr2 
Str.28286.1.S1_at 4,51 RNA binding motif protein 25 rbm25 
Str.15853.1.S1_at 4,49 
pleckstrin homology domain-
containing family N member 1-
like 
LOC100491834 
Str.6156.1.S1_a_at 4,49 forkhead box C1 foxc1 
StrJgi.7085.1.S1_s_at 4,49 PR domain containing 9 prdm9 
Str.18694.2.S1_a_at 4,49 uncharacterized protein ywlC-like              hypothetical protein  
LOC100497798 
LOC100498107 
Str.15587.1.S1_at 4,48 hypothetical protein LOC100487200 LOC100487200 
Str.1567.1.S2_at 4,47 
ST6 (alpha-N-acetyl-neuraminyl-
2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-
sialyltransferase 2 
st6galnac2 
Str.28803.2.S1_a_at 4,47 hypothetical LOC100486098 LOC100486098 
Str.37570.1.S1_at 4,45 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 3 
slc7a3 
Str.51825.1.S1_at 4,44 Hypothetical protein LOC733820 LOC733820 
Str.10072.1.S2_at 4,43 Solute carrier family 2 (facilitated glucose transporter), member 2 slc2a2 
Str.24244.1.S1_at 4,41 SRY (sex determining region Y)-box 21 sox21 
Str.31333.1.S1_a_at 4,40 
protein kinase domain 
containing, cytoplasmic 
homolog, gene 2 
pkdcc.2 
Str.11402.1.A1_at 4,35 
protein phosphatase 1, 
regulatory (inhibitor) subunit 3C, 
gene 1 
ppp1r3c.1 
Str.10016.1.S1_at 4,35 cdc42 effector protein (Rho GTPase binding) 4 cdc42ep4 
Str.10174.1.A1_at 4,32 
single-strand-selective 
monofunctional uracil-DNA 
glycosylase 1 
smug1 
Str.10713.1.S1_at 4,30 growth arrest-specific 1 gas1 
Str.14504.1.S1_at 4,29 rho GTPase-activating protein 39-like LOC100485974 
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Str.1093.1.S1_at 4,26 ADP-ribosylation factor-like 4C arl4c 
Str.9958.1.S1_at 4,25 chromosome 7 open reading frame 11 c7orf11 
Str.954.1.S1_at 4,24 
potassium channel 
tetramerisation domain 
containing 15 
kctd15 
Str.5982.1.S1_a_at 4,22 darmin darmin 
StrEns.1208.1.S1_at 4,18 nodal homolog 2-A-like LOC100496994 
Str.21565.4.S1_at 4,17 RNA binding motif protein, X-linked rbmx 
Str.24254.1.S1_at 4,15 wingless-type MMTV integration site family, member 5B wnt5b 
Str.5804.3.S1_a_at 4,12 
hypothetical LOC100487483  
hypothetical LOC100490010  
hypothetical LOC100490596 
hypothetical LOC100491185 
hypothetical LOC100492994 
hypothetical LOC100493564 
LOC100487483 
LOC100490010 
LOC100490596 
LOC100491185 
LOC100492994 
LOC100493564 
Str.26607.1.S1_at 4,11 protein unc-80 homolog LOC100492079 
Str.6167.1.S1_at 4,09 phosphorylase, glycogen, muscle pygm 
Str.26626.1.S1_at 4,06 growth arrest and DNA-damage-inducible, alpha gadd45a 
Str.7519.1.S1_at 4,01 ras homolog gene family, member B rhob 
Str.916.1.S1_at 4,00 lin-28 homolog A (C. elegans) lin28a 
Str.51815.1.S1_at 3,98 notochord homeobox not 
Str.1180.1.S2_at 3,98 forkhead box A1 foxa1 
Str.15005.1.S1_at 3,98 hairy and enhancer of split 3, gene 1 hes3.1 
Str.27547.1.S3_at 3,96 hypothetical protein LOC550042 LOC550042 
Str.4965.1.S1_at 3,96 minichromosome maintenance complex component 6 mcm6.2 
Str.3344.1.S1_at 3,94 novel protein similar to hatching enzymes LOC594901 
Str.993.1.S1_a_at 3,91 mex-3 homolog C mex3c 
Str.11106.1.S1_at 3,90 hypothetical protein LOC100488554 LOC100488554 
Str.35184.1.A1_s_at 3,88 capping protein (actin filament) muscle Z-line, alpha 1 capza1 
Str.643.1.S1_a_at 3,88 hypothetical LOC100486597 LOC100486597 
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Str.5849.2.A1_s_at 3,87 zinc finger E-box binding homeobox 2 zeb2 
Str.16322.1.S1_at 3,86 Sp9 transcription factor homolog sp9 
Str.514.1.S1_at 3,83 pim-1 oncogene pim1 
Str.28107.1.S1_at 3,83 snail homolog 1 snai1 
Str.51836.1.S1_at 3,80 angiopoietin 4 angpt4 
Str.15072.2.A1_a_at 3,77 delta-like 1 dll1 
Str.24583.1.S1_at 3,75 leucine-rich repeats and immunoglobulin-like domains 3 lrig3 
Str.15996.4.S1_at 3,74 hypothetical LOC100490120 LOC100490120 
Str.13766.1.S1_at 3,73 zinc finger protein 608 znf608 
Str.27389.1.S1_at 3,69 transmembrane protein 150B tmem150b 
Str.7002.1.S1_at 3,69 hypothetical LOC100497373 LOC100497373 
Str.21604.1.S1_at 3,69 5'-nucleotidase, cytosolic III nt5c3 
StrJgi.5287.1.S1_s_at 3,68 kin of IRRE like 2 kirrel2 
StrJgi.6058.1.S1_at 3,67 LIM/homeobox protein Lhx3-like LOC100496651 
Str.3082.1.S1_at 3,62 wnt11 protein wnt11 
Str.5394.1.S1_at 3,61 carboxylesterase 2 ces2 
Str.11087.1.S1_at 3,60 distal-less homeobox 5 dlx5 
Str.20011.1.S1_at 3,59 receptor tyrosine kinase-like orphan receptor 2 ror2 
Str.49050.1.S1_at 3,58 Fast skeletal myosin light chain 2 TNeu107a14.1 
Str.10659.1.S1_at 3,57 
transcription factor AP-2 epsilon 
(activating enhancer binding 
protein 2 epsilon) 
tfap2e 
Str.24871.1.S1_x_at 3,56 zinc finger protein 33B znf33b 
Str.6103.1.S1_at 3,55 
MID1 interacting protein 1 
(gastrulation specific G12 
homolog) 
mid1ip1 
Str.10076.1.S1_at 3,52 angiomotin like 2 amotl2 
Str.42133.3.A1_x_at 3,52 
zinc finger protein 502-like  
gastrula zinc finger protein 
XlCGF57.1-like                   zinc 
finger protein 613-like  
MGC146893                      zinc 
finger protein 3          zinc finger 
protein 33A       zinc finger 
protein 33B      zinc finger protein 
665 
LOC100485089  
LOC100489449 
LOC100493688  
MGC146893  
znf3          
znf33a       
znf33b       
znf665 
Str.24842.3.S1_at 3,51 ropporin 1-like ropn1l 
Str.11288.1.S1_at 3,51 hypothetical LOC100486074 LOC100486074 
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Str.13147.1.A1_at 3,50 zinc finger protein 219-like LOC100495520 
Str.21950.2.S1_a_at 3,49 hypothetical LOC100488570 LOC100488570 
Str.16343.1.A1_at 3,48 Hypothetical protein LOC100145152 LOC100145152 
Str.10208.1.S1_at 3,47 
solute carrier family 12 
(sodium/chloride transporters), 
member 3, gene 2 
slc12a3.2 
Str.9193.1.A1_a_at 3,46 UPF0632 protein C2orf89-like LOC100491951 
Str.6363.1.S2_at 3,45 
acidic (leucine-rich) nuclear 
phosphoprotein 32 family, 
member C 
anp32c 
Str.49171.3.S1_at 3,45 hypothetical LOC100488154 LOC100488154 
Str.38997.1.A1_at 3,42 proprotein convertase subtilisin/kexin type 9-like LOC100484989 
Str.10900.1.S1_at 3,41 serum/glucocorticoid regulated kinase 1 sgk1 
Str.6695.1.S2_at 3,40 zinc finger, MIZ-type containing 2 zmiz2 
Str.39816.2.S1_at 3,28 hypothetical LOC100488648 LOC100488648 
Str.21565.6.A1_at 3,28 hypothetical LOC100485563 LOC100485563 
Str.7820.2.S1_a_at 3,24 immediate early response gene 2 protein-like LOC100491464 
Str.29569.1.S1_at 3,23 Meningioma (disrupted in balanced translocation) 1, gene 1 mn1.1 
Str.2514.1.S1_a_at 3,22 NIMA (never in mitosis gene a)-related kinase 2 nek2 
Str.22063.1.S1_at 3,20 hypothetical LOC100489698 LOC100489698 
Str.51755.2.A1_a_at 3,19 hypothetical protein LOC100491437 LOC100491437 
Str.10330.1.S2_at 3,16 sprouty homolog 1, antagonist of FGF signaling spry1 
Str.2247.1.S1_at 3,15 RAB34, member RAS oncogene family rab34 
Str.51988.1.S1_at 3,14 serine/arginine-rich splicing factor 11 srsf11 
Str.33742.1.A1_a_at 3,13 hypothetical protein LOC100494123 LOC100494123 
Str.51680.1.A1_at 3,12 zinc finger protein 721 znf721 
Str.15643.1.A1_at 3,10 hypothetical protein LOC100145695 LOC100145695 
Str.1973.2.A1_a_at 3,05 huntingtin-associated protein 1 hap1 
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Str.10123.1.S1_at 3,02 glucose-fructose oxidoreductase domain containing 1 gfod1 
Str.16252.1.S1_at 3,02 SRY (sex determining region Y)-box 1 sox1 
Str.10371.1.S1_at 3,00 chromosome 8 open reading frame 4 c8orf4 
Str.51787.1.S1_at 3,00 histone cluster 1, H2ah hist1h2ah 
Str.40984.1.S1_at 2,98 hypothetical protein LOC100494082 LOC100494082 
Str.27184.1.S1_a_at 2,98 matrix metallopeptidase 1 (interstitial collagenase) mmp1 
Str.51982.1.A1_s_at 2,96 iroquois homeobox 3 irx3 
Str.11815.1.S1_at 2,95 
protein phosphatase 1, 
regulatory (inhibitor) subunit 
15B 
ppp1r15b 
Str.40960.1.S1_at 2,95 zinc finger, SWIM-type containing 5 zswim5 
Str.2514.4.A1_a_at 2,94 NIMA (never in mitosis gene a)-related kinase 2 nek2 
Str.30747.1.A1_at 2,94 regulator of G-protein signaling 16 rgs16 
Str.4877.1.S1_at 2,94 caudal type homeobox 4 cdx4 
StrJgi.6297.1.S1_at 2,92 homeobox protein siamois-like LOC100489935 
Str.15740.1.A1_at 2,92 MAP kinase interacting serine/threonine kinase 2 mknk2 
Str.50722.6.S1_at 2,90 
transient receptor potential 
cation channel subfamily M 
member 4-like 
LOC100491327 
Str.49514.1.S1_at 2,89 T-box 3 tbx3 
Str.49437.1.S1_at 2,82 Hypothetical protein LOC100144964 LOC100144964 
Str.30700.3.A1_s_at 2,82 solute carrier family 41, member 2 slc41a2 
Str.169.2.S1_a_at 2,81 sal-like 1 sall1 
Str.23452.1.A1_at 2,79 empty spiracles homeobox 1 emx1 
Str.40558.2.A1_at 2,79 Hypothetical protein LOC100158524 LOC100158524 
Str.246.1.S1_at 2,79 mab-21-like 2 mab21l2 
Str.8107.1.S1_at 2,77 forkhead box A2 foxa2 
Str.27386.1.S1_at 2,74 RasGEF domain family, member 1B rasgef1b 
Str.10824.1.S1_at 2,74 KIT ligand kitlg 
Str.6084.1.S2_at 2,73 lymphocyte antigen 6 complex, similar to G6C ly6g6c 
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Str.27109.1.S1_at 2,72 oligodendrocyte transcription factor 3 olig3 
Str.2696.1.S1_at 2,71 forkhead box C2 (MFH-1, mesenchyme forkhead 1) foxc2 
Str.5969.1.S1_at 2,70 CDGSH iron sulfur domain 1 cisd1 
Str.28780.1.S1_at 2,65 RAS-like, family 11,    member B rasl11b 
Str.15404.1.S1_at 2,64 
carbohydrate (N-
acetylglucosamine-6-O) 
sulfotransferase 2 
chst2 
StrJgi.8558.1.S1_x_at 2,63 hypothetical protein LOC100494089 LOC100494089 
Str.10666.1.S1_at 2,63 follistatin fst 
Str.19278.2.S1_at 2,61 hypothetical protein LOC100491368 LOC100491368 
Str.2504.2.S1_at 2,59 RNA binding motif protein 6 rbm6 
Str.5989.1.S1_at 2,59 retinoblastoma binding protein 6 rbbp6 
Str.10221.1.S2_at 2,58 hypothetical LOC100495650 LOC100495650 
Str.11224.1.S1_at 2,57 zinc finger protein 238.2-like LOC100489646 
StrEns.4639.1.S1_s_at 2,56 arachidonate 5-lipoxygenase-activating protein alox5ap 
Str.20309.1.A1_at 2,54 cyclin-dependent kinase 6 cdk6 
Str.24871.1.S2_s_at 2,54 zinc finger protein 613-like LOC100493688 
Str.11302.1.S1_at 2,54 forkhead box D3 foxd3 
Str.8068.3.S1_at 2,53 Solute carrier family 5 (iodide transporter), member 8 slc5a8 
Str.303.1.S1_at 2,50 G protein-coupled receptor, family C, group 5, member C gprc5c 
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Listed are all genes, downregulated ≥ 5.65 fold change and with an adjusted p-value ≤ 0.05. 
Set-probe number 
 fold 
change 
[log2] 
gene name symbol 
Str.49500.1.S2_at -3,71 stearoyl-CoA desaturase (delta-9-desaturase) scd 
Str.27228.1.S1_at -2,84 cyclin B5 LOC394448 
Str.27519.1.S1_at -2,83 TATA box binding protein like 2 tbpl2 
Str.26929.1.S1_at -2,78 novel trypsin family protein LOC733551 
Str.38389.1.S1_at -2,74 hypothetical LOC100327245 LOC100327245 
Str.51968.1.S1_at -2,70 ribonuclease H1 rnaseh1 
Str.52195.1.S1_s_at -2,67 ankyrin repeat domain 37 ankrd37 
Str.27358.1.S1_at -2,55 transmembrane protease, serine 11F tmprss11f 
Str.17786.1.S1_at -2,52 adaptor-related protein complex 4, sigma 1 subunit ap4s1 
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BMO1/MBT microarray 
Listed are all genes, which are upregulated ≥ 5.65 fold at the MBT and show transcriptional changes 
upon BMO1 injections. 
fold 
change 
[log2] 
gene name symbol 
3,196 Hypothetical protein LOC550005 LOC550005 
2,167 histone cluster 1, H2ah hist1h2ah 
1,482 histone H4-like LOC100496593 
1,129 hypothetical protein LOC100496030 LOC100496030 
0,907 mesendoderm nuclear factor, gene 1 menf.1 
0,756 RNA binding motif protein 6 rbm6 
0,625 histone H3.2-like LOC100496129 
0,592 transportin 1 tnpo1 
0,523 hypothetical protein LOC100145106 LOC100145106 
-0,343 hypothetical protein LOC100216037 LOC100216037 
-0,383 
hypothetical protein 
LOC100494704                VENT 
homeobox 2, gene 1 
LOC100494704  
ventx2.1 
-0,397 MGC89648 protein MGC89648 
-0,519 growth arrest and DNA-damage-inducible, alpha gadd45a 
-0,536 hypothetical protein LOC100495042 LOC100495042 
-0,537 cdc42 effector protein (Rho GTPase binding) 4 cdc42ep4 
-0,556 
leucine-rich repeats and 
immunoglobulin-like domains 
3 
lrig3 
-0,578 
hypothetical protein      
hypothetical protein 
hypothetical protein  
LOC100489830 
LOC100494885 
LOC100495042 
-0,604 growth arrest and DNA-damage-inducible, gamma gadd45g 
-0,623 RAS, dexamethasone-induced 1 rasd1 
-0,629 cyclin-dependent kinase 6 cdk6 
-0,641 cone-rod homeobox crx 
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-0,642 
glucose-fructose 
oxidoreductase domain 
containing 1 
gfod1 
-0,646 hypothetical LOC100496454 LOC100496454 
-0,653 VENT homeobox 3, gene 1 ventx3.1 
-0,660 NIMA (never in mitosis gene a)-related kinase 2 nek2 
-0,686 
transcription factor AP-2 alpha 
(activating enhancer binding 
protein 2 alpha) 
tfap2a 
-0,696 filamin C, gamma flnc 
-0,713 hypothetical protein LOC100493690 LOC100493690 
-0,732 
single-strand-selective 
monofunctional uracil-DNA 
glycosylase 1 
smug1 
-0,736 forkhead box I4, gene 2 foxi4.2 
-0,756 
carbohydrate (N-
acetylglucosamine-6-O) 
sulfotransferase 2 
chst2 
-0,777 mab-21-like 2 mab21l2 
-0,777 hairy and enhancer of split 4 hes4 
-0,781 dual specificity phosphatase 5 dusp5 
-0,787 hypothetical protein MGC76328 MGC76328 
-0,792 phosphatidic acid phosphatase type 2B ppap2b 
-0,811 hypothetical protein LOC550042 LOC550042 
-0,814 
minichromosome 
maintenance complex 
component 6 
mcm6.2 
-0,840 sal-like 1 sall1 
-0,843 hairy and enhancer of split 6, gene 1 hes6.1 
-0,889 hypothetical LOC100496939 LOC100496939 
-0,896 phosphorylase, glycogen, muscle pygm 
-0,900 lysophosphatidic acid receptor 6 lpar6 
-0,901 huntingtin-associated protein 1 hap1 
-0,902 T, brachyury homolog t 
-0,907 hypothetical protein   hypothetical protein 
LOC100486038 
LOC100487146 
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-0,923 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 3 
slc7a3 
-0,924 Hypothetical protein LOC779546 LOC779546 
-0,926 G2/M-phase specific E3 ubiquitin protein ligase g2e3 
-0,932 PR domain containing 1, with ZNF domain prdm1 
-0,967 zinc finger protein 608 znf608 
-0,969 hypothetical LOC100497373 LOC100497373 
-0,986 VENT homeobox 1, gene 1 VENT homeobox 1, gene 2 ventx1.1  ventx1.2 
-0,993 Nucleolar protein 5A (56kDa with KKE/D repeat) TEgg001j23.1 
-0,997 kin of IRRE like 2 kirrel2 
-0,999 POU domain, class 5, transcription factor 1.2-like LOC100498076 
-1,005 
hypothetical LOC100484994  
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical protein 
hypothetical LOC100498560 
LOC100484994 
LOC100486020  
LOC100489931 
LOC100490293 
LOC100492588 
LOC100498560 
-1,007 hypothetical protein LOC100487199 LOC100487199 
-1,017 serine/arginine-rich splicing factor 1 srsf1 
-1,021 receptor-interacting serine-threonine kinase 4 ripk4 
-1,033 hypothetical LOC100486098 LOC100486098 
-1,053 MAP kinase interacting serine/threonine kinase 2 mknk2 
-1,060 retinoblastoma-like 1 (p107) rbl1 
-1,080 LIM homeobox 1 lhx1 
-1,098 arachidonate 5-lipoxygenase-activating protein alox5ap 
-1,100 novel zinc finger protein LOC733912 
-1,102 potassium channel, subfamily K, member 6 kcnk6 
-1,115 
wingless-type MMTV 
integration site family, 
member 5B 
wnt5b 
-1,125 hypothetical LOC100486074 LOC100486074 
-1,129 VENT homeobox 1, gene 1 ventx1.1 
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-1,132 hypothetical protein LOC100489354 LOC100489354 
-1,141 High-mobility group nucleosomal binding domain 2 TEgg003n10.1 
-1,148 hypothetical LOC100495377 LOC100495377 
-1,152 hypothetical LOC100495538 LOC100495538 
-1,156 nerve growth factor receptor ngfr 
-1,158 zinc finger protein 568 znf568 
-1,172 transmembrane protein 127 tmem127 
-1,205 lin-28 homolog A (C. elegans) lin28a 
-1,213 TSC22 domain family, member 3 tsc22d3 
-1,227 Heterogeneous nuclear ribonucleoprotein D-like hnrpdl 
-1,232 serine/arginine-rich splicing factor 6 srsf6 
-1,278 rho GTPase-activating protein 39-like LOC100485974 
-1,280 Death inducer-obliterator 1 dido1 
-1,303 hypothetical protein MGC69473 MGC69473 
-1,312 uncharacterized protein ywlC-like LOC100497798 
-1,312 regulator of G-protein signaling 16 rgs16 
-1,319 
uncharacterized protein ywlC-
like                               
hypothetical protein  
LOC100497798 
LOC100498107 
-1,339 forkhead box D4-like 1, gene 1 foxd4l1.1 
-1,351 SRY (sex determining region Y)-box 1 sox1 
-1,352 immediate early response gene 2 protein-like LOC100491464 
-1,352 
ER degradation enhancer, 
mannosidase alpha-like 1  
angiopoietin-related protein 1-
like 
edem1 
LOC100491105 
-1,353 
Meningioma (disrupted in 
balanced translocation) 1, 
gene 1 
mn1.1 
-1,360 forkhead box C1 foxc1 
-1,363 SRY (sex determining region Y)-box 21 sox21 
-1,383 T-box 3 tbx3 
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-1,431 ankyrin repeat domain 10 ankrd10 
-1,451 uroplakin 2 upk2 
-1,457 cornifelin homolog cnfn 
-1,470 eukaryotic translation initiation factor 4A2 eif4a2 
-1,506 LIM homeobox 5 lhx5 
-1,510 zinc finger protein 750 znf750 
-1,517 serine/arginine-rich splicing factor 11 srsf11 
-1,524 hypothetical protein LOC100498107 LOC100498107 
-1,536 angiopoietin 4 angpt4 
-1,542 Fast skeletal myosin light chain 2 TNeu107a14.1 
-1,552 angiomotin like 2 amotl2 
-1,555 GATA binding protein 4 gata4 
-1,557 
potassium channel 
tetramerisation domain 
containing 15 
kctd15 
-1,561 hypothetical protein LOC100487200 LOC100487200 
-1,580 novel protein similar to hatching enzymes LOC594901 
-1,593 
transcription factor AP-2 
epsilon (activating enhancer 
binding protein 2 epsilon) 
tfap2e 
-1,595 deoxyribonuclease gamma-like LOC100497175 
-1,603 cyclin E2 ccne2 
-1,629 iroquois homeobox 2 irx2 
-1,631 zinc finger protein ZIC 4-like LOC100493609 
-1,648 forkhead box D3 foxd3 
-1,713 lymphocyte antigen 6 complex, similar to G6C ly6g6c 
-1,719 X-box binding protein 1 xbp1 
-1,731 transcription factor HES-1-like LOC100496131 
-1,738 hypothetical LOC100486597 LOC100486597 
-1,761 ADP-ribosylation factor-like 4C arl4c 
-1,764 
Solute carrier family 2 
(facilitated glucose 
transporter), member 2 
slc2a2 
-1,771 ATPase, Na+/K+ transporting, beta 2 polypeptide atp1b2 
-1,889 homeobox C8 hoxc8 
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-1,902 zinc finger E-box binding homeobox 2 zeb2 
-1,930 cell division cycle 25 homolog B cdc25b 
-1,964 delta-like 1 dll1 
-2,016 distal-less homeobox 5 dlx5 
-2,038 hypothetical LOC100495344 LOC100495344 
-2,044 
neural precursor cell 
expressed, developmentally 
down-regulated 9 
nedd9 
-2,078 phospholipase A2, group XIIB pla2g12b 
-2,083 keratin krt 
-2,107 Sp9 transcription factor homolog sp9 
-2,112 sphingosine-1-phosphate receptor 5 s1pr5 
-2,126 calponin 1, basic, smooth muscle cnn1 
-2,155 chromosome 7 open reading frame 11 c7orf11 
-2,180 UPF0632 protein C2orf89-like LOC100491951 
-2,190 hypothetical LOC100494381 LOC100494381 
-2,311 hypothetical protein LOC100491368 LOC100491368 
-2,366 gastrula-specific protein 17 gs17 
-2,414 zinc finger protein 219-like LOC100495520 
-2,598 
sarcoplasmic/endoplasmic 
reticulum calcium ATPase 2-
like 
LOC100489059 
-2,706 uroplakin 3B upk3b 
-3,857 purinergic receptor P2Y, G-protein coupled, 2 p2ry2 
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BMO2/MBT microarray 
Listed are all genes, which are upregulated ≥ 5.65 at the MBT and show transcriptional changes upon 
BMO2 injections. 
fold 
change 
[log2] 
gene name symbol 
2,113 5'-nucleotidase, cytosolic III nt5c3 
1,747 
protein phosphatase 1, 
regulatory (inhibitor) subunit 3C, 
gene 1 
ppp1r3c.1 
1,105 hypothetical LOC100486074 LOC100486074 
1,071 fused in sarcoma fus 
1,045 hairy and enhancer of split 5, gene 1 hes5.1 
0,955 histone H3.2-like LOC100496129 
0,782 histone cluster 1, H2ah hist1h2ah 
0,758 ferritin, heavy polypeptide 1 fth1 
0,717 
ER degradation enhancer, 
mannosidase alpha-like 1  
angiopoietin-related protein 1-
like 
edem1    
LOC100491105 
0,674 Hypothetical protein LOC550005 LOC550005 
0,660 fibroblast growth factor 20 fgf20 
-0,372 Hypothetical protein LOC733820 LOC733820 
-0,445 MGC89648 protein MGC89648 
-0,447 
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 3 
slc7a3 
-0,462 hypothetical LOC100491682 LOC100491682 
-0,477 Fast skeletal myosin light chain 2 TNeu107a14.1 
-0,514 
single-strand-selective 
monofunctional uracil-DNA 
glycosylase 1 
smug1 
-0,531 
carbohydrate (N-
acetylglucosamine-6-O) 
sulfotransferase 2 
chst2 
-0,536 hypothetical protein LOC100487199 LOC100487199 
-0,549 retinoblastoma-like 1 (p107) rbl1 
-0,559 frizzled homolog 10 fzd10 
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-0,603 hypothetical LOC100486098 LOC100486098 
-0,638 
neural precursor cell expressed, 
developmentally down-regulated 
9 
nedd9 
-0,661 cdc42 effector protein (Rho GTPase binding) 4 cdc42ep4 
-0,705 Calponin 2 cnn2 
-0,771 serine/arginine-rich splicing factor 11 srsf11 
-0,792 hypothetical LOC100486597 LOC100486597 
-0,820 nerve growth factor receptor ngfr 
-0,841 hypothetical LOC100495377 LOC100495377 
-0,868 Y box binding protein 2 ybx2 
-0,894 ankyrin repeat domain 10 ankrd10 
-0,899 hypothetical protein LOC100493690 LOC100493690 
-0,952 immediate early response gene 2 protein-like LOC100491464 
-1,008 
ABO blood group (transferase A, 
alpha 1-3-N-
acetylgalactosaminyltransferase; 
transferase B, alpha 1-3-
galactosyltransferase) 
abo 
-1,021 hypothetical LOC100488570 LOC100488570 
-1,078 hypothetical LOC100495861 LOC100495861 
-1,110 
transcription factor AP-2 epsilon 
(activating enhancer binding 
protein 2 epsilon) 
tfap2e 
-1,206 sarcoplasmic/endoplasmic reticulum calcium ATPase 2-like LOC100489059 
-1,230 hypothetical protein LOC100487200 LOC100487200 
-1,303 l-amino-acid oxidase-like LOC100496394 
-1,344 SRY (sex determining region Y)-box 21 sox21 
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